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Abstract 
 
Pancreatic ductal adenocarcinoma (PDAC), the most common form of 
pancreatic cancer, develops through progression of premalignant pancreatic 
intraepithelial neoplasias (PanINs).  In mouse-models, KRAS-activation in acinar 
cells induced an acinar-to-ductal metaplasia (ADM), and mutation of the Kras 
oncogene is believed to initiate PanIN formation. ADM is also promoted by 
pancreatic injury, which cooperates with activated KRAS to stimulate PanIN and 
PDAC formation from metaplastic ducts.  
Our lab, and others, have shown that the downstream PI3K/AKT pathway 
is important for KRAS-mediated proliferation and survival in vitro and in vivo. 
Prior studies have demonstrated that full activation of AKT requires both PDK1-
mediated phosphorylation of AKTT308 and mTOR complex 2 (mTORC2)-mediated 
phosphorylation of AKTS473. Given the importance of the PI3K/AKT signaling 
axis, I hypothesized that mTORC2 is required for KRAS-driven pancreatic 
tumorigenesis and investigated this relationship in mice by combining pancreas-
specific expression of an activated KRASG12D molecule with deletion of the 
essential mTORC2 subunit RICTOR. 
 In the context of activated KRAS, Rictor-null pancreata developed fewer 
PanIN lesions; these lesions lacked mTORC2 signaling and their proliferation 
and progression were impaired.  Higher levels of nuclear cyclin dependent kinase 
inhibitors (CDKIs) were maintained in Rictor-null lesions, and nuclear BMI1, a 
known regulator of the CDKI Cdkn2a, inversely correlated with their expression. 
#""
Rictor was not required for KRAS-driven ADM following acute pancreatitis, 
however the inverse correlation between CDKIs and BMI1 was maintained in this 
system.  Treatment of PDX-Cre;KRASG12D/+;Trp53R172H/+ mice with an mTORC1/2 
inhibitor delayed tumor formation, and prolonged the survival of mice with late 
stage PDAC.  Knockdown of Rictor in established PDAC cell lines impaired 
proliferation and anchorage independent growth supporting a role for mTORC2 in 
fully transformed cells. 
These data suggest that mTORC2 cooperates with activated KRAS in the 
initiation and progression of PanIN lesions and is required for the transformation 
and maintenance of PDAC. My work illustrates phenotypic differences between 
pancreatic loss of Rictor and PDK1 in the context of KRAS, broadens our 
understanding of this signaling node and suggests that mTORC2 may potentially 
be a viable target for PDAC therapies. 
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Chapter I: 
Introduction 
  
%
A diagnosis of pancreatic cancer carries one of the worst prognoses in 
modern medicine.  It is currently the fourth leading cause of cancer related death 
in the United States and although survival rates for various other malignancies 
have dramatically improved in recent decades, progress in the treatment of 
pancreatic cancer has been tepid at best (Siegel, Miller et al. 2015). Early 
symptoms of pancreatic cancer are rare and reliable screening methods for 
identification of early stage disease are not yet available. At the time of diagnosis 
most patients present with distant metastasis and have a dismal 2% 5-year 
survival rate (Siegel, Miller et al. 2015).  Only 9% of patients are diagnosed with 
localized disease.  These patients are eligible for potentially curative surgery, and 
while their 5-year survival increases to 25% (Siegel, Miller et al. 2015), it is clear 
from the frequent recurrences of this malignancy that even “localized” disease 
has often disseminated.  Primary and metastatic pancreatic cancers are often 
resistant to current chemotherapeutics and even resected local disease 
frequently recurs despite supplementary chemotherapeutic treatment.  A better 
understanding of this disease will allow for the development of more effective 
therapies that are desperately needed to improve patient outcomes and survival. 
 
Overview of Pancreatic Endocrine and Exocrine Function 
The pancreas is comprised of both endocrine and exocrine tissues.  The 
endocrine component of the pancreas includes #, %, &, ' and PP cells which 
produce glucagon, insulin, somatostatin, ghrelin and pancreatic-polypeptide 
&
respectively (Jain and Lammert 2009).  Pancreatic endocrine cells reside in the 
islets of Langerhans, spherical structures comprised predominantly of %-cells 
(28% to 75%), #-cells (10% to 65%), and &-cells (1.2% to 22%) (Figure 1.1).  In 
humans the organization of cells is heterogeneous, while mice display a more 
core-mantle structure with centralized %-cells and #, and & cells localized to the 
periphery. (Brissova, Fowler et al. 2005, Jain and Lammert 2009).   
Islets account for only 2% of the human pancreas; the majority of the 
organ is comprised of acinar tissue responsible for the secretion of digestive 
enzymes, including trypsinogen, chymotrypsinogen, #-amylase, and pancreatic 
lipase (Maclean and Ogilvie 1955, Leung and Ip 2006). The architecture of the 
pancreatic exocrine system has been described as a cluster of grapes on the 
vine (Figure 1.1). Groups of acinar cells form grape like acini around centroacinar 
cells at the terminal ends of intercalated ducts. Apically located zymogen 
granules in acinar cells secrete inactive digestive enzymes into the ductal lumina, 
which empty into progressively larger intralobular, small interlobular and large 
interlobular (main) ducts (Reichert and Rustgi 2011).   The large interlobular duct 
junctions with the common bile duct shortly before emptying into the duodenum.  
In the small intestine entropeptidase initiates the cleavage of trypsinogen 
resulting in active trypsin protease.  This active enzyme then cleaves and 
activates other trypsinogen and chymotrypsinogen molecules (Rinderknecht 
1986, Hofbauer, Saluja et al. 1998). Secretion of digestive enzymes by acinar 
cells is stimulated by cholecystokinin, a hormone produced by duodenal 
'
enteroendocrine I-cells in response to the amino acid phenylalanine (Mangel, 
Prpic et al. 1995).  
 
Pancreatic Ductal Adenocarcinoma  
Pancreatic ductal adenocarcinomas (PDACs) are the most common and 
deadly pancreatic tumors.  They comprise over 85% of pancreatic malignancies 
while cystic neoplasms, acinar carcinomas, and islet cell endocrine tumors are 
less frequent (Bardeesy and DePinho 2002).  Symptoms of PDAC are non 
specific including lower back pain, weight loss, fatigue, and, in instances where 
the tumor compresses the bile duct, jaundice (Livstone E.P. 2014).  The central 
abdominal position of the pancreas, dorsal to the liver and ventral to the kidneys, 
likely contributes to this lack of specific symptoms; diagnosis is difficult and 
usually requires expensive and invasive techniques such as contrast-enhanced 
computed tomography (CT) scan and endoscopic ultrasound with needle biopsy.  
At the time of diagnosis over half of patients with PDAC have distant metastases 
and only 9% have localized disease; the majority of pancreatic tumors detected 
at an early stage are identified during imaging for unrelated pathologies (Siegel, 
Miller et al. 2015).  Patients with regional or distant metastases have 10% and 
2% 5-year survival rates respectively. Individuals diagnosed with localized 
disease are eligible for potentially curative surgery and their 5-year survival 
increases to 25%(Siegel, Miller et al. 2015). Although the lifetime risk for 
developing PDAC is approximately 1.5% (SEER, 2015), only 1 in 8000 
(
individuals will be diagnosed in a given year (Siegel, Miller et al. 2015).  The low 
incidence in the general population, coupled with the expensive and invasive 
nature of tests used to confirm the diagnosis, demands that any widely used 
screening technology be highly sensitive with a very low false positive rate.  For 
individuals known to be at high risk for developing PDAC, the carbohydrate 
antigen 19-9 is an FDA approved blood biomarker for the disease.  However, the 
specificity (87%), and sensitivity (70%) of these tests are too low to be of value in 
screening the general population (Becker, Hernandez et al. 2014).  The advent of 
newer methods in which circulating tumor cells or circulating tumor exosomes are 
isolated from blood samples via EPCAM or Glypican-1 epitopes may achieve the 
high specificity and sensitivity needed for screening of lower risk populations, but 
these technologies require further development (Yu, Ting et al. 2012, Melo, 
Luecke et al. 2015). 
 
Environmental Risk Factors for PDAC 
Epidemiological studies have identified various risk factors that increase 
the risk of developing PDAC.   Chronic pancreatitis and tobacco use are the most 
common of these environmental risks, with 13-27 and 3.2-4.8 fold increases 
respectively (Talamini, Bassi et al. 1999, Malka, Hammel et al. 2002). The 
increased risk of PDAC from obesity and diabetes are smaller but still significant 
(Lowenfels and Maisonneuve 2006).  Excessive alcohol consumption can cause 
)
pancreatitis and increases the risk of PDAC in that context (Talamini, Bassi et al. 
1999). 
Pancreatitis is an inflammatory response in the pancreas that can be 
either acute or chronic.  The inflammation is associated with upper abdominal 
pain, which is more severe in acute cases.  Acute pancreatitis is, by definition, 
temporary; the inflammatory response resolves and the pancreatic composition 
returns to normal.  Acute acinar cell injury initiates a pro-inflammatory response, 
mediated primarily by lymphocytes and macrophages; this response also 
activates pancreatic stellate cells.  Following an initial phase of inflammation, 
anti-inflammatory cytokines such as interlukin-10 and transforming growth factor 
% are produced, promoting stellate cell production of extracellular matrix proteins.  
Barring further injury or genetic predisposition, acinar tissue will recover to a 
normal state; however, repeated pancreatic injury and recurrent acute 
pancreatitis can maintain the fibrotic response resulting in a chronic pancreatitis 
phenotype (Whitcomb 2003).  Chronic pancreatitis results in fibrosis, which 
permanently alters the makeup of the organ and may result in both exocrine and 
endocrine pancreatic insufficiency (Freedman, S.D. 2012).  While patients with 
acute pancreatitis and chronic pancreatitis both had elevated levels of the 
cytokine interlukin-6 (IL-6), interlukin-12 levels were elevated only in the blood of 
chronic pancreatitis patients.  Furthermore, while T-cell populations in acute 
pancreatitis patients remained mixed, T-helper 1 cells were the predominant 
subtype in patients with chronic pancreatitis (Bhatnagar, Wig et al. 2003). 
*
Any event preventing the efficient drainage of pancreatic ducts, such as 
inflammation-induced pressure on these ducts, presents a risk for premature 
activation of digestive enzymes.  Activation of these enzymes within the 
pancreas evokes a positive feedback loop, cleaving and activating additional 
digestive enzymes, which induce necrotic death of acinar cells and subsequent 
inflammatory responses (Willemer, Kloppel et al. 1989).  Models of pancreatitis 
induced by the cholecystokinin analogue caerulein, showed independent 
activation of both trypsinogen and the inflammatory NF-"B pathway; both 
contributed to necrotic cell death and induction of acute pancreatitis (Han, Ji et 
al. 2001, Dawra, Sah et al. 2011).  While environmental factors such as chronic 
pancreatitis or smoking increase the risk of developing PDAC, many cases 
develop in the absence of these factors.  Although pancreatitis is known to 
increase the risk for developing pancreatic cancer, and accelerates the formation 
of pancreatic cancers in mouse models, the effect of pancreatitis on pancreatic 
cancer outcomes in humans has not been studied.  It is possible that increased 
surveillance of this higher risk population could be used to detect disease at an 
earlier stage and thus improve survival. 
 
 
Hereditary Risk Factors for PDAC 
Roughly 10% of patients who develop PDAC have a genetic 
predisposition to the disease (Sheridan and Downward 2013).  According to the 
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National Familial Pancreas Tumor Registry at Johns Hopkins University 
individuals with family histories that include two or more first degree relatives 
diagnosed with pancreatic cancer, have a 6.8-fold increased risk of developing 
the disease themselves (nfptr.org, 2015). Germ-line mutations and genetic 
syndromes have been identified in roughly 20% of these families (Whitcomb, 
Shelton et al. 2015).  Individuals with Peutz-Jeghers syndrome develop multiple 
hamartomas in their gastrointestinal tracts and present with hyper-pigmentation 
of the lips and hands (Wolfgang, Herman et al. 2013).  This autosomal dominant 
disorder is most often caused by mutations in the serine-threonine-protein kinase 
11/ liver kinase B1 (LKB1) gene, a master regulator of the AMPK serine 
threonine kinase family, and these individuals have a 132-fold increased risk of 
developing PDAC (Hezel and Bardeesy 2008, Wolfgang, Herman et al. 2013).  
Individuals with familial atypical multiple mole melanoma syndrome caused by 
germ line mutations in the CDKN2A tumor suppressor gene have a 38-fold 
increased risk of developing PDAC in addition to a dramatically elevated risk of 
melanoma (Wolfgang, Herman et al. 2013).  Individuals with hereditary 
pancreatitis caused by mutations in either the cationic trypsinogen gene (PRSS1) 
or the serine protease inhibitor gene (SPINK1) have a 58-fold increased risk of 
PDAC (Wolfgang, Herman et al. 2013).  Additionally, germ-line mutations in the 
BRCA2, PALB2, and BRCA1 genes also increase the risk of PDAC, although 
mutations in these DNA damage repair genes are less penetrant than the 
previously discussed syndromes. (Downward 2009, Castellano and Downward 
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2010, Sheridan and Downward 2013).  As is often the case, analysis of 
hereditary mutations that predispose individuals to cancer has helped inform the 
field with regards to sporadic malignancies.  This is highlighted by the frequent 
deletions and mutations of the CDKN2A locus, and less frequent but clinically 
relevant alterations of BRCA2 (7%) and LKB1(5%) in sporadic PDAC (Morran, 
Wu et al. 2014, Waddell, Pajic et al. 2015). 
 
Current Treatments for PDAC 
 Surgical resection is currently the only curative option for PDAC, though 
the surgery, usually a Whipple procedure, carries great risk and is available only 
to the minority of patients diagnosed with localized disease. All patients, whether 
surgical candidates or not, are offered cytotoxic chemotherapy.  The pre-
operative, neo-adjuvant, and post-operative, adjuvant, use of chemotherapeutics 
significantly improves outcomes for patients undergoing surgical resection of 
PDAC, although the disease will recur in the majority of these patients 
(Hattangadi, Hong et al. 2009).  In the absence of surgery, chemotherapy 
provides a palliative benefit and a small but significant increase in survival. Prior 
to 1997 the standard of care was 5 fluoro-uricil (5FU).  The 2’ difluorinated 
deoxycytidine analog gemcitabine provided a minimal 1.2-month increase in 
survival relative to 5FU; however, the drug was well tolerated and 24% of 
patients reported a clinical benefit, mainly reduced pain, whereas only 5% of 
patients on 5FU reported a benefit (Burris, Moore et al. 1997).  Gemcitabine 
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became the standard of care for treatment of PDAC in the United States and is 
still widely used in combination therapies.  Recently, FOLFIRINOX, a four drug 
cocktail consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil showed a 
median survival of 11.1 months compared to 6.8 months for patients receiving 
gemcitabine (Conroy, Desseigne et al. 2011)  This drug combination, while the 
most effective to date, is highly toxic and is not well tolerated by many patients 
(Thota, Pauff et al. 2014).  Combined therapy with gemcitabine and nanoparticle 
albumin-bound (nab)-paclitaxel, a less toxic therapy, was approved for first line 
treatment of PDAC in 2013 (Von Hoff, Ervin et al. 2013).  This combination 
therapy provided a median survival roughly 2-months better than gemcitabine 
and due to favorable patient tolerance is becoming the preferred treatment (Von 
Hoff, Ervin et al. 2013).  While these advances in treatment are significant, they 
are far from a cure and represent a relatively modest improvement in PDAC 
treatment relative to the progress that has been made in treating other cancers 
over the last two decades.  The recurrence of resected disease and emergence 
of metastatic lesions in spite of these therapies suggests that these metastatic 
cells possess an intrinsic resistance to cytotoxic therapies.  Identifying and 
targeting signaling pathways essential to the survival of PDAC may provide more 
effective therapeutic options. 
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Diagnosis and Staging of PDAC 
Pancreatic cancer is most often visualized and diagnosed by contrast-
enhanced CT scan, magnetic resonance imaging (MRI), or endoscopic 
ultrasound.  While CT and MRI allow the tumor to be visualized and staged in the 
context of surrounding tissue, endoscopic ultrasound provides the opportunity to 
biopsy the mass, providing tissue for a definitive pathological diagnosis (Hidalgo 
2010, Wolfgang, Herman et al. 2013). PDAC are staged from I-to-IV according to 
the tumor–node–metastasis classification set forth by the American Joint 
Committee on Cancer, which attempts to classify these tumors based on 
resectability (Edge, Byrd et al.  2010).  Stage-Ia and stage-Ib are restricted to the 
pancreas with no involvement of the lymph nodes or metastatic disease.  Stage-
IIa tumors have extended beyond the pancreas, but neither the celiac axis nor 
the superior mesenteric artery are involved.  Stage-IIb includes any tumor without 
involvement of the celiac axis or the superior mesenteric artery, but with nodal 
involvement.  Stage-I and stage-II tumors are defined as candidates for surgical 
resection (Wolfgang, Herman et al. 2013). Stage-III tumors have involvement of 
either the celiac axis or the superior mesenteric artery and while some are 
classified as borderline resectable, others are locally advanced and are no longer 
surgical candidates.  Any tumor which has metastasized from the pancreas is 
defined as stage-IV, for which surgery is contraindicative (Wolfgang, Herman et 
al. 2013)( AJCC, 2009). 
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The Role of Stromal Tissue in PDAC 
Stromal tissue often makes up the majority of a PDAC tumor’s mass, and 
is comprised of proliferating fibroblast, pancreatic stellate cells, endothelial, and 
immune cells (Feig, Gopinathan et al. 2012).  Pancreatic stellate cells proliferate 
and deposit a dense extracellular matrix (ECM) of fibronectin, and type I and III 
collagen in response to signals from PDAC (Bachem, Schunemann et al. 2005).  
Growth factors and cytokines secreted by immune cells, endothelial cells, and 
tumor cells are held in close proximity to the tumor by the ECM, increasing 
proliferation of both tumor cells and pancreatic stellate cells (Mews, Phillips et al. 
2002, Korc 2007, Feig, Gopinathan et al. 2012). Secretions of pancreatic stellate 
cells have been shown to increase proliferation and migration as well as pro-
oncogenic AKT and ERK signaling in PDAC cell lines (Hwang, Moore et al. 2008, 
Vonlaufen, Joshi et al. 2008). These findings were supported in vivo by an 
orthotropic model in which co-injection of PDAC and pancreatic stellate 
increased tumor progression and metastasis (Hwang, Moore et al. 2008).    
The role of the overall tumor micro-environment is quite nuanced.  In 
addition to proliferative signals, pancreatic stellate cells produce collagen and 
express #-smooth muscle actin (Apte, Park et al. 2004). While high #-smooth 
muscle actin levels correlate with a poor patient prognosis, tumors with high 
collagen levels carry a better prognosis (Erkan, Michalski et al. 2008). The 
importance of stromal tissue in treating PDAC was firmly established in 2009 
when Olive et al. identified a shielding effect of tumor associated pancreatic 
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stromal tissue in a mouse-model of PDAC, and showed that small molecule 
delivery to tumor cells could be dramatically improved through depletion of this 
tissue using a Sonic Hedgehog (SHH) inhibitor (Olive, Jacobetz et al. 2009).   
However, subsequent models using genetic or small molecule disruption of the 
SHH pathway to decrease the stromal component of PDAC resulted in 
accelerated growth of precursor lesions and resulted in more aggressive 
undifferentiated tumors with increased vasculature and metastatic potential (Lee, 
Perera et al. 2014, Rhim, Oberstein et al. 2014).  A popular notion explaining 
these seemingly contradictory roles of the stromal response is that the fibrotic 
deposition of ECM provides a nourishing and protective environment for 
neoplastic cells while at the same time inhibiting angiogenesis and the metastatic 
potential of these tumors.  While inhibition of the SHH pathway in mouse-models 
accelerated tumor growth, the success of combined nab-paclitaxel-gemcitabine 
therapy in humans is attributed to secreted protein acidic and rich in cysteine 
(SPARC) sequestration of paclitaxel in stromal fibroblasts; this results in gradual 
disruption of the ECM and improved delivery of gemcitabine to the tumor cells 
(Rhim, Oberstein et al. 2014, Thota, Pauff et al. 2014).  This suggests that 
cautious targeting of the stromal response in PDAC through additional 
mechanisms may provide therapeutic benefits. 
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Precursor Lesions Giving Rise to PDAC  
PDAC is believed to arise from one of three non-metastatic neoplastic 
lesions, pancreatic intraepithelial neoplasias (PanINs), mucinous cystic 
neoplasms (MCNs), and intraductal papillary mucinous neoplasms (IPMNs) 
(Gomez, Lee et al. 2001, Hezel, Kimmelman et al. 2006, Morris, Wang et al. 
2010).  The best studied and most common precursor lesions, PanINs, arise in 
the smaller caliber ducts (Hruban, Adsay et al. 2001, Morris, Wang et al. 2010).  
These lesions are graded histologically from PanIN-1a to PanIN-3 with increasing 
levels of dysplasia.  While normal pancreatic ducts are characterized by low 
cuboidal cells, PanIN-1a lesions are hyperplastic and contain epithelial cells with 
a high columnar architecture, abundant supranuclear mucin, and basally located 
nuclei lacking atypia (Hruban, Adsay et al. 2001). PanIN-1b lesions have similar 
cellular attributes, and are differentiated by the formation of hyperplastic papillary 
structures.  Lesions that have developed low to moderate levels of nuclear atypia 
are classified as PanIN-2; lesions of this grade tend to have papillary 
architecture, although this is not required.  PanIN-3 lesions are classified as 
carcinoma in situ with advanced nuclear atypia and luminal budding of papillary 
structures (Hruban, Adsay et al. 2001).  Once these neoplastic cells cross the 
basement membrane they become invasive carcinoma (Hanahan and Weinberg 
2011).  Stromal reactivity increases with the progression of PanIN lesions.  This 
is likely a response to the increased dysplasia of the epithelial PanIN cells, but 
this stromal response may also promote PanIN progression and recent work 
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shows IL-6, secreted by stromal macrophages, to be involved in this process 
(Lesina, Kurkowski et al. 2011). 
Surveys of human pancreata show an increased incidence of PanIN 
lesions with age and suggest that sporadic PanIN1a lesions are common in 
adults over age fifty.  These studies also demonstrated an increased prevalence 
of PanIN lesions associated with chronic pancreatitis (60%) and in non-tumor 
pancreas tissue from PDAC patients (82%) relative to normal pancreas (16%) 
(Strobel, Dor et al. 2007).  These findings reveal that early PanINs are not rare in 
the general population and suggest that only a small minority of these lesions will 
progress.  
While MCNs and IPMNs are bona fide precursor lesions (Li, Hu et al. 
2014), they take longer than PanINs to become dysplastic.  Due to their larger 
size they can be identified by imaging, monitored, and removed prior to 
malignancy (Wolfgang, Herman et al. 2013).  IPMN lesions are characterized by 
papillary growth in the main or branch ducts.  Notably, lesions in the branch ducts 
are more likely to become neoplastic and require intervention (Tanaka, Chari et 
al. 2006). Alternatively MCNs tend to occur in small ducts at the tail of the 
pancreas; they are characterized by the involvement of ovarian-like stroma and 
are most common in women of child-bearing age (Tanaka, Chari et al. 2006).  
While pancreatic cysts are common, only 3.4% of the population harbors cystic 
neoplastic precursor lesions (Kimura, Nagai et al. 1995) 
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Genetics of PDAC 
The KRAS Oncogene 
 Among all the genetic changes seen in PDAC, mutations in the Kirsten rat 
sarcoma viral oncogene homolog (KRAS) gene are the most frequent with 
activating mutations being present in greater than 95% of tumors (Kanda, 
Matthaei et al. 2012, Waddell, Pajic et al. 2015). Activating mutations in KRAS 
are also the earliest and most frequent mutation seen in PanIN lesions.  They are 
found in over 90% of micro-dissected human PanIN-1a lesions and in greater 
than 95% of PanIN3 lesions (Kanda, Matthaei et al. 2012, Waddell, Pajic et al. 
2015).  MCNs and IPMNs harbor fewer KRAS mutations than PanIN lesions, 
33% and 81% respectively (Wu, Matthaei et al. 2011).  Given the prevalence of 
activating KRAS mutations in PDAC, studies involving this gene play a central 
role in pancreatic cancer research.  
KRAS is a member of the RAS family of small GTPase proteins, which 
also include NRAS and HRAS.  All three family members are highly homologous 
in their first 168 residues, which contain the switch domains, GTP binding 
domains, and effector binding domains (Prior, Lewis et al. 2012).  They also 
contain a short C-terminal variable domain by which these proteins are localized 
to various membranes within the cell (Wright and Philips 2006).  These proteins 
are signaling molecules and their constitutive activation by point mutations is 
frequently observed in human cancers (Prior, Lewis et al. 2012). RAS proteins 
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with these activating mutations were shown in 1982 to have the potential to 
transform mammalian cells (Der, Krontiris et al. 1982, Parada, Tabin et al. 1982).  
Under normal circumstances KRAS is maintained in a GDP bound state 
and signal transduction is absent.  A guanine exchange factor (GEF) facilitates 
the removal of GDP from an inactive RAS protein, and the subsequent binding of 
a GTP molecule in its place. RAS binding of GDP induces a conformational 
change in the Switch1 (amino acids 30–38) and Switch2  (amino acids 59–67) 
domains of RAS (Jancik, Drabek et al. 2010). In its GTP bound form RAS is a 
signal transducer and activates downstream signaling pathways including but not 
limited to the RAF/MEK/ERK, PI3K/PDK1/AKT, RALGDS/RAL, RAC, and PLC' 
pathways (Gupta, Ramjaun et al. 2007, Young, Lyons et al. 2009). The intrinsic 
GTPase activity of RAS proteins is enhanced by GTPase activating proteins 
(GAPs) which catalyze GTP hydrolysis by up to 105 fold, thus inhibiting RAS 
mediated signaling (Gideon, John et al. 1992). The neurofibromin 1 (NF1) tumor 
suppressor protein acts as a GAP and its loss has been shown to increase KRAS 
signaling (Cichowski and Jacks 2001).  
Point mutations that prevent the hydrolysis of GTP by RAS, thus 
constitutively activating RAS signal transduction, are present in17- 30% of all 
human tumors (Prior, Lewis et al. 2012).  While RAS family members are largely 
homologous, they are not equivalent.  Despite expression of all three RAS 
isoforms in most tissues, preferential mutation of individual isoforms is observed 
in a tumor specific manner.  NRAS mutations are prevalent in skin (16-29%) 
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malignancies and acute myeloid leukemia (AML)(10-15%) while KRAS mutations 
are less common in AML (5%) but frequent in lung (17%), intestinal (20-34%), 
biliary tract (31%) and pancreatic (80-95%) malignancies.  HRAS is most 
commonly mutated in salivary gland and urinary tract tumors (Ball, Yohn et al. 
1994, Renneville, Roumier et al. 2008, Forbes, Bindal et al. 2011, Prior, Lewis et 
al. 2012, Waddell, Pajic et al. 2015).  Ninety-nine percent of RAS activating 
mutations affect 3 codons, Gly-12, Gly-13, and Gln-61 (Prior, Lewis et al. 2012).  
Gln-61 is required to stabilize a water molecule used in GTP hydrolysis while 
Gly-12 and Gly-13 orient the Gln-61 residue and form Vander Waals interactions 
between the RAS-GTP loop and a GAP (Gideon, John et al. 1992, Scheffzek, 
Ahmadian et al. 1997, Jancik, Drabek et al. 2010, Pylayeva-Gupta, Grabocka et 
al. 2011).  All three mutations impair the ability of RAS to hydrolyze GTP, locking 
RAS into its active conformation and activating its effectors (Malumbres and 
Barbacid 2003).  For reasons yet unknown, the vast majority of KRAS mutations 
in PDAC affect the Gly-12 residue (Prior, Lewis et al. 2012).  
Membrane localization of RAS plays an important role in signal 
transduction (Song, Hu et al. 2001).  This localization is mediated by 
posttranslational modifications to their variable c-terminal regions (Hancock, 
Paterson et al. 1990, Jackson, Cochrane et al. 1990).  All RAS family members 
contain a c-terminal CAAX motif (C is cysteine, A is any aliphatic residue, and X 
is any residue).  Prenylation (farnesylation or geranylgeranylation) of the cysteine 
residue by farnesyltransferase or geranylgeranyltransferase provides a 
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hydrophobic anchor allowing the protein to associate with the lipid bi-layer of the 
endoplasmic reticulum (ER) where the Ras-converting enzyme 1 (RCE1) cleaves 
the AAX residues (Wright and Philips 2006).  Unlike HRAS and NRAS, KRAS 
encodes 2 isoforms, KRAS4A and KRAS4B. Alternative splicing of exon 4 
produces distinct variable c-terminal regions and changes the mechanisms by 
which these splice isoforms localize to the membrane (Tsai, Lopes et al. 2015).  
NRAS, HRAS, and KRAS4A have additional cysteine residues in their C-terminal 
region, which allow for palmitoylation in the ER or Golgi and subsequent plasma 
membrane localization (Hancock, Magee et al. 1989, Laude and Prior 2008).  
KRAS4B lacks a palmitoylation site and is localized to the plasma membrane via 
a lysine rich polybasic region (Hancock, Paterson et al. 1990). Notably, KRAS4A 
also contains two smaller polybasic regions and is capable of membrane 
localization independent of palmitoylation (Tsai, Lopes et al. 2015).  These 
posttranslational modifications and localizations play an important role in 
oncogenic RAS signaling. 
 
Loss of Tumor Suppressors in PDAC 
The CDKN2A locus encodes the Inhibitor of CDK4-a (p16INK4A) gene, a 
member of the INK4 family of CDKIs which also includes p15INK4B, p18INK4C, and 
p19INK4D (Roussel 1999).  INK4 proteins inhibit cell cycle progression by 
preventing cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 6 
(CDK6) from binding Cyclin D, thus maintaining active retinoblastoma (RB) and 
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inhibiting the activity of E2F transcription factors (Russo, Tong 1998). 
Homozygous deletion of the CDKN2A locus is frequent in PDACs (Schutte, 
Hruban et al. 1997).  Tumors lacking homozygous deletions often carry 
intragenic mutations, resulting in complete functional loss of p16INK4A in 85% of 
cases.  Epigenetic silencing is also common and overall, as many as 98% of 
PDACs may lack p16INK4A expression. (Rozenblum, Schutte et al. 1997, Schutte, 
Hruban et al. 1997, Waddell, Pajic et al. 2015). The loss of CDKN2A has also 
been identified in PanIN precursor lesions. Deletions in this gene have been 
reported in 11.5% of PanIN1/2 lesions (Kanda, Matthaei et al. 2012), and 
expression of this tumor suppressor was lacking in 30% of PanIN-1a, 26% of 
PanIN-1b, 55% of PanIN-2 and 71% of PanIN3 as measured by immunostaining 
(Wilentz, Geradts et al. 1998). 
In addition to coding for p16INK4A, the CDKN2A locus also encodes the 
Alternative Reading Frame (p14ARF, p19ARF in rodents) protein (Serrano, Hannon 
et al. 1993).  Their transcriptional start sites are separated by 13 kilobases, and 
although exons 2 and 3 overlap, p16INK4A and p14ARF translations occur in 
different reading frames and yield entirely unique proteins (Quelle, Zindy et al. 
1995, Stone, Jiang et al. 1995).  p14ARF is a suppressor of the MDM2 protein and 
thus it functions to activate the tumor suppressor TP53 (Weber, Taylor et al. 
1999).  While deletions of these overlapping transcripts are frequent in PDAC, 
inactivating point mutations disrupting only the p16INK4A encoding transcript have 
also been identified. In contrast mutations specifically targeting the p14ARF 
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protein product have not been identified (Rozenblum, Schutte et al. 1997, 
Schutte, Hruban et al. 1997). This suggests that p16INK4A plays the more 
important role in PDAC.  Despite the lack of p14ARF specific mutations, mouse-
models show cooperation between deficiencies in p16INK4A and TRP53 tumor 
suppressor pathways, indicating that deletion of p14ARF benefits PDAC 
(Bardeesy, Aguirre et al. 2006).  
The CDKN2A and CDKN2B loci encoding p16Ink4A and P15Ink4B 
respectively are separated by only 7,870 base pairs and are co-deleted in 29% of 
PDACs. However, lack of inactivating point mutations in CDKN2B suggest a 
proximal rational for these deletions rather than a tumor suppressive role for 
P15INK4B in PDAC (Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013, Waddell, 
Pajic et al. 2015). 
Inactivation of a second major tumor suppressor gene, TP53 (Trp53 in 
mice), was observed in 50-75% of PDACs (Scarpa, Capelli et al. 1993, 
Rozenblum, Schutte et al. 1997). Loss of this tumor suppressor gene appears to 
occur later in the PanIN to PDAC progression as deletions were not observed in 
PanIN-1 or PaIN-2 lesions, and were found in only 12% of PanIN-3 lesions 
(DiGiuseppe, Hruban et al. 1994).  Regulation of cell cycle arrest or apoptosis in 
response to DNA damage, hypoxia or oncogenic signaling, is coordinated by the 
TP53 transcription factor (Giaccia and Kastan 1998, Hu, Feng et al. 2012).  TP53 
protein function and levels are negatively regulated by the E3 ubiquitin ligase 
MDM2 which binds to and ubiquitinates TP53 resulting in its nuclear export and 
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proteasomal degradation (Roth, Dobbelstein et al. 1998). DNA damage and 
ribosomal stress activate TP53 by inhibition of MDM2 (Hu, Feng et al. 2012). The 
p14ARF protein directly inhibits MDM2 by nucleolar sequestration and inhibition of 
ubiquitin ligase activity, thus activating TP53 (DeGregori, Leone et al. 1997). In 
rat fibroblasts, overexpression of the RB pathway targets E2F1 or E2F2 induced 
expression of p19ARF, but not p16INK4A (DeGregori, Leone et al. 1997).  The 
CDKN1A gene codes the cyclin dependent kinase inhibitor p21CIP. Like p16INK4A, 
p21CIP1 inhibits the function of E2F transcription factors through the RB pathway, 
and is a transcriptional target of the TP53 transcription factor (el-Deiry, Harper et 
al. 1994). This highlights the interconnected nature of the RB and TP53 
pathways; the tumor suppressor pathways most commonly impaired in PDAC 
(Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013). 
 
TGF-! Signaling in PDAC 
  Disruption of the TGF- % signaling pathway is also common in PDAC.  
While TGF-% receptor 1 and 2 (TGFBR1 and TGFBR2) are inactivated through 
deletion or mutation in only 1-7% and 4-7% of PDACs respectively (Cerami, Gao 
et al. 2012, Gao, Aksoy et al. 2013), the downstream SMAD4 protein, also known 
as Deleted in Pancreatic Carcinoma 4, is frequently lost (Hahn, Schutte et al. 
1996, Goggins, Shekher et al. 1998).  Biallelic deletion of SMAD4 is seen in 30% 
of PDAC and an additional 25% of tumors loose expression due to intragenic 
mutations (Hahn, Schutte et al. 1996).  Smad4 loss occurs later in PanIN 
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progression with expression being retained in PanIN-1/2 lesions but lost in 30% 
of PanIN-3 lesions (Wilentz, Iacobuzio-Donahue et al. 2000). 
TGF- % is a well-studied inhibitory cytokine family involved in signaling of 
multiple cell types with tissue specific effects.  Signaling through the TGF- % 
pathway is broadly grouped into TGF- % signaling and bone morphogenic protein 
(BMP) signaling.  Upon binding to ligands such as TGF%1, TGF%2, TGF%3, 
BMP2, BMP4 or BMP7, TGF- % type-1, and 2 receptors form a complex in which 
type-2 receptors phosphorylate type-1 receptors.  The heterodimeric composition 
of these receptor complexes provides ligand specificity, and directs downstream 
signaling (Shi and Massague 2003).  Phosphorylated type-1 receptors signaling 
through the TGF-% arm of this pathway phosphorylate SMAD2 and SMAD3, while 
type-1 receptors signaling through the BMP arm phosphorylate SMAD1, SMAD5, 
and SMAD8 (Shi and Massague 2003).  These receptor-regulated SMAD 
proteins (R-SMAD) are phosphorylated on their C terminal SXS motif causing the 
release of cytosol-sequestering cofactors, and the formation of heterodimers or 
heterotetramers with the SMAD4 protein (Siegel and Massague 2003).  These R-
SMAD-SMAD4 complexes are shuttled to the nucleus, where together with other 
DNA binding cofactors, they selectively bind and regulate hundreds of genes 
including CDKN2A and CDKN2B (Shi and Massague 2003, Siegel and 
Massague 2003). Therefore, loss of SMAD4 inhibits TGF- % signaling through 
both the TGF- % and BMP pathways (Bierie and Moses 2006).  
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Paradoxically, TGF- % ligands are overexpressed in numerous tumor types 
including PDAC (Friess, Yamanaka et al. 1993, Bierie and Moses 2006, Bierie 
and Moses 2006).  While loss of SMAD4, and thus TGF- % signaling, correlates 
with poor surgical outcomes and increased metastasis (Blackford, Serrano et al. 
2009, Iacobuzio-Donahue, Fu et al. 2009), expression of TGF- % ligands also 
correlates with decreased survival (Friess, Yamanaka et al. 1993). These 
contradictory results support a duel role for TGF- % signaling in PDAC. TGF- % 
signals in epithelial tumor cells inhibit the initial formation and early progression 
of neoplasia, while in established disease these same signals shape the stromal 
reaction into an environment favorable for tumor growth and dissemination 
(Bierie and Moses 2006).   
 
Genetics of IPMNs and MCNs 
In addition to PanIN lesions, PDAC may also arise from IPMN and MCN 
precursor lesions.  The early genetic profiles of IPMN and MCN lesions differ 
from those of PanINs, and, consistent with the clonal nature of cancer, these 
genetics are carried into the subset of PDACs arising from these lesions (Kanda, 
Matthaei et al. 2012). Guanine nucleotide binding protein, alpha stimulating 
activity polypeptide 1 (GNAS) encodes the Gs-alpha subunit of heterotrimeric G-
proteins, and activating mutations in codon 201 result in constitutive activation of 
the cAMP pathway. These GNAS mutations are seen in roughly 11% of PanIN 
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lesions but are much more common in IPMNs (66%); they are absent in MCN 
lesions (Wu, Matthaei et al. 2011). Coincident mutations of GNAS and KRAS 
were frequent in IPMN with 51% of these lesions harboring both KRAS and 
GNAS mutations; 96% of IPMNs contained activating mutations in at least one of 
these genes (Wu, Jiao et al. 2011, Wu, Matthaei et al. 2011). Roughly 33% of 
MCN lesions had activating mutations in KRAS, but no GNAS mutations were 
identified (Wu, Jiao et al. 2011, Hosoda, Sasaki et al. 2015)   
The ubiquitin E3 ligase ring finger 43 (RNF43) targets the WNT ligand 
receptor frizzled, and its inactivation has been shown to induce a WNT-
dependent phenotype in PDAC cell lines (Jiang, Hao et al. 2013).  Activation of 
the WNT/%-catenin pathway is common in MCNs (Sano, Driscoll et al. 2014), and 
genetic inactivation or deletion of the RNF43 gene is common in both IPMNs 
(75%) and MCNs(50%) (Wu, Jiao et al. 2011). This gene was mutated in only 7% 
of PanIN lesions (Forbes, Bindal et al. 2011, Wu, Jiao et al. 2011).   Slow 
growing IMPN and MCN lesions, if identified, have the potential to be observed 
and resected prior to malignant progression.  Therefore, understanding the 
genetics of these lesions and how they relate to progression could provide 
invaluable information regarding the necessity of high-risk surgery. 
 
Other Pathways Altered in PDAC 
The prevalence of KRAS mutations and CDKN2A, TP53 and SMAD4 loss 
%)
in PDAC can lead to the false impression that PDAC is genetically 
homogeneous. Recent sequencing efforts have identified hundreds of mutations, 
amplifications and deletions, which provide a layer of variability to the disease.  
Although alterations in any one gene are rare, grouping the proteins affected into 
broad functional categories highlights a number of pathways known to play a role 
in PDAC (Jones, Zhang et al. 2008, Biankin, Waddell et al. 2012).  An example of 
this is seen in the frequent inactivation of the SWI/SNF chromatin-remodeling 
complex, which antagonizes polycomb group complex inhibition of p16INK4A 
expression (Kia, Gorski et al. 2008, Wilson, Wang et al. 2010).  Although genetic 
inactivation of any one component is infrequent, loss of at least one subunit, and 
thus SWI/SNF complex inactivation, was seen in roughly 33% of PDAC (Shain, 
Giacomini et al. 2012).  Further studies identified aberrations in the Robo2/Slit2 
axon guidance pathway, and found that decreased ROBO2 expression 
correlated with worse patient outcomes (Biankin, Waddell et al. 2012).   
While it is clear that alterations in only 4 genes, KRAS, CDKN2A, TP53 
and SMAD4, constitute the core of genetic changes in PDAC, pharmacological 
exploitation of these changes has thus far been unsuccessful.  The newly 
identified layer of genetic diversity presents an opportunity for highly 
personalized therapies.  As a proof of principal, Waddell et al recently published 
a study showing a robust response to platinum based therapies in 4 of 5 of 
patients with BRCA1, BRCA2, or PALB2 deficient PDACs (Waddell, Pajic et al. 
2015).  While previous drug trials often had a few patients with robust responses, 
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we may now be able to mine such studies for clues that will help to replicate 
these “anomalies” in tumors with similar genetic profiles.  
 
Attempts to Pharmacologically Inhibit KRAS 
In 1990, the cysteine residue on which farnesylation occurs was shown to 
be required for the transformative abilities of mutant KRAS (Jackson, Cochrane 
et al. 1990).  Given the interest in RAS as a therapeutic target, a race to develop 
inhibitors of farnesyltransferase ensued.  While preclinical reports of 
farnesyltransferase inhibitors were extraordinary, essentially curing Mouse 
Mammary Tumor Virus-HRAS induced breast and salivary gland tumors, clinical 
trials were a disappointment (Kohl, Omer et al. 1995, Berndt, Hamilton et al. 
2011).  Farnesyltransferase inhibitors provided no survival benefit to patients with 
pancreatic cancer, colorectal cancer or acute myeloid leukemia (Rao, 
Cunningham et al. 2004, Van Cutsem, van de Velde et al. 2004, Harousseau, 
Martinelli et al. 2009).  Subsequent studies showed that while HRAS relies 
exclusively on farnesyltransferase, geranylgeranylation can act as a substitute in 
KRAS and NRAS (Lerner, Zhang et al. 1997, Rowell, Kowalczyk et al. 1997, 
Whyte, Kirschmeier et al. 1997, Sun, Qian et al. 1998).  
Despite the failure of farnesyltransferase inhibitors to provide significant 
benefits in the clinic, some individuals did respond positively.  Neither the clinical 
responses nor the preclinical successes correlated with KRAS status implying 
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that these diseases may be “addicted” to a different protein or proteins that 
depend exclusively on farnesylation (End, Smets et al. 2001, Kurzrock, 
Kantarjian et al. 2003). One such protein that merits mention is RAS homologue 
enriched in brain (RHEB).  A small GTPase, RHEB acts downstream of AKT to 
activate mTOR complex1 (mTORC1), and shows elevated expression in some 
cancers.  Farnesyltransferase inhibition resulted in decreased mTORC1 activity 
and increased apoptosis in breast and ovarian cancer cell lines. These 
phenotypes were reversed upon expression of a mutant RHEB designed to be 
geranylgeranylated (Basso, Mirza et al. 2005).  
 Additional drugs designed to inhibit geranylgeranyltransferase have since 
been developed. One has undergone phase 1 clinical trials yielding stable 
disease in 2 of 9 patients with refractory colon cancer (Berndt, Hamilton et al. 
2011, Holstein and Hohl 2012).   Both farnesyltransferase and 
geranylgeranyltransferase1 inhibitors are highly toxic due to the wide range of 
proteins modified by these enzymes (Lobell, Omer et al. 2001, Cox and Der 
2002). Fears of synergistic toxicity from combination of these inhibitors have 
shifted current enthusiasm towards understanding the downstream effectors of 
activated KRAS.  These downstream effectors contain a plethora of kinase rich 
signaling pathways with vast potential for specific inhibition by small molecules.  
However, they are also riddled with feedback loops and cross talk, making a 
thorough understanding of these pathways essential before targeting them in 
humans. 
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KRAS-driven Signaling Cascades 
 The activation of KRAS results in constitutive signaling through its 
downstream effectors and should make activating mutations in these effectors 
redundant.  The low prevalence of activating mutations in the RAF and PI3K 
effector pathways, such as BRAFV600 and PI3KCAH1047 respectively, suggests 
that they are indeed redundant and that PDAC benefits from activation of multiple 
KRAS effector pathways (Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013).  
Although KRASG12D causes constitutive activation of multiple pathways (Figure 
1.1), the RAF/MEK/ERK, and PI3K/AKT pathways are the best studied and 
arguably the most important in the context of PDAC (Lim, Cho et al. 2005, 
Feldmann, Mishra et al. 2010, Eser, Schnieke et al. 2014). 
 
BRAF Signaling in PDAC 
 BRAF is a member of the RAF family of serine/threonine kinases, which 
also include ARAF, and CRAF.  RAF proteins contain an N-terminal auto-
inhibitory domain, which obscures the catalytic domain of RAF.  This N-terminal 
domain binds to activated RAS, altering the conformation of RAF to make its 
catalytic site accessible (Tran, Wu et al. 2005).  RAS bound BRAF is localized to 
the plasma membrane where it undergoes additional phosphorylation events and 
forms a dimer, primarily with CRAF (Weber, Slupsky et al. 2001). Activated 
BRAF protein phosphorylates and activates MEK1 and MEK2, which 
subsequently phosphorylate and activate ERK1 and ERK2 (Figure 1.1).  The 
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activated ERK proteins translocate to the nucleus where they lead to activation of 
the AP1 transcription factor and subsequent expression of D-type cyclins (Pruitt 
and Der 2001, Downward 2003).  In pancreatic ductal cells BRAF-MEK-ERK 
signaling imparts proliferative and pro-survival cellular responses.  These 
responses are dependent on IGF1R and PI3K signaling (Appleman, Ahronian et 
al. 2012).  While constitutively active KRAS activates the RAF-MEK-ERK 
signaling cascade in the majority of PDACs, BRAFV600 mutations activate this 
pathway in 9 to 37% of tumors without mutant KRAS (Calhoun, Jones et al. 
2003, Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013).  
 
PI3K Signaling in PDAC 
The PI3K signaling pathway also plays a crucial role in human PDAC. 
PI3Ks are lipid kinase heterodimers comprised of catalytic and regulatory 
subunits. Class1 PI3Ks have been implicated in oncogenic transformation (Yuan 
and Cantley 2008). These dimers are composed of a p110#, p110%, or p110& 
catalytic subunit, which bind to a p85 regulatory subunit, or a p110( catalytic 
subunit which binds to either a p110 or a p87 regulatory subunit (Castellano and 
Downward 2011). These heterodimers are activated via receptor tyrosine kinases 
(RTKs) at the plasma membrane (Castellano and Downward 2011). Src 
homology 2 domains on the p85 subunit can interact with the phosphorylated 
kinase directly, via a GRB2-GAB adaptor complex (McGlade, Ellis et al. 1992) or 
via insulin-receptor substrate 1 or 2 (IRS1/2) (Sun, Rothenberg et al. 1991, Araki, 
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Lipes et al. 1994).  Alternatively, RTK bound GRB2 can activate SOS, a GEF 
responsible for RAS activation (Figure 1.1) (Boriack-Sjodin, Margarit et al. 1998).   
Active PI3K converts phosphatidylinositol 4,5- bisphosphate (PIP2) to 
phosphatidylinositol3,4,5-triphosphate (PIP3), which binds pleckstrin homology 
(PH) domains to localize proteins such as AKT and 3-phosphoinositide-
dependent kinase 1 (PDK1) to the plasma membrane, a crucial step in their 
activation (Figure 1.1)(Pearce, Komander et al. 2010, Castellano and Downward 
2011).  The phosphatase and tensing homolog (PTEN) acts contra to PI3K by 
dephosphorylating PIP3, and is widely described as a tumor suppressor.  Low 
PTEN levels in PDAC patient samples correlates with poor outcomes(Morran, 
Wu et al. 2014), and murine models of PTEN-deficient KRAS-driven PDAC 
respond to the mTOR inhibitor rapamycin (Morran, Wu et al. 2014).  
  
Additional RAS effector pathways 
Constitutively activated RAS signaling activates a number of downstream 
pathways in addition to the RAF/MEK/ERK and PI3K/AKT. The Ral, Tiam1/RAC, 
and PLC' pathways are downstream effector pathways of RAS that have been 
implicated in RAS-mediated tumorigenesis (Figure 1.1). In humans the Ras-like 
(Ral) family of GTPases are highly conserved from Caenorhabditis elegans to 
Homo sapiens (Neel, Martin et al. 2011). To enable efficient signal transduction, 
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these GTPases require GEF mediated replacement of RAL bound GDP with 
GTP.  Four of the six RAL specific GEFs , RALGDS and RalGDS-like 1,2, and 3, 
contain highly conserved C-terminal RAS binding domains (Neel, Martin et al. 
2011).  Elevated levels of GTP bound RALA and RALB were observed in human 
PDAC; isoform specific knockdown with shRNA implicated the former in tumor 
growth and the latter in metastasis (Lim, O'Hayer et al. 2006). Like RAS, RAL 
proteins influence multiple downstream pathways including RAC, CDC42 and 
NF"B (Figure 1.1)(Neel, Martin et al. 2011).  RAL binding protein 1 (RALBP1) 
interacts with GTP bound RAL via a RAL binding domain to regulate RALBP1 
cellular localization (Matsubara, Hinoi et al. 1997).  RALBP1 acts as a GAP for 
the Rho family members RAC and Cdc42.  By catalyzing the GTPase activity of 
these family members RALBP1, mediates cytoskeletal organization; by 
regulating RALBP1 localization, RAL regulates the formation of RAC1 mediated 
membrane ruffling and CDC42 mediated filopodia formation (Neel, Martin et al. 
2011).  RAL activity can also influence cell cycle progression by inducing 
transcription of Cyclin D1 in an NF-"B dependent, RALBP1 independent manner 
(Matsubara, Hinoi et al. 1997). 
Ras activity can also regulate RAC1 activation through the T lymphoma 
invasion and metastasis 1 (TIAM1) protein (Figure 1.1).  TIAM1 is a RAC specific 
GEF, which associates with GTP bound RAS via a RAS binding domain and 
increases RAC1-GTP levels (Lambert, Lambert et al. 2002).  RAC1 activation by 
TIAM1 is independent of PI3K activity, and is constitutively activated by mutant 
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RAS (Matsubara, Hinoi et al. 1997, Nimnual, Yatsula et al. 1998, Scita, 
Nordstrom et al. 1999, Lambert, Lambert et al. 2002).    
Direct binding of the C-terminal region of RAC1 with mTOR has led to the 
suggestion that localization of mTORC1 and mTORC2 are mediated by RAC1 
(Saci, Cantley et al. 2011).  The significance of these findings is supported by the 
co-localization of both mTORC1 and mTORC2 components with RAC1 at the 
plasma membrane, the failure of both complexes to properly localize in the 
absence of RAC1, and the down regulation of both mTORC1 and mTORC2 
signaling in the absence of RAC1 (Saci, Cantley et al. 2011).  Notably, these 
effects appeared to be independent of the GDP/GTP binding status of RAC1 
(Saci, Cantley et al. 2011). 
Members of the phospholipase C (PLC) protein family act to hydrolyze 
phosphatidylinositol 4,5 bisphosphate to produce two second-messenger 
molecules, 1,4,5 triphosphate (IP3) and diacylglycerol (DAG) in response to RAS 
activation (Figure 1.1)(Rhee and Bae 1997).  The presence of IP3 results in the 
cytoplasmic release of Ca2+, and DAG is involved in the activation of PKC 
proteins (Reuther and Der 2000).  The PLC' member of this family contains two 
RAS-association domains, which, upon expression of activated HRAS, bound to 
the HRAS and increased PLC' activity (Kelley, Reks et al. 2001).  This activation 
appears to be the result of active RAS localizing PLC' to the plasma membrane 
(Song, Hu et al. 2001).   
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Figure 1.1 Schematic representation of oncogenic KRAS signaling.  
Active receptor tyrosine kinases bind GRB2, which binds and activates SOS.  As 
a guanine exchange factor (GEF), SOS facilitates the removal of GDP and 
binding of a GTP molecule to KRAS, thus activating KRAS.  GAP proteins, such 
as NF1, catalyze hydrolysis of GTP by KRAS; activating mutations in KRAS 
impair GTP hydrolysis constitutively activating the protein.  Active KRAS signals 
through multiple tumorigenic pathways including the PI3K-AKT and RAF-MEK-
ERK pathways which promote proliferation and survival.  KRAS also activates 
the TIAM1 and RALGDS GEFs resulting in RAC and RAL activation respectively 
and promote cell motility and inflammation.  Active RAL binds and localizes 
RALBP1 a GAP that regulates RAC activity.  KRAS also activates PLC' which 
hydrolyzes PIP2 to form IP3 and DAG lipids.  These lipids promote cytoplasmic 
release of Ca2+ and activation of PKC proteins respectively. 
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Receptor Tyrosine Kinase Signaling in PDAC 
Upon ligand interaction with their extracellular regions, the receptor 
tyrosine kinase (RTK) class of trans-membrane signaling molecules homo or 
heterodimerize resulting in conformational changes, post-translational 
modifications, and kinase activity (Lemmon and Schlessinger 2010).  The 
epidermal growth factor receptor (EGFR) and insulin growth factor receptor 
(IGF1R) family members are among these proteins and are known to be involved 
in PDAC development.  High levels of EGFR expression are ubiquitous in PDAC, 
and expression of its family member and occasional heterodimeric partner, ERB-
B2, was elevated in 68% of moderately differentiated PDACs (Korc, 
Chandrasekar et al. 1992).  A canonical view of these RTKs places them 
upstream of KRAS, with GRB2 bound RTKs activating SOS, a RAS activating 
guanine exchange factor (Figure 1.1). In this simplistic model, constitutive KRAS-
activation would make these signals irrelevant.  The mutual exclusivity of EGFR 
and KRAS mutations in non-small cell lung cancers (NSCLCs), the 
contraindication of mutant KRAS to EGFR targeted therapies in NSCLCs, and 
genetic mouse-models of this disease support this pathway model (Shigematsu, 
Takahashi et al. 2005, Amado, Wolf et al. 2008, Karapetis, Khambata-Ford et al. 
2008). In PDAC however, KRAS mutations are found in concert with EGFR 
overexpression (Korc, Chandrasekar et al. 1992), amplifications (2%) (Biankin, 
Waddell et al. 2012), and activating mutations (4%) (Kwak, Jankowski et al. 
2006, Cerami, Gao et al. 2012, Gao, Aksoy et al. 2013).  Mouse-models also 
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show that EGFR signaling is essential for KRAS-driven PDAC initiation, contrary 
to the canonical view from lung cancer (Navas, Hernandez-Porras et al. 2012).  
Indeed, erlotinib combined with gemcitabine provided a small but significant 
increase in survival for patients suffering from PDAC and is the first molecular 
targeted therapy to do so (Moore, Goldstein et al. 2007).  Furthermore, work by 
Appleman et al. showed signaling through the RAF-MEK-ERK pathway activated 
IGF1R signaling which was required for subsequent activation of the PI3K 
pathway (Appleman, Ahronian et al. 2012). These studies have led to a much 
greater appreciation for the non-linear and complex roles RTK signaling plays in 
PDAC. 
 
The mTOR Kinase Complexes 
The mammalian target of rapamycin (mTOR) kinase acts both upstream 
and downstream of the PI3K-AKT signaling pathway.  It regulates growth, 
proliferation and survival in response to nutrient availability and growth factor 
signaling (Sengupta, Peterson et al. 2010, Zoncu, Efeyan et al. 2011).  The 
mTOR kinase protein is the catalytic subunit in two distinct complexes.  Both 
mTOR complex1 (mTORC1) and mTOR complex2 (mTORC2) contain the DEP 
domain-containing mTOR-interacting protein (DEPTOR) and mammalian lethal 
with SEC13 protein 8 (mLST8 also known as GBL) in addition to the mTOR 
kinase (Figure 1.2).   The Regulatory-associated protein of mTOR (RAPTOR) 
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and 40-kDa pro-rich AKT-substrate (PRAS40) are unique to mTORC1, while the 
rapamycin-insensitive companion of mTOR (RICTOR), the protein observed with 
RICTOR (PROTOR), and the mammalian stress-activated map kinase-
interacting protein 1 (mSIN1 also known as MAPKAP1) are all specific to 
mTORC2 (Figure 1.2) (Loewith, Jacinto et al. 2002, Jacinto, Loewith et al. 2004, 
Sarbassov, Ali et al. 2004, Frias, Thoreen et al. 2006, Jacinto, Facchinetti et al. 
2006, Yang, Inoki et al. 2006, Pearce, Huang et al. 2007, Thedieck, Polak et al. 
2007, Woo, Kim et al. 2007, Peterson, Laplante et al. 2009).  mTOR kinase 
phosphorylates members of the AGC kinase family, including AKT, SGK and 
S6K, at a hydrophobic motif (Figure 1.2) (F-X-X-F/Y-S/T-F/Y) adjacent to the 
kinase domain (Huang, Wu et al. 2009). Growth of mice lacking mTORC1 is 
arrested at embryonic day 5.5 and while some embryos are able to implant, they 
cannot proliferate and die at or shortly after embryonic day 6.5 (Gangloff, Mueller 
et al. 2004, Guertin, Stevens et al. 2006).  In the absence of mTORC2 signaling 
mice die by embryonic day 10.5 (Guertin, Stevens et al. 2006, Shiota, Woo et al. 
2006). 
 
mTOR Complex 1 Signaling 
 Signaling through mTORC1 provides a single hub through which cells can 
respond to growth signals, nutrient, and oxygen levels to influence cellular 
responses including protein synthesis, lipid metabolism, and autophagy (Hung, 
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Garcia-Haro et al. 2012).  Regulation of protein synthesis is largely accomplished 
by mTORC1 phosphorylation of S6K and 4EBP1 proteins.  Phosphorylation of 
the hydrophobic motif of S6K at the threonine 389 residue results in activation of 
numerous proteins responsible for mRNA maturation and protein translation (Ma 
and Blenis 2009).  In addition mTORC1 phosphorylates the eukaryotic translation 
initiation factor 4E (eIF4E) inhibitory protein, eiF4E binding protein 1 (4EBP1) at 
multiple sites, decreasing the affinity of these two proteins, and freeing the eIF4E 
protein to initiate cap-dependent translation (Figure 1.2)(Ma and Blenis 2009).  
The sterol regulatory element-binding protein (SREBP) family of transcription 
factors control expression of multiple fatty acid and cholesterol biogenesis genes 
(Horton, Goldstein et al. 2002).  Activity of these proteins is inhibited by nuclear 
LIPIN 1, and phosphorylation of LIPIN 1 by mTORC restricts its access to the 
nucleus, allowing SREBP1 mediated expression of fatty acid and cholesterol 
biosynthetic programs (Figure 1.2)(Peterson, Sengupta et al. 2011). Inhibition of 
autophagy by mTORC 1 is achieved by direct phosphorylation of the unc-51 like 
autophagy activating kinase 1 (ULK1) and autophagy related 13 (ATG13) 
members of the ULK complex (Figure 1.2).   In a nutrient sufficient setting, 
mTORC1 phosphorylation of these proteins inhibits the induction of autophagy 
(Shang, Chen et al. 2011).   Through these pathways mTORC1 allows cells to 
regulate their biosynthetic processes, building when materials are plentiful, and 
recycling through autophagy when resources are scarce. 
mTORC1 activity is modulated by intracellular energy levels and amino 
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acid availability.  In a glucose deficient environment, adenosine triphosphate 
(ATP) levels decrease and adenosine monophosphate (AMP) levels increase.  
Increased AMP activates AMPKinase, which directly phosphorylates and 
activates tuberous sclerosis complex 2 (TSC2) (Inoki, Li et al. 2002).  TSC2 and 
its binding partner tuberous sclerosis complex 1 (TSC1) inhibits the small 
GTPase Ras Homolog Enriched In Brain (RHEB) by acting as a GAP protein to 
promote hydrolysis of RHEB-bound GTP (Manning and Cantley 2007).  Active 
RHEB is a potent activator of mTORC1, and TSC1/2 deactivation of RHEB 
results in mTORC1 inhibition (Figure 1.2)(Inoki, Li et al. 2003).  The importance 
of this regulatory mechanism is underscored by apoptosis of TSC2-/- cells upon 
glucose starvation (Inoki, Zhu et al. 2003).  TSC2 deletion uncouples cell growth 
from resource availability placing cells in crisis.  While some details remain 
unresolved, the depletion of ATP likely leads to increased AMPK mediated TP53 
stabilization.  In addition, hyper-activation of mTORC1 and its subsequent 
activation and stabilization of S6K and GRB10 respectively, results in the 
inhibition of IRS1 and mTORC2, decreasing PI3K/AKT survival signals and 
promoting cell death (Hsu, Kang et al. 2011, Zoncu, Efeyan et al. 2011, Hung, 
Garcia-Haro et al. 2012)  AMP kinase can also phosphorylate the mTORC1 
subunit RAPTOR; this phosphorylation of RAPTOR inhibits mTORC1 activity 
(Gwinn, Shackelford et al. 2008). 
mTORC1 activity is also responsive to amino acid availability.  Although 
cells require RHEB for amino acid induced mTORC1 activation, TSC2-deficient 
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cells remain sensitive to amino acid depletion, indicating that the mTORC1 
response to amino acid levels is TSC1/2 independent (Smith, Finn et al. 2005).  
In the presence of lysosomal amino acids, RAG GTPase, tethered to the 
lysosome by RAGULATOR, binds to and recruits mTORC1 to the lysosome 
(Kim, Goraksha-Hicks et al. 2008, Sancak, Peterson et al. 2008, Sancak, Bar-
Peled et al. 2010).  This is presumed to bring mTORC1 into proximity with RHEB 
proteins residing on the lysosome to allow for mTORC1 activation (Hung, Garcia-
Haro et al. 2012) 
 
mTOR Complex 2 Signaling  
mTORC2 was identified well after mTORC1 and comparatively little is 
known about this complex. In vitro stimulation with insulin or insulin-like growth 
factor 1 increases mTORC2 kinase activity, and this activity has been shown to 
induce hydrophobic motif phosphorylation of AKT at the serine 473 residue, and 
SGK at the serine 422 residue as well as some members of the PKC family, 
including PKC# (Figure 1.2)(Sarbassov, Ali et al. 2004, Sarbassov, Guertin et al. 
2005, Frias, Thoreen et al. 2006, Jacinto, Facchinetti et al. 2006, Garcia-Martinez 
and Alessi 2008) In addition, mTORC2-dependent phosphorylation of turn motifs 
has also been identified in AKT and PKC family members (Figure 1.2) 
(Facchinetti, Ouyang et al. 2008, Ikenoue, Inoki et al. 2008). 
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Cellular location of mTORC2 likely modulates its activity.  It has been 
reported that prostate epithelial cells lacking PTEN have increased localization of 
RICTOR to the plasma membrane (Guertin, Stevens et al. 2009). However, 
fractionation of cell lines derived from lung carcinoma and melanoma identified 
the endoplasmic reticulum as the primary site of the mTORC2 components 
RICTOR, mSIN1 and mTOR.  While mTORC2 activity in the plasma membrane 
fraction required insulin-like growth factor stimulation, mTORC2 activity the ER 
and cytoplasm was not altered by this growth factor (Boulbes, Shaiken et al. 
2011).  Further studies have shown that mTORC2 localizes to the mitochondria-
associated sub-compartment of the endoplasmic reticulum in a growth factor 
dependent manner and mediates mitochondrial integrity via AKT activity (Betz, 
Stracka et al. 2013).  The discovery of a pleckstrin homology like domain in mSIN 
suggested a possible mechanism for membrane localization via PtdIns(3,4,5)P3  
(Schroder, Buck et al. 2007).  Recent findings showed that the PH domain of 
mSIN inhibits mTOR catalytic activity in mTORC2.  This inhibition is removed 
upon PIP3 - PH domain interaction (Liu, Gan et al. 2015).  An additional level of 
regulation may be afforded by S6K phosphorylation of RICTOR, which creates a 
14-3-3 binding site, and appears to regulate AKTS473 phosphorylation but not 
phosphorylation of SGK or PKC# (Dibble, Asara et al. 2009). 
The TSC1/2 complex responsible for inhibiting mTORC1 may also 
promote mTORC2 activity independent of mTORC1 inhibitory feedback (Huang 
and Manning 2008).  These findings are supported by a decrease in mTORC2 
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signaling in the absence of TSC1/2 that is not reversed by mTORC1 inhibition 
(Huang and Manning 2008).  Furthermore, altering RHEB expression levels 
caused no change in mTORC2 activity levels (Yang, Inoki et al. 2006, Huang and 
Manning 2008, Sancak, Peterson et al. 2008).   
Transcriptional regulation of mTORC2 subunits is also likely to regulate 
mTORC2 levels, and thus its activity.  The AKT target FOXO1 can induce 
expression of Rictor mRNA and increase its protein levels (Chen, Jeon et al. 
2010).  Regulation of RICTOR and mSIN1 through expression and post-
translational modification likely provide a series of regulatory mechanisms by 
which mTORC2 activity is regulated independently of its mTOR subunit.  While 
an understanding of mTORC2 regulation is still emerging, it is clear that activity 
of this complex plays a role in activating the AKT, SGK and PKC signaling 
pathways.  
 
Activation and Effects of the AKT Kinase Family 
The AKT signaling pathway is one of the most studied pathways in cancer.  
The three AKT kinase family members, AKT1, AKT2 and AKT3, are involved in 
regulating numerous hallmarks of cancer, including proliferation, survival, and 
metabolism (Gonzalez and McGraw 2009).  The three isoforms are expressed 
from distinct genetic loci but are highly homologous (Hanada, Feng et al. 2004).    
Despite this homology, whole animal knockout of individual isoforms in mice has 
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shown that these proteins are not fully redundant.  Akt1 knockout mice are 
smaller, Akt2 knockout mice develop insulin resistance, and Akt3 knockout mice 
have defects in brain development (Chen, Xu et al. 2001, Cho, Mu et al. 2001, 
Cho, Thorvaldsen et al. 2001, Garofalo, Orena et al. 2003, Tschopp, Yang et al. 
2005).  AKT1 over-expression failed to rescue insulin dependent glucose 
transport in the absence of AKT2 supporting non-redundant roles for each 
isozyme (Bae, Cho et al. 2003).  However, membrane targeted versions of AKT1 
were able to rescue this phenotype (Gonzalez and McGraw 2009) supporting a 
role for subcellular localization of AKT isoforms in their specificity. 
Multiple post-translational modifications are involved in the activation of 
AKT.  Phosphorylation of the turn motif at AKTT450 occurs in an mTORC2-
dependent manner, during or soon after translation, and is believed to stabilize 
phosphorylation of the hydrophobic motif (Facchinetti, Ouyang et al. 2008, 
Ikenoue, Inoki et al. 2008).  In the absence of this phosphorylation, the HSP90 
protein acts as a chaperone to prevent ubiquitin-mediated degradation of the 
AKT protein allowing for the maintenance of AKT protein levels and a basal level 
of signaling even in the absence of mTORC2 (Facchinetti, Ouyang et al. 2008).   
AKT is recruited to the membrane by interaction of its pleckstrin homology (PH) 
domain with PIP3 (Calleja, Alcor et al. 2007).  This interaction also induces a 
conformational change in AKT allowing phosphorylation of the activation motif, at 
the threonine 308 residue, by PDK1 (Alessi, Deak et al. 1997). This level of 
phosphorylation activates AKT signaling (Guertin, Stevens et al. 2006, Jacinto, 
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Facchinetti et al. 2006, Shiota, Woo et al. 2006), however, full activation requires 
phosphorylation of the hydrophobic motif at AKTS473 by mTORC2 (Sarbassov, 
Guertin et al. 2005, Jacinto, Facchinetti et al. 2006).  
AKT activity results in cell survival, cell growth, proliferative, and metabolic 
phenotypes.  AKT mediated phosphorylation of R-X-R-X-X-S/T-B motifs, where B 
is a bulky hydrophobic residue and X is any residue, is context specific and can 
moderate the activity of numerous proteins (Alessi, Caudwell et al. 1996).  
Phosphorylation of pro-apoptotic BCL-2 family members such as BAD on S136 
results in a 14-3-3 protein binding site that removes the inhibitory BAD protein 
from pro-survival BCL-2 family members (Figure 1.2)(Datta, Katsov et al. 2000).  
Nuclear activity of AKT can also regulate cell survival through phosphorylation of 
FOXO family members such as FOXO1 at T24 and S256 (Figure 1.2).  
Phosphorylation of these sites creates a 14-3-3 protein binding site, and such 
binding results in nuclear export of these proteins (Tran, Brunet et al. 2003).  The 
FOXO family of transcription factors induces expression of pro-apoptotic genes 
such as Fas ligands and BIM (Brunet, Bonni et al. 1999, Dijkers, Birkenkamp et 
al. 2002).  MDM2 mediated TP53 degradation is also regulated by AKT; MDM2 is 
localized to the nucleus upon phosphorylation of residues S166 and S186 by 
AKT (Mayo and Donner 2001, Zhou, Liao et al. 2001). Inhibitory AKT 
phosphorylation of Glycogen synthase kinase-3 beta (GSK3%) impacts numerous 
downstream targets including its activation of pro-apoptotic c-Jun N-terminal 
kinase (JNK) signaling and inhibition of the MCL-1, a pro survival BCL-2 family 
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member (Maurer, Charvet et al. 2006, Marchand, Tremblay et al. 2012).  AKT 
can also negatively regulate this pathway by inhibition of apoptosis signal-
regulating kinase 1 (ASK1) upstream of JNK (Kim, Khursigara et al. 2001). 
In addition to restraining apoptotic signaling, AKT can regulate cell cycle 
arrest.  AKT has been shown to phosphorylate human p21CIP1 and p27KIP1 at 
T145 and T157 respectively.  In both cases these modifications result in protein 
localization to the cytoplasm and subsequent loss of their nuclear functions as 
cell cycle inhibitors (Zhou, Liao et al. 2001, Sekimoto, Fukumoto et al. 2004).  
The T157 residue of p27KIP1 is not conserved in mice, however the regulation of 
p27KIP1 by AKT is maintained at a transcriptional level by the inhibition of FOXO 
transcription factors by AKT (Medema, Kops et al. 2000).  Expression of p21CIP1 
may also be regulated by AKT driven inactivation of the TP53 transcription factor 
via MDM2 (Mayo and Donner 2001, Zhou, Liao et al. 2001). 
AKT plays multiple roles in the regulation of metabolism.  As described 
above, the TSC1/TSC2 heterodimer inhibits the potent mTORC1 activating 
protein RHEB.  AKT phosphorylates TSC2 at multiple sites, of which S939 and 
T1462 are evolutionarily conserved through drosophila, and inactivates the 
protein resulting in mTORC1 activation (Figure 1.2) (Inoki et al., 2002; Manning 
et al., 2002; Potter et al., 2002).   A second mechanism for AKT-dependent 
mTORC1 activation is through its inhibition of proline-rich Akt substrate of 40 kDa 
(PRAS40). This protein binds to and negatively regulates mTORC1, but upon 
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AKT phosphorylation at T246, 14-3-3 proteins bind PRAS40, dissociating it from 
mTORC1 and targeting it for degradation (Kovacina, Park et al. 2003, Sancak, 
Thoreen et al. 2007, Vander Haar, Lee et al. 2007).  These parallel pathways 
allow AKT to enhance anabolic processes such as protein synthesis and cap 
dependent mRNA translation through mTORC1 activity.   
Stimulation of glucose uptake in response to insulin is also mediated by 
AKT.  Upon insulin stimulation, AKT, primarily AKT2, associates with glucose 
transporter 4 (GLUT4) containing vesicles and stimulates the translocation of 
GLUT4 to the plasma membrane (Kohn, Summers et al. 1996, Calera, Martinez 
et al. 1998).  Furthermore, insulin stimulated AKT activity can, through mTORC1, 
induce translational expression of Glucose transporter 1 (Taha, Liu et al. 1999).  
In the context of PDAC, KRAS-activation has been shown to enhance glucose 
uptake, glycolysis and ribosome biogenesis; this metabolic shift is essential for 
tumor survival (Ying, Kimmelman et al. 2012).  Despite the multiple mechanisms 
through which AKT impacts cell metabolism, small molecule inhibition of 
PI3K/AKT did not greatly affect KRAS-driven metabolic reprograming in PDAC 
(Ying, Kimmelman et al. 2012).   
The extent to which differential AKT phosphorylation regulates target 
specificity has not been fully defined.  While phosphorylation of some AKT 
targets, such as FoxO1T24 and FoxO3aT32, appears to require AKTS473, other 
pathways, such as mTORC1 activation, do not (Guertin, Stevens et al. 2006, 
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Jacinto, Facchinetti et al. 2006).  The potential for differential signaling based on 
AKT phosphorylation status suggests that blocking AKTS473 phosphorylation may 
inhibit a subset of AKT effectors, while maintaining signaling through other, 
potentially beneficial pathways. 
 
Activation and Effects of the SGK Kinase Family 
 The serum and glucocorticoid-regulated kinase (SGK) family is also 
activated by mTORC2.  It contains three family members; SGK1, and SGK3, 
which are expressed in all tissues, and SGK2, which is expressed specifically in 
the pancreas, liver, and kidneys (Kobayashi, Deak et al. 1999). These proteins 
are involved in the cellular stress response and in parallel to AKT regulation of 
glucose transport, SGK1 regulates sodium, calcium, potassium and chlorine 
channels (Lang and Shumilina 2013).  Most notably, Sgk1-/- mice are unable to 
stem the efflux of Na+ upon dietary restriction of Sodium Chloride (Wulff, Vallon 
et al. 2002).  Unlike AKT proteins, this family of proteins lacks PH domains and 
requires mTORC2 phosphorylation of the hydrophobic motif at SGKS422 as a 
primer for activation (Figure 1.2)(Garcia-Martinez and Alessi 2008). This 
phosphorylated residue of SGK interacts with the PDK1-interacting fragment 
(PIF) pocket of PDK1, stimulating phosphorylation of the SGK activation motif by 
PDK1 and thus activating SGK (Pearce, Komander et al. 2010).  
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The consensus target sequence for phosphorylation by SGK proteins is R-
X-R-X-X-S/T, a motif shared by the AKT family(Kobayashi, Deak et al. 1999).   
Multiple proteins, such as GSK3% and p27KIP1, are phosphorylated by AKT and 
SGK at the same residues (Kobayashi and Cohen 1999, Hong, Larrea et al. 
2008).  Other proteins such as FOXO3a are selectively phosphorylated by AKT 
and SGK at independent residues, although low levels of cross reactivity 
between target residues were observed in the presence of constitutively active 
AKT or SGK proteins (Brunet, Park et al. 2001).  
The N-myc downstream regulated gene (NDRG) family contains 4 
proteins, two of which, NDRG1 and NDRG2, have been identified as targets for 
SGK1 (Murray, Campbell et al. 2004).  Under physiological conditions, these 
proteins are phosphorylated at multiple sites in an SGK1 specific manner (Figure 
1.2) (Murray, Campbell et al. 2004). NDRG1 expression is down regulated by 
MYC and MYCN oncoproteins and is upregulated by numerous stresses 
including hypoxia and oxidative stress (Said, Stein et al. 2009, Cheng, Xie et al. 
2011). Although often referred to as a metastasis suppressor, the effect of 
NDRG1 expression in cancer appears to vary based on malignancy type.  In 
PDAC, NDRG1 levels appear to correlate with improved survival, possibly due to 
reduced metastatic and angiogenic potential (Maruyama, Ono et al. 2006).  
However, in a recent study looking at glioblastoma, NDRG1 expression was 
shown to provide resistance to alkylating chemotherapy in an MGMT-dependent 
manner (Weiler, Blaes et al. 2014).  SGK1 phosphorylation of NDRG1 at T328, 
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S330, and T346 primes this protein for phosphorylation by GSK3% at S342, S352 
and S362 (Murray, Campbell et al. 2004).  The effect of NDRG1 phosphorylation 
is unclear, but phosphorylation of the previously mentioned residues is often 
used as a measure of SGK1 activity.  
 
Activation and Effects of the PKC Kinase Family 
Some members of the protein kinase C (PKC) family are also activated by 
mTORC2 kinase activity.  The PKC family contains three sub categories;  
conventional PKCs include PKC#, PKC% and PKC(, novel PKCs include PKC&, 
PKC', PKC) and PKC*, and atypical PKCs include PKC+ and PKC, (Pearce, 
Komander et al. 2010).  The activation of PKCs requires phosphorylation events 
in the activation domain, the hydrophobic motif, and the turn motif.  These steps 
prime the protein for activation which is achieved by binding of the auto-inhibitory 
N-terminal domains to diacylglycerol and calcium, thus exposing the activation 
domain (Newton 2003).  Although phosphorylation of the hydrophobic and turn 
motifs was originally classified as autophosphorylation, mTORC2 is now known 
to be responsible for phosphorylation of the PKC# hydrophobic motif (S657), and 
turn motif (T638) (Figure 1.2) (Newton 2003, Sarbassov, Ali et al. 2004, Guertin, 
Stevens et al. 2006, Ikenoue, Inoki et al. 2008).  These sites may be 
phosphorylated by mTORC2 in additional PKC family members, however, 
phosphorylation of PKC' and PKC) hydrophobic motifs were insensitive to 
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mTORC2 depletion suggesting that alternative methods exist for activation of 
these sites in other PKC family members(Sarbassov, Ali et al. 2004). 
 Despite extensive study, the role of PKC isozymes in cancer remains 
unclear, as numerous studies have produced conflicting results.  This is not 
unexpected in a large and diverse family of kinases, however disagreement 
exists regarding the oncogenic function of individual isozymes even within the 
same tumor and cell types.  For instance, PKC# activity was shown to both 
enhance and suppress cell line proliferation in colon cancer cell lines (Walsh, 
Woo et al. 2004, Gwak, Jung et al. 2009, Wu, Zhou et al. 2013).  Likewise, PKC+ 
loss both increased and decreased growth of colorectal tumors (Luna-Ulloa, 
Hernandez-Maqueda et al. 2011, Ma, Tao et al. 2013).  PKC& overexpression in 
a pancreatic cancer cell line promoted tumor growth and metastasis upon 
subcutaneous injection of nude mice (Mauro, Grossoni et al. 2010).  The 
prevailing view that PKC proteins have a net oncogenic effect has been revised 
based on two recent studies.  The only phase III trial of a PKC inhibitor showed 
decreased survival in NSCLC patients (Mackay and Twelves 2007).  In addition, 
it was recently determined that the majority of mutations in human PKC isozymes 
resulted in suppression rather than activation of PKC activity.  In fact, some 
mutations were dominant negative while others had no functional impact, but no 
mutations tested increased PKC activity when tested in their respective cell types 
(Antal, Hudson et al. 2015).  These findings suggest that the actual role of PKC 
proteins is tumor suppressive rather than oncogenic. 
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Figure 1.2: Signaling through mTORC1 and mTORC2 in cancer. 
Activation of PI3K by KRAS or IRS mediated receptor tyrosine kinase interaction 
results in PIP2 phosphorylation and produces a PIP3 signaling lipid.  Binding of 
PH domains by PIP3 localizes both PDK1 and mTORC2, via its mSIN1 subunit, 
to the plasma membrane.  PDK1 phosphorylates the activation motif of S6K, 
AKT, SGK and some PKC family members.  mTORC2 phosphorylates the 
hydrophobic motif of SGK and the hydrophobic and turn motifs of AKT and some 
PKC family members.  mTORC1 is activated downstream of mTORC2 in 
response to inhibitory phosphorylation of TSC2 by AKT.  Low cellular ATP levels 
result in elevated AMPK which impairs mTORC1 by activating TSC2 and 
phosphorylating the mTORC1 subunit RAPTOR.  Active mTORC1 
phosphorylates and activates S6K, which phosphorylates and inhibits mSIN1, 
RICTOR and IRS, providing a negative feedback loop. 
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Mouse-models of KRAS Induced PDAC 
The current standard in the field of KRAS initiated PDAC mouse-models 
was first described by Hingorani et al in 2003.  In this study they used mice with 
one wild-type allele of Kras and one mutant allele preceded by a Lox-P flanked 
stop cassette.  Placing a CRE recombinase under either the Pdx1 or the Ptf1a-
promoter resulted in excision of the stop cassette in pancreatic progenitor cells 
beginning at embryonic day 8.5 or 9.5 respectively, and the subsequent 
expression of the mutant Kras allele from its endogenous locus (Offield, Jetton et 
al. 1996, Kawaguchi, Cooper et al. 2002, Hingorani, Petricoin Iii et al. 2003).  
Beginning as early as two weeks of age, these mice develop PanIN lesions that 
mirror human pathology.  These lesions develop into invasive and metastatic 
PDAC over a long latency with about half of these mice developing tumors by 
400 days of age (Tuveson and Hingorani 2005).  Lineage tracing versions of this 
model showed that PanIN lesions can arise from acinar cells through a process 
known as acinar-to-ductal metaplasia (ADM)(Habbe, Shi et al. 2008).  During this 
process acinar cells dedifferentiate, altering their transcriptional program to a 
more embryonic state (Fendrich, Esni et al. 2008).  These primitive pancreatic 
progenitor cells can repopulate exocrine cells in the pancreas, but in the context 
of mutant KRAS they develop into neoplastic duct like lesions (Habbe, Shi et al. 
2008).  Given the success of Hingorani’s model, it was quickly adopted as the 
field standard.  Commonly referred to as LSL-Kras or “KC” mice, they have been 
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combined with many additional genetic models to enhance our understanding of 
PDAC.   
Given the prevalence of CDKN2A, TP53 and SMAD4 loss in human 
PDAC, KC mouse-models deficient in the murine equivalent of these genes were 
developed to better understand their roles in the disease.  Additional deletion of 
the Cdkn2a locus in the KC mouse-model resulted in formation of PanIN lesions 
by 3 weeks of age, and poorly differentiated PDAC by 6 weeks of age.  All mice 
succumbed to disease between 7 and 11 weeks and distant metastases were 
detected in 21% of mice (Aguirre, Bardeesy et al. 2003).  Further efforts to tease 
apart the different roles of p16INK4A and P14ARF contributions to PDAC found that 
KC mice with germ line loss of the p16INK4A Cdkn2a product that retained wild-
type P19ARF, developed ductal adenocarcinoma with sarcomatoid differentiation.  
These tumors developed with an average latency of 18.3 weeks and 33% of 
these tumors were metastatic (Bardeesy, Aguirre et al. 2006). By comparison, 
KC mice developed tumors of similar histology but the latency was 57 weeks and 
67% of animals developed metastatic disease. These studies also showed that 
mice lacking a single allele of Cdkn2a produced tumors with adenocarcinoma 
and sarcomatoid histology in which the remaining copy of Cdkn2a is lost, 
reducing survival of these mice to 34.2 weeks (Bardeesy, Aguirre et al. 2006).  
Additionally, tumor lysates and cell lines from tumors arising in tumor suppressor 
wild-type KC mice lacked expression of both p16INK4A and P19ARF (Bardeesy, 
Aguirre et al. 2006).  These findings suggested that KRAS-activation was not 
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sufficient for PDAC formation and that additional loss of tumor suppressors was 
required.  
Conditional loss of Trp53 in KC mouse-models accelerated disease 
progression to 6.2 weeks (Bardeesy, Aguirre et al. 2006).  Loss of a single Trp53 
allele resulted in adenocarcinoma at a mean age of 21.8 weeks, and these 
tumors were found to have inactivated the second copy of Trp53, mirroring the 
loss of wild-type alleles seen in the KC-Cdkn2a model (Bardeesy, Aguirre et al. 
2006).  A second study using the Trp53R172H allele, which has been shown to 
inactivate wild-type TRP53 as well as display oncogenic gain of functions (de 
Vries, Flores et al. 2002), also showed acceleration of PDAC with mice 
succumbing to the disease around 5 months of age  (Hingorani, Wang et al. 
2005). Although mice with bi-allelic deletion of Trp53 rapidly developed malignant 
disease, they did not develop metastatic disease and showed few sites of micro-
metastasis (Bardeesy, Aguirre et al. 2006). Mice with single copy loss of Trp53 
had a metastasis rate of 33%, and 74% of KC mice with germ line Trp53R172H 
mutations presented with metastatic disease upon necropsy, suggesting that the 
increased latency of these models may afford the opportunity for metastatic 
disease (Hingorani, Wang et al. 2005, Bardeesy, Aguirre et al. 2006). 
Tumors arising in pancreata with heterozygous loss of the Cdkn2a 
p16INK4A transcript and Trp53 frequently developed complete genetic loss of 
Trp53, and decreased or lost their expression of p16INK4A, suggesting that both 
the p16INK4A and TP53 pathways play important roles in the development of 
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KRAS-driven PDAC (Bardeesy, Aguirre et al. 2006).   In KC mice with 
homozygous deletion of Trp53, the subsequent heterozygous or homozygous 
loss of p16INK4A coding Cdkn2a, altered the dominant histology from 
adenocarcinoma, defined as neoplastic ductal epithelial cells in a dense stromal 
deposition, to an anaplastic histology, defined by ductal differentiation with 
detached tumor cells of varying sizes, however the latency of tumor formation 
was not altered (Bardeesy, Aguirre et al. 2006).  This suggests a limitation of the 
KC-Trp53fl/fl model in that further acceleration of tumor growth has proven 
difficult.   
Pancreas specific Smad4 knockout in KC mice also accelerated PDAC 
formation(Bardeesy, Cheng et al. 2006, Izeradjene, Combs et al. 2007, Kojima, 
Vickers et al. 2007). As with other tumor suppressor deficient backgrounds, these 
mice developed rapidly-progressing PanIN lesions(Bardeesy, Cheng et al. 2006, 
Izeradjene, Combs et al. 2007, Kojima, Vickers et al. 2007).  They also formed 
IPMN lesions as identified by positive staining for MUC1, MUC4, and MUC5AC 
indicating that these lesions are similar to “gastric” type human IPMNs 
(Bardeesy, Cheng et al. 2006, Kojima, Vickers et al. 2007) and MCN lesions 
identified by expanded epithelial cysts surrounded by ovarian-like stroma 
(Izeradjene, Combs et al. 2007).  Despite accelerated tumor formation, the 
invariable loss of either TRP53 or p16INK4A expression in tumors derived from a 
KC-Smad4 deficient background suggests that SMAD4 loss is not a sufficient 
second hit for KRAS-driven tumorigenesis (Izeradjene, Combs et al. 2007).  
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Models with conditional deletion of Smad4 and Cdkn2a support this notion by 
further accelerating KRAS-driven tumor development (Bardeesy, Cheng et al. 
2006).  Further mouse studies in which TGF-% receptor 2, an upstream 
component of the TGF-% signaling pathway, was knocked out conditionally in KC 
mice, showed dramatic acceleration of PDAC.  The majority of these mice 
succumbed to the disease between 7 and 10 weeks and mice that lived beyond 
23 weeks developed metastatic lesions in the liver (Ijichi, Chytil et al. 2006).  
These findings not only support an important role for TGF-% signaling, but also fit 
a more general inverse correlation between the aggressiveness of a primary 
tumor and the development of metastatic disease in mouse-models.  This 
highlights a limitation of current mouse-models, that the burden of an aggressive 
primary tumor is often lethal to a mouse, precluding the development of 
metastatic disease so commonly seen in human PDAC.  
Activation of KRAS in the KC models occurs during embryogenesis, but in 
humans, the average age of PDAC onset is 71 years old, and it is presumed to 
arise from somatic mutations occurring in adult cells (Whitcomb, 2015).  To 
address this discrepancy, mouse-models with Elas-tTA/tetO-Cre (Guerra, 
Schuhmacher et al. 2007) have been combined with a conditional LSL-KRASG12V 
strain allowing doxycycline inducible acinar (and centroacinar) specific 
expression of activated KRAS from the endogenous locus.  While these mice 
develop PanINs when KRAS is activated during embryogenesis, delayed KRAS-
activation decreases the efficiency of PanIN formation and progression, a finding 
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confirmed by a Pdx1-CreERT inducible model (Guerra, Schuhmacher et al. 2007, 
Gidekel Friedlander, Chu et al. 2009).  Delaying KRAS-activation until postnatal 
day 60 completely prevented the formation of PanIN lesions in the model 
described by Guerra et al., while KRAS-activation at postnatal day 56 
dramatically reduced the number of PanIN lesions and prevented their 
progression beyond PanIN-1 in the model used by Gidekel et al. (Guerra, 
Schuhmacher et al. 2007, Gidekel Friedlander, Chu et al. 2009).  Chronic 
pancreatitis induced by the cholecystokinin analogue caerulein was sufficient to 
induce ADM, PanIN lesions and PDAC in adult mice with activated KRAS 
(Guerra, Schuhmacher et al. 2007).  
Induction of pancreatitis in with the choleocystokinin analogue caerulein 
also induces rapid and widespread PanIN formation in KC models with 
embryonic activation of KRAS (Lerch and Gorelick 2013).  In the context of a 
KRAS wild-type pancreas, acute pancreatitis results in acinar cell 
dedifferentiation followed by recovery of the acinar tissue; however, in the 
context of activated KRAS caerulein induced acute pancreatitis causes ADM and 
PanIN lesions following KRAS activation in adult mice (Lerch and Gorelick 2013). 
Models of pancreatitis induced by caerulein, show independent activation 
of trypsinogen and the inflammatory NF-"B pathway, and demonstrate that both 
contribute to necrotic cell death and induction of acute pancreatitis (Han, Ji et al. 
2001, Dawra, Sah et al. 2011). Similar models using adult onset KRAS-activation 
found that the inflammatory NF-"B pathway played an important role in KRAS-
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driven ADM and PanIN formation, and maintenance of elevated KRAS activity 
(Daniluk, Liu et al. 2012).   The importance of trans-signaling between myeloid 
cells and PDAC cells through the IL6-signal transducer and activator of 
transcription 3 (STAT3) pathway was determined in the conditional KC model 
and further supports a vital role for inflammation in PanIN progression and PDAC 
development (Lesina, Kurkowski et al. 2011).  Furthermore, work by Bielas et al.  
shows mutation rates are increased roughly 4 fold in inflammatory 
microenvironments relative to normal tissue (Bielas, Loeb et al. 2006).  
Mutational analysis of TP53 in human samples of chronic pancreatitis identified 
an increase in polymorphisms, both silent and deleterious, providing additional 
evidence that chronic pancreatitis can promote genetic instability (Gansauge, 
Schmid et al. 1998).  Therefore, chronic pancreatitis not only provides pro-tumor 
signals, but it increases the rate of mutation within pancreatic cells, increasing 
the risk for the acquisition of oncogenic mutations. 
The requirement for sustained KRAS signaling in PDAC was a long-
standing assumption that has now been confirmed in vivo.  By using a KrasG12D 
transgene under a Tet-O-promoter, and Ptf1a driven CRE mediated activation of 
a reverse tetracycline trans-activator, Collins et al. developed a mouse in which 
pancreas specific expression of KRASG12D  could be turned on by administration 
of doxycycline and expression of KRASG12D  could be ablated by removal of the 
drug.  Concurrent with KRASG12D expression pancreatitis was induced with 
caerulein.  They showed that when oncogenic KRAS signal was eliminated 3-
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weeks after pancreatitis, PanIN lesions reverted to acinar cells.  However, 
removal of mutant KRAS expression following 5 weeks of its expression induced 
apoptosis (Collins, Bednar et al. 2012).  In addition, mono-allelic and bi-allelic 
deletion of Trp53 in tetracycline inducible KRAS models produced PDAC that 
regressed dramatically upon KRAS ablation (Collins, Bednar et al. 2012, Ying, 
Kimmelman et al. 2012).  These experiments show that KRAS-activation is 
responsible not only for initiation of neoplastic lesions, but is required for 
maintenance of both PanINs and PDAC. Subsequent research by Collins et al. 
showed that KRAS is also required for the maintenance of metastatic lesions 
(Collins, Brisset et al. 2012). 
Mouse-models of PDAC have recently begun to illuminate downstream 
pathways required for KRAS-driven initiation and progression of PDAC.  By 
activating and knocking out critical components of KRAS signaling pathways we 
are not only gleaning a better understanding of this disease, but we are 
identifying pathways of potential therapeutic value in this disease.  Two recent 
studies by Collisson and Eser, while contradictory in some respects, highlight the 
power of this approach.   In 2011 Collisson found that conditional activation of 
BRAFV600E in 2 week postnatal pancreata resulted in PanIN development, but 
these lesions did not progress to PDAC.  When combined with mutant Trp53,  
BrafV600E mice developed PDAC at about 6 months of age (Collisson, 
Sadanandam et al. 2011).  Eser et al. did not directly address BRAF in their 
work, however they used a knockout of the related CRAF gene and showed its 
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requirement for non-small cell lung cancer but not PDAC initiation (Eser, Reiff et 
al. 2013). Treatment with the MEK1/2 inhibitor, PD325901, stabilized disease in a 
KRAS mutant, Cdkn2afl/+ orthotropic injection model of PDAC for two weeks 
(Collisson, Trejo et al. 2012).  These studies also investigated the role of the 
PI3K pathway.  Eser showed that activating mutations in the p110# subunit of 
PI3K were sufficient to induce acinar-to-ductal metaplasia, PanIN lesions and 
PDAC in a wild-type KRAS background (Eser, Reiff et al. 2013).  Deletion of the 
p110# subunit of PI3K, but not the p110% subunit, was subsequently shown to 
block KRAS-driven PanIN formation even in the context of caerulein-induced 
pancreatitis (Baer, Cintas et al. 2014). The prominence of this pathway in PDAC 
was further supported by data showing that PDK1 is required for KRAS-driven 
PDAC in mice(Eser, Reiff et al. 2013). Conflicting results published by Collisson 
et al. showed the same p110 alpha mutation to be insufficient for PanIN or PDAC 
formation (Collisson, Trejo et al. 2012). This discrepancy may be explained by 
Collisson’s use of a tamoxifen inducible PDX1-Cre ER system and activation PI3K 
at postnatal day 14 while Eser used a Ptf1a-Cre system in which Cre was 
activated in pancreatic precursor cells at embryonic day 9.5.  Temporal 
differences in CRE activation as well as changes in the cell types expressing 
CRE may account for this difference.  Collinsson et al. did not address the 
requirement of p110 alpha in KRAS-driven PDAC (Collisson, Trejo et al. 2012).   
The use of small molecule inhibitors of PI3K and MEK inhibitors in mouse-
models of PDAC has provided further insight into the therapeutic potential of 
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targeting these pathways.  Treatment with the pan class I PI3K inhibitor GDC-
0941 stabilized disease in KC-Trp53R172H/fl mice during the two weeks of 
treatment, a finding that was not maintained in non-small cell lung cancer (Eser, 
Reiff et al. 2013).  These findings were supported by data from an additional 
study, which showed a mild increase in survival of KC-Trp53fl/+ mice treated with 
the BMK120 PI3K inhibitor (Alagesan, Contino et al. 2015). This study found that 
dual inhibition of PI3K and MEK significantly delayed the onset of PDAC relative 
to gemcitabine treatment alone (Alagesan, Contino et al. 2015).  A similar set of 
experiments were done in KC-Cdkn2afl/fl mice, and although dual inhibition of 
PI3K and MEK significantly increased survival relative to vehicle treated animals, 
the survival benefit was not significant when the dual inhibition was combined 
with gemcitabine and compared with a gemcitabine treated control arm (Junttila, 
Devasthali et al. 2015).  The difference in responses observed in these studies 
suggests that the tumor suppressor background of individual tumors may dictate 
their responses to targeted therapies. 
The role of the EGFR in the development of PDAC has recently gained 
attention.  As previously mentioned, conditional mouse-models of KRAS-driven 
PDAC lacking EGFR or ADAM17, a sheddase which activates EGFR ligands, 
failed to form tumors or PanIN lesions, while a similar model of NSCLC and 
intestinal carcinomas were unaffected by the status of EGFR (Ardito, Gruner et 
al. 2012, Navas, Hernandez-Porras et al. 2012).  Trp53 deletion allowed the 
development of EGFR-deficient KRAS-driven PanINs and PDAC, while loss of 
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Cdkn2a did not (Navas, Hernandez-Porras et al. 2012).  These data provide 
further support for a differential role of these tumor suppressors in the regulation 
of oncogenic signaling in PDAC.  These findings are also consistent with studies 
showing over expression of EGFR ligands can cause in vivo and in vitro ADM 
and acceleration of KRAS-driven PDAC by the EGFR ligand TGF# (Wagner, 
Greten et al. 2001, Means, Meszoely et al. 2005, Siveke, Einwachter et al. 2007).  
 
A Role for mTORC2 in the Development of PDAC 
Given the importance of the PI3K and AKT signaling pathways in various 
cancers the mTOR inhibitor rapamycin was tested as a targeted therapy and 
tumors with PTEN loss were found to have an increased sensitivity to the drug 
(Morran, Wu et al. 2014).  While rapamycin treatment showed promising results 
in PDAC model systems with enhanced PI3K-AKT activity (Sun, Rosenberg et al. 
2005, Morran, Wu et al. 2014), phase II human trials of two rapamycin analogues 
failed to provide clinical benefit to PDAC patients and were terminated early 
(Javle, Shroff et al. 2010).  One potential explanation for this outcome is a loss of 
negative feedback loops associated with the mTORC1 targets S6K and growth 
factor receptor bound 10 (GRB10) (Yu, Yoon et al. 2011, Soares, Ni et al. 2013).  
Upon mTORC1 down-regulation, S6K mediated IRS1 inhibition is removed 
resulting in amplification of Pi3K-AKT signaling (Sun, Rosenberg et al. 2005, 
O'Reilly, Rojo et al. 2006).  Inhibition of mTORC1 impairs phosphorylation of 
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GRB10, destabilizes this protein, and subsequently increases PI3K and ERK 
signaling (Yu, Yoon et al. 2011).   Loss of the inhibitory phosphorylation of the 
essential mTORC2 component mSIN by either S6K or GRB10 can further amplify 
PI3K-AKT signaling upon mTORC1 inhibition (Liu, Gan et al. 2013). 
A recent mouse model of EGFR driven glioblastoma placed mTORC2 
activation downstream of the tyrosine kinase receptor and found that its 
activation was PTEN-dependent (Tanaka, Babic et al. 2011).  Prior to this, 
mTORC2 signaling was demonstrated to have an essential role in the formation 
of PTEN mutant murine prostate cancers (Guertin, Stevens et al. 2009).  Both 
the EGF and IGF1 receptors play important roles in PDAC, and are upstream of 
mTORC2 signaling, suggesting that mTORC2 may play a role in the pathology of 
this disease.  Both tumor types in which mTORC2 has been shown to play an 
essential role have enhanced PI3K signaling, a pathway that is also essential for 
PDAC (Liu, Gan et al. 2015).  To date, a role for mTORC2 in KRAS-driven 
tumors has not been identified.  This body of work uses multiple in vivo and in 
vitro models to identify and characterize an essential role for mTORC2 signaling 
in the initiation, progression, and maintenance of KRAS-driven PDAC. 
Although the PI3K-AKT-mTOR signaling pathway is altered in roughly 1/3 
of all human cancers (Shaw and Cantley 2006, Akinleye, Avvaru et al. 2013), the 
importance of mTORC2 signaling in oncogenesis is only now coming to light.  
With the advent of whole genome sequencing and copy number variant analysis, 
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recent studies have identified amplifications of mTORC2 subunits.  When 
combined, amplifications in RICTOR, SIN1, DEPTOR, and mTOR genes were 
observed in 28% of human pancreatic cancers (Witkiewicz, McMillan et al. 2015). 
Furthermore, these genes were amplified in 38% of human prostate 
adenocarcinomas (Kumar, Coleman et al. 2016), 23% of invasive lobular breast 
carcinomas (Ciriello, Gatza et al. 2015), 14% of lung adenocarcinomas (Cancer 
Genome Atlas Research 2014), 23% of esophageal carcinomas, and 39% of 
ovarian serous cystadenocarcinoma (These results are based upon data 
generated by the TCGA Research Network: http://cancergenome.nih.gov/). The 
frequent amplification of mTORC2 subunits in multiple human tumor types 
suggests that mTORC2 signaling plays an important role in oncogenic PI3K-AKT 
signaling.  Although the mTORC1 specific component Raptor is amplified in 8% 
of cases it is also deleted in 4% of human PDACs.  Furthermore the mTORC1 
inhibitor TSC2 is amplified in 14% of cases (Witkiewicz, McMillan et al. 2015), 
suggesting that reduction of mTORC1 activity may, in some contexts benefit 
these tumors.  This is consistent with the failure of Rapamycin analogues to 
improve survival in clinical trials of PDAC. 
Recently, a keen interest in developing both isoform specific and pan-PI3K 
inhibitors as therapeutics agents has led to the production and clinical testing of 
many such compounds.  The clinical benefit of this class of drugs has been less 
than ideal, and although many compounds have been shown to effectively inhibit 
PI3K signaling, the few responses recorded have been limited to temporary 
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stabilization of disease rather than regression (Khan, Yap et al. 2013).   Clinical 
attempts to combine various PI3K inhibitors with other kinases inhibitors, such as 
AKT, MEK and mTOR inhibitors, are ongoing.  Although currently available 
mTOR kinase inhibitors target both mTORC1 and 2, no mTORC2 specific 
inhibitors currently exist.  My work demonstrates an important role for mTORC2 
signaling in the initiation of progression of PDACs, and supports the possibility 
that specific inhibition of mTORC2 may be a viable therapeutic strategy by which 
to modulate the PI3K-AKT-mTOR signaling pathway.
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Chapter II: 
mTORC2 signaling is required for pancreatic cancer development and 
progression 
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Abstract 
Pancreatic cancer is a devastating disease with limited therapeutic options. 
Therefore, new strategies are urgently required. mTOR signaling controls several 
critical cellular functions and is deregulated in many cancers including pancreatic 
cancer.  To date, most effort has focused on inhibiting the mTORC1 complex, 
however clinical trials of mTORC1 inhibitors in pancreatic cancer have failed, 
raising questions about this therapeutic approach. Recent publications have 
confirmed that PI3K and PDK1 are essential for PDAC initiation, but the role of 
mTORC2 signaling, which converges with PDK1 signaling, and is required for full 
activation of multiple downstream kinases, has not been studied.  We now use a 
genetic approach to delete the obligate mTORC2 subunit Rictor and identify the 
critical times during tumorigenesis where mTORC2 signaling is important. We 
find that Rictor deletion results in profoundly delayed tumorigenesis. Whereas we 
previously showed that most pancreatic tumors were insensitive to rapamycin, 
we demonstrate that treatment with a dual mTORC1/2 inhibitor strongly 
suppresses tumorigenesis, while in late-stage tumor-bearing mice, combined 
mTORC1/2 and PI3K inhibition significantly increases survival. Thus, targeting 
mTOR may be a potential therapeutic strategy in pancreatic cancer. 
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Statement of Significance 
Novel therapeutic strategies are urgently required in pancreatic cancer.  We now 
identify a key role for mTORC2 signaling in pancreatic cancer and demonstrate a 
novel potential therapeutic strategy for use in this disease. 
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Introduction 
 
Pancreatic Ductal Adenocarcinoma (PDAC) accounts for 85% of all cases of 
pancreatic cancer and is a highly aggressive form of the disease (Ryan, Hong et 
al. 2014). Indeed, PDAC is predicted to become the second leading cause of 
cancer death in the US by 2030 (Rahib, Smith et al. 2014). At diagnosis, the 
disease is characterized by invasion into adjacent anatomic structures and 
distant metastases, features that render > 80% of patients ineligible for tumor 
resection (Ryan, Hong et al. 2014). Even the few patients eligible for potentially 
curative resection inevitably develop recurrent or metastatic disease (Ryan, Hong 
et al. 2014). Indeed recent work has demonstrated that cells in PDAC precursor 
lesions migrate and seed distant sites prior to the presence of overt carcinoma 
(Rhim, Oberstein et al. 2014). Moreover, most systemic therapies are largely 
ineffective, and as a result, PDAC is almost universally lethal, with a 5-year 
survival rate of ~7% (Siegel, Miller et al. 2015). Up until the recent adoption of 
combination chemotherapy regimens - FOLFIRINOX (5-FU, Leucovorin, 
Irinotecan and Oxaliplatin) and gemcitabine combined with albumin-bound 
paclitaxel - gemcitabine monotherapy had been the standard of care for PDAC 
patients since 1997 (Burris, Moore et al. 1997, Conroy, Desseigne et al. 2011, 
Goldstein, El-Maraghi et al. 2015). Yet, median survival with FOLFIRINOX or 
gemcitabine combined with albumin-bound paclitaxel is 11 months and 9 months 
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respectively. Thus, PDAC presents a significant therapeutic challenge and novel, 
effective therapies are required.  
 
The genetic drivers of pancreatic cancer development and progression have 
been well studied. Activating mutations in KRAS occur in around 90% of cases 
and are thought to be the initiating event driving the formation of precursor 
lesions termed pancreatic intraepithelial neoplasia (PanINs) (Almoguera, Shibata 
et al. 1988). Accumulation of further mutations in a number of tumor suppressor 
genes, including CDKN2A, TP53, DPC4 and BRCA2 occurs throughout tumor 
development and progression (Hruban, Wilentz et al. 2000). Moreover, recent 
wide-scale genomic studies have revealed that, in fact, 100s of genetic 
aberrations exist in this pathology (Biankin, Waddell et al. 2012). In addition, 
pancreatic tumors are histologically complex, and interactions between the tumor 
cells and the microenvironment also contribute to tumor progression. Indeed, the 
extensive desmoplastic stroma that characterizes PDAC - consisting of 
pancreatic stellate cells, fibroblasts and immune cells and a dense collagenous 
matrix - may also protect tumor cells from a number of stresses, including 
chemotherapy, although this is somewhat controversial (Olive, Jacobetz et al. 
2009, Lee, Perera et al. 2014, Ozdemir, Pentcheva-Hoang et al. 2014, Rhim, 
Oberstein et al. 2014). Therefore, a greater understanding of the signals that 
drive tumor progression is required to develop more effective drug therapies.  
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Activated KRAS drives a complex signaling network, involving multiple 
downstream effectors, including the MEK/ERK, PI3K/AKT and RAL pathways 
(Baines, Xu et al. 2011). The PI3K pathway regulates a number of processes 
integral to cancer development and progression including cell growth, cell cycle 
entry, cell survival and metabolism (Cully, You et al. 2006). Indeed, PI3K 
signaling has been shown to be a key mediator of the effects of oncogenic KRAS 
in the pancreas (Eser, Reiff et al. 2013). PI3K inhibitors have been developed for 
clinical trials, however, the pathway interacts with many other signals and there 
are several feedback loops making it difficult to predict the effects of suppressing 
the pathway (O'Reilly, Rojo et al. 2006, Rodon, Dienstmann et al. 2013).   
 
One of the major downstream effectors of PI3K signaling is mTOR, a 
serine/threonine kinase that acts as part of two distinct complexes, mTOR 
Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) (Huang and Fingar 
2014). The mTORC1 complex, of which Raptor is an essential subunit, is 
responsible for several well-studied functions of mTOR, including sensing 
nutrient stress and regulating translation through interaction with p70S6K and 
4E-BP1 (Huang and Fingar 2014). p70S6K can also phosphorylate IRS1 on an 
inhibitory serine residue, thus causing a negative feedback loop that inhibits 
insulin and IGF signaling to PI3K and AKT (Zhang, Gao et al. 2008). In addition, 
inhibition of mTORC1 can lead to feedback activation of MEK/ERK signaling 
(Carracedo, Ma et al. 2008).  
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The mTORC2 complex, which includes the essential subunit RICTOR, regulates 
cell growth, metabolism and survival, as well as organization of the actin 
cytoskeleton, through activation of AKT (at Ser473), SGK and PKC (Guertin, 
Stevens et al. 2006, Garcia-Martinez and Alessi 2008). We previously showed 
that high levels of phospho-AKTS473 in human PDAC were significantly 
associated with poor survival (Kennedy, Morton et al. 2011). More recently, 
RICTOR amplifications have been described in human lung cancers and 
melanomas (Cheng, Zou et al. 2015, Laugier, Finet-Benyair et al. 2015). 
However, since the tumor promoting properties of mTORC2 signaling have only 
recently been identified (Guertin, Stevens et al. 2009, Nardella, Carracedo et al. 
2009, Roulin, Cerantola et al. 2010, Gupta, Hau et al. 2013), a full understanding 
of the mechanisms underlying this effect is still developing.  
 
Initial strategies to inhibit mTOR function focused on mTORC1 and the 
development of analogs of the potent mTORC1 inhibitor rapamycin (Nelson, 
Altman et al. 2013). However, clinical trials using these compounds have proved 
disappointing, with the exception of a few rare responders (Klumpen, Queiroz et 
al. 2011). More recently, small molecule inhibitors that block mTOR kinase 
activity, and therefore impair both mTORC1 and mTORC2 have been developed. 
Not only do these inhibitors target both arms of mTOR signaling, they also target 
4E-BP1 phosphorylation, and thus translational initiation, more efficiently than 
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rapalogs, which primarily inhibit S6 kinase (Guertin and Sabatini 2009). We 
recently showed in a PDAC genetically engineered mouse-model (GEMM) that 
mice bearing pancreas-specific mutations in Kras and Pten, a negative regulator 
of PI3K-mTOR signaling, were exquisitely sensitive to rapamycin whereas mice 
wild-type for Pten, but expressing mutant Trp53, were resistant (Morran, Wu et 
al. 2014). These findings suggest that mTORC2 signaling may play a critical role 
downstream of commonly occurring PDAC gene mutations and that inhibition of 
this complex may enhance therapeutic efficacy in PDAC.  
 
Global deletion of Rictor or Raptor in the mouse embryo results in embryonic 
lethality (Guertin, Stevens et al. 2006, Shiota, Woo et al. 2006), however, 
conditional models of Rictor and Raptor deletion are now available, and these 
allow interrogation of tissue-specific roles of mTORC1 and 2 (Shiota, Woo et al. 
2006, Bentzinger, Romanino et al. 2008). We have now utilized pancreas-
specific deletion of Rictor to discern the requirement for mTORC2 signaling 
during pancreatic tumorigenesis. We show that genetic inactivation of mTORC2 
significantly blocks precursor PanIN development, impairs progression to 
invasive carcinoma, and prolongs survival in a PDAC GEMM. Moreover, 
pharmacologic inhibition of mTOR function extends survival, even in mice with 
late stage disease. Our findings demonstrate an important role for mTORC2 
signaling during pancreatic tumorigenesis and support the potential use of mTOR 
inhibitors as part of therapeutic strategies in PDAC.  
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Results 
 
Loss of Rictor does not impair pancreas differentiation and function 
To determine the impact of mTORC2 inactivation on pancreas 
development, we generated mice lacking the essential mTORC2 subunit Rictor, 
specifically within the pancreas, by crossing mice bearing Ptf1a-cre and Rictorflox 
alleles (Kawaguchi, Cooper et al. 2002, Shiota, Woo et al. 2006) (Figure 2.1A). 
The absence of Rictor protein was confirmed by immunoblotting of protein 
lysates isolated from 2-month old pancreata (Figure 2.1B).  Mice lacking 
pancreatic Rictor were viable and showed no difference in body weight relative to 
their wild-type littermates (Figure 2.1C). However, Rictor-null pancreata weighed 
significantly less than Rictor intact pancreata (Figure 2.1D).   Measurement of 
cell size (Figure 2.1E) and quantification of the total amount of genomic DNA as 
a surrogate measurement for cell number (Figure 2.1F), demonstrated that the 
reduced pancreas size likely results from decreased cell numbers. Importantly, 
Rictor deletion did not impair pancreas differentiation as evidenced by histologic 
appearance as well as the relative abundance of acinar, #- and %-cells as 
determined by immunostaining for the markers amylase, glucagon and insulin, 
respectively (Figure 2.2). In combination with the normal weight gain displayed 
by mice with Rictor deleted pancreata, these data demonstrate that mTORC2 
activity is not required for pancreas differentiation and function. 
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Figure 2.1: Pancreatic Loss of Rictor does not impair fitness  
 
(A) Schematic showing the pancreas specific deletion of Rictor. (B) Western blot 
showing Rictor levels in pancreas tissue lysate from 2-month old mice. #-tubulin 
is shown as a loading control. (C) Total mouse weight of 2-month old males of 
the indicated genotypes. (D) Weight of pancreata isolated from 2-month old 
males of the indicated genotypes. (E) Average cell area in pancreatic cross 
section of 2-month old males. (F) Total genomic DNA per pancreas, as an 
estimation of relative cell number, in 2-month old males (n=4 mice per cohort for 
C-F). * p<0.05, ** p<0.01, *** p < 0.001 by student’s t-test. 
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Figure 2.2: Loss of Rictor does not prevent formation or function of the 
pancreas 
 
 H&E staining (top row), IHC for amylase (2nd row) and glucagon (3rd row), and IF 
for insulin (bottom row) in 2-month old males. 
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mTORC2 deficiency impairs development and progression of KRASG12D 
driven PanIN lesions  
Both 3-phosphoinositide-dependent protein kinase 1 (PDK1) and 
mTORC2 are required for full activation of AKT and SGK family members.  PDK1 
is essential for the development of KRAS-driven PanIN lesions and PDAC (Eser, 
Reiff et al. 2013).  We therefore hypothesized that mTORC2 is similarly required 
for KRAS-driven tumorigenesis.  The well-established Ptf1aCre/+; LSL-KrasG12D/+ 
mouse-model develops PanIN lesions that mirror the human lesions and can 
progress to PDAC after a long latency (Hingorani, Petricoin et al. 2003).  To 
investigate the role of mTORC2 signaling in this model, Ptf1aCre/+; LSL-
KRASG12D/+;Rictor+/+ (KC) and Ptf1aCre/+; LSL-KRASG12D/+;Rictorfl/fl (KC-Rictor!/!) 
siblings were produced and their pancreata analyzed at 4 or 8-months of age.  
Consistent with published studies, significant replacement of acinar cells by 
PanIN lesions containing abundant reactive stroma was evident in KC mice at 4-
months of age (Figure 2.3A, B). In contrast, KC-Rictor!/! pancreata displayed 
fewer PanIN lesions and significant retention of acinar tissue (Figure 2.3A, B). 
Moreover, while KC pancreata displayed PanIN1B and PanIN2 lesions, 
precursors lesions observed in KC-Rictor!/! pancreata were restricted to 
PanIN1A. Quadchrome staining, which allows the simultaneous visualization of 
apical mucins produced by PanIN cells and the collagen deposited by the 
reactive stromal cells, highlighted the differences between pancreata of the two 
genotypes (Figure 2.3A).  KC-Rictor!/+ pancreata observed by H+E staining at 4 
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and 8-months of age were phenotypically similar to KC organs of the same age 
(Data not shown).   
Acinar replacement in KC mice was nearly complete by 8-months and 
most PanIN lesions had progressed to PanIN2 (Figure 2.4A, B).  This KRAS-
driven phenotype is significantly impaired in KC-Rictor!/! pancreata, with 
retention of acinar tissue, fewer PanIN lesions and reduced reactive stroma 
(Figure 2.4A, B). Moreover, the PanIN lesions present failed to progress beyond 
PanIN1 (Figure 2.4B).  Together, these data indicate that Rictor deletion impairs 
the development of KRAS-driven PanIN lesions and blocks their progression to 
higher-grade lesions.  
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Figure 2.3: Loss of Rictor impairs the development of KrasG12D driven PanIN 
lesions 
 
Histological evaluation of PanIN lesions in pancreata from 4-month old KC and 
KC-Rictor!/! mice. (A) Representative images from hematoxylin and eosin (H&E) 
stained tissues (25x magnification, top panels; 100x magnification, middle 
panels), and quadchrome stained tissues (simultaneous Alcian Blue and Sirius 
Red staining; 50x magnification, bottom panels) are shown. The quadchrome 
stain marks collagen red, mucin blue, cytoplasm yellow-brown, and nucleic acids 
black. (B) Quantification of normal and neoplastic cell types as a percentage of 
total tissue area in 4-month old KC and KC-Rictor!/! pancreata. p values as 
determined by student’s t test:  *p<0.05,  **p<0.01,  ***p < 0.001. 
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Figure 2.4: Loss of Rictor impairs the progression of KrasG12D driven PanIN 
lesions 
 
Histological evaluation of PanIN lesions in pancreata from 8-month old KC and 
KC-Rictor!/! mice. (A) Representative images from hematoxylin and eosin (H&E) 
stained tissues (25x magnification, top panels; 100x magnification, middle 
panels), and quadchrome stained tissues (simultaneous Alcian Blue and Sirius 
Red staining; 50x magnification, bottom panels) are shown. The quadchrome 
stain marks collagen red, mucin blue, cytoplasm yellow-brown, and nucleic acids 
black. (B) Quantification of normal and neoplastic cell types as a percentage of 
total tissue area in 8-month old KC and KC-Rictor!/! pancreata.  p values as 
determined by student’s t test:  *p<0.05,  **p<0.01. 
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Rictor-null PanIN lesions display impaired mTORC2 signaling 
To determine the status of mTORC2 signaling in PanIN lesions, pancreata from 
8-month old mice were stained for mTORC2 targets.  Relative to PanINs present 
in KC mice, KC-Rictor!/! PanIN lesions displayed significantly reduced mTORC2 
signaling, as measured by phospho-AKTS473 and phospho-NDRG1T346 (Figure 
2.5). The reduced activity was specific to mTORC2 as PDK1-dependent 
phosphorylation of AKT on Thr308 was unaffected, as was phosphorylation of 
the mTORC1 downstream target phospho-S6S235/236, and the MAP kinase 
signaling components ERK1/2 (Figure 2.5). Thus, the PanIN lesions present in 
KC-Rictor!/! pancreata have not escaped Rictor gene deletion and develop in the 
absence of active mTORC2 signaling. 
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Figure 2.5:  mTORC2, but not mTORC1, is functionally absent in KC-
Rictor!/! PanIN lesions 
 
Immunostaining for the phosphorylated forms of AKT, NDRG1, ERK and S6 at 
the indicated epitopes, in pancreata harvested from 8-month old KC and KC-
Rictor!/! mice (200x magnification). 
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Loss of mTORC2 signaling induces proliferative arrest 
The lack of compensatory activation in the PDK1, mTORC1, and MEK signaling 
pathways and the limited progression of KC-Rictor!/! PanIN lesions indicated 
fundamental phenotypic differences between KC and KC-Rictor!/! PanIN lesions. 
We therefore compared the proliferation and apoptosis rates in PanIN lesions 
from the two genotypes. Since comparison of different grade PanINs might 
confound the findings, analysis was restricted to PanIN1 lesions. We observed 
that the percentage of Ki67-positive nuclei in KC-Rictor!/! PanIN1 lesions was 
significantly lower than PanIN1 lesions in KC mice at both 4 and 8-months 
(Figure 2.6A, B). Apoptosis rates, as assessed by cleaved caspase 3 staining, 
were very low in lesions found in both genotypes and not different between the 
groups (Figure 2.6C, D). Together, these data suggest that mTORC2 inactivation 
impairs cell cycle progression in early PanIN lesions.  
 
The cyclin dependent kinase (CDK) inhibitor p16INK4A has been proposed as a 
barrier to KRAS-driven PDAC development (Aguirre, Bardeesy et al. 2003).  We 
therefore assessed p16INK4A expression in KC and KC-Rictor!/! PanIN lesions by 
immunostaining.  We found that the number of cells with nuclear localized 
p16INK4A was significantly increased in KC-Rictor!/! PanIN lesions, relative to KC 
PanINs, at both the 4 and 8-month time points (Figure 2.7A, Figure 2.8A). We 
have shown that the levels of the CDK inhibitor p21CIP1 correlate with survival 
following tumor resection and that heterozygous Cdkn1a deletion accelerates 
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PanIN development and progression to PDAC (Morton, Jamieson et al. 2010). 
We therefore evaluated expression of p21CIP1 and another CDK inhibitor p27KIP1 
in PanIN lesions observed in KC and KC-Rictor!/! mice. The number of p21CIP1 
and p27KIP1-positive nuclei was similar between groups at the 4-month time point 
(Figure 2.7B, C; Figure 2.8B, C). However, we observed that while the number of 
positive nuclei decreased in PanIN lesions in 8-month old KC mice, they 
remained elevated in KC-Rictor!/! PanIN lesions (Figure 2.7B, C; Figure 2.8B, 
C). Thus, KC-Rictor!/! PanIN lesions display coordinate elevation of multiple 
CDK inhibitors. 
 
The concomitant elevation in p16INK4A, p21CIP, and p27KIP1 levels suggested the 
possibility that their expression may be regulated by a common factor. The 
polycomb repressor group complex 1 protein BMI1 is an established negative 
regulator of CDKN2A expression and has been implicated in CDKN1A and 
CDKN1B down-regulation (Jacobs, Kieboom et al. 1999, Zheng, Wang et al. 
2014). Moreover, BMI1 is required for KRAS-driven PanIN formation and 
progression (Bednar, Schofield et al. 2015).  We therefore evaluated BMI1 
expression in KC and KC-Rictor!/! PanIN1 lesions by immunostaining. We found 
that the percentage of cells with nuclear BMI1 staining was decreased in KC-
Rictor!/! PanIN lesions relative to KC controls at both the 4-month and 8-month 
time points (Figure 2.7D, Figure 2.8D). 
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Figure 2.6: Rictor deletion decreases proliferation in PanIN1 lesions  
 
Immunostaining for Ki67 in the pancreata of (A) 4-month old mice and (B) 8-
month old mice of the indicated genotypes. Quantification is shown in the panels 
on the right. Immunostaining for cleaved caspase 3 in the pancreata of (C) 4-
month old mice and (D) 8-month old mice of the indicated genotypes. 
Quantification is shown in the panels on the right. N=4 for each group. * p<0.05, 
** p<0.01 by student’s t-test. 
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Figure 2.7 Rictor-deficient PanIN lesions display increased nuclear 
expression of cyclin-dependent kinase inhibitors and decreased nuclear 
expression of BMI1   
 
(A-D) Quantification of positive nuclei in PanIN1 lesions identified in pancreata 
harvested from 4- (left) and 8- (right) month old KC and KC-Rictor!/! mice and 
stained for (A) p16INK4A, (B) p21CIP1, (C) p27KIP1 and (D) BMI1. *p<0.05,  **p<0.01,  
***p < 0.001 as determined by student’s t-test. 
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Figure 2.8: Rictor deletion alters CDKI and BMI1 expression and 
localization 
 
(A-D) Immunostaining for the CDK inhibitors p16INK4A, p21CIP1 and p27KIP1 and 
BMI1 in the pancreata of 4- and 8-month old KC and KC-Rictor$/$ mice (200x 
magnification).  
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We next sought to model the effect of mTORC2 inhibition in PanIN cells in an in 
vitro system. We performed shRNA-mediated knockdown of Rictor in two primary 
PanIN cell lines, AH2375 and RP2294 established from KC mice with early 
PanIN lesions (Corcoran, Contino et al. 2011). Rictor knockdown significantly 
reduced proliferation in both cell lines and enhanced the expression of the 
senescence-associated beta galactosidase (Figure 2.9A, B; Figure 2.10A). 
However, in contrast to our observations in vivo, we did not observe any changes 
in the expression of the CDK inhibitors p16INK4A, p21CIP1 or p27KIP1, nor did we 
observe changes in BMI1 expression (Figure 2.10B, C). Nonetheless, our data 
suggest that Rictor knockdown impairs PanIN development and progression at 
least in part by robustly blocking cell proliferation.  
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Figure 2.9 Rictor-knockdown impairs proliferation and induces senescence 
in cultured PanIN cells 
 
(A) Doubling time of a PanIN derived cell line 4-6 days following shRNA-
mediated Rictor knockdown. (B) Senescence associated %-galactosidase 
positivity in a PanIN derived cell line 4 days following shRNA-mediated Rictor 
knockdown. P values in (A) determined by counter variance analysis of inverse 
slopes.  P values in (B) determined by student’s t-test.  **p<0.01,  ***p < 0.001. 
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Figure 2.10: Rictor knockdown induces senescence but does not alter CDKI 
or BMI1 levels in cultured PanINs 
 
(A) Staining for senescence associated %-galactosidase activity in the PanIN 
derived cell lines RP 2294 and AH 2375 4 days following Rictor knockdown. (B) 
Western blot for RICTOR, indicated CDKIs, and BMI1 in PanIN derived cell line 
AH 2375 6 days post Rictor knockdown. (C) Quantification of CDKI levels in 
western blots for the proteins shown in (B) (n=4 for each antibody). 
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mTORC2 loss impairs PanIN progression following pancreas injury 
Pancreatitis is a major risk factor for the development of PDAC and can be 
modeled in mice using caerulein-induced pancreatic injury (Lerch and Gorelick 
2013). To determine whether Rictor deletion impacted the response to caerulein-
induced injury we performed serial caerulein injections in 6-week old wild-type 
and Rictor!/! mice. Wild-type and Rictor!/! mice displayed similar responses with 
stereotypical histologic changes - including acinar-to-ductal metaplasia (ADM) 
and increased separation of acinar lobules - evident 2 days following injection 
(Figure 2.11) (Morris, Cano et al. 2010). As expected, injury was fully resolved by 
21 days post-injection (Figure 2.11).  The effect of caerulein insult was not 
investigated in Rictor heterozygous animals.  
 
The expression of activated Kras enhanced the response to caerulein injection, 
with extensive ADM visible 2 days following caerulein treatment (Figure 2.12). 
However, Rictor deletion blunted ADM development (Figure 2.12). Moreover, 
while KC mice evaluated 21 days following caerulein injection displayed 
complete replacement of the pancreas parenchyma with PanIN lesions, many of 
which had progressed to PanIN1B and PanIN2, KC-Rictor!/! pancreata displayed 
significant retention of normal acinar tissue, more areas with ADM and 
significantly fewer PanIN1B and PanIN2 lesions and associated stroma (Figure 
2.12; Figure 2.13).  
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Evaluation of mTORC2 signaling via immunostaining for p-AKTS473 demonstrated 
that mTORC2 activity was impaired in KC-Rictor!/! lesions as compared to KC 
lesions (Figure 2.14). By contrast, p-AKTT308 staining was equivalent between 
both genotypes (Figure 2.14). Intriguingly, we observed that p-ERK staining was 
elevated in KC lesions relative to KC-Rictor!/! lesions, suggesting that mTORC2 
signaling is required for activation of the MEK/ERK signaling cascade following 
caerulein injury-mediated PanIN progression (Figure 2.14). To ascertain whether 
similar mechanisms mediate inhibition of PanIN progression in the caerulein 
injury model, we assessed the presence of nuclear localization of the CDK 
inhibitors p16INK4A, p21CIP1 and p27KIP1. We found that KC-Rictor!/! lesions had 
elevated levels of these markers (Figure 2.15A-C; Figure 2.16A-C). Moreover, 
the CDK inhibitor levels inversely correlated with nuclear BMI1 localization 
(Figure 2.15D; Figure 2.16D). Together, these data suggest that the absence of 
mTORC2 signaling impairs the progression of PanIN lesions following pancreatic 
injury. 
  

,(
Figure 2.12: Rictor deletion impairs the formation of pancreatitis-induced 
PanIN lesions  
 
H&E and quadchrome staining of pancreata from KC and KC-Rictor!/! mice 
harvested 2 or 21 days following injection of caerulein, or PBS as a control (100x 
magnification).  
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Figure 2.13: Rictor deletion impairs the progression of pancreatitis-induced 
PanIN lesions 
 
Quantification of normal and neoplastic cell types as a percentage of total tissue 
area in pancreata harvested from KC and KC-Rictor!/! mice 21 days post 
caerulein injection (n=5-6 mice per cohort). p values as determined by student’s 
t-test:  *p<0.05,  **p<0.01,  ***p < 0.001. 
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Figure 2.14: mTORC2 is functionally absent in pancreatitis-induced KC-
Rictor!/! PanIN lesions  
 
IHC for pAKTS473, pAKTT308, and pERK1/2T202/Y204 in pancreata harvested from 
KC and KC-Rictor!/! mice 21 days post caerulein injection (200x magnification).  
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Figure 2.15: Rictor-deficiency increases the frequency of nuclear cyclin-
dependent kinase inhibitor expression in pancreatitis induced PanIN 
lesions 
 
 Quantification of positive nuclei in PanIN1 lesions identified in pancreata 
harvested from KC and KC-Rictor!/! mice 21 days post caerulein injection. (A) 
p16INK4A, (B) p21Cip, (C) p27KIP1 and (D) BMI1. P values as determined by 
student’s t-test:  *p<0.05,  **p<0.01,  ***p < 0.001. 
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Figure 2.16: Absence of mTORC2 activity increases the nuclear expression 
of CDKIs in PanIN1 lesions driven by KRASG12D and caerulein-induced 
pancreas injury  
 
(A-D) Immunostaining for the CDK inhibitors p16INK4A, p21CIP1 and p27KIP1 and 
BMI1 in the pancreata of KC and KC-Rictor$/$ mice harvested 21 days following 
caerulein injection (200x magnification). 
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Rictor deletion delays tumor formation in KPC mice 
Our data above demonstrated that Rictor gene deletion severely impairs PanIN 
development and progression. To determine whether Rictor deletion inhibits the 
progression from PanIN to PDAC in an aggressive model of pancreatic 
tumorigenesis, we crossed Rictorfl/fl mice with KPC (Pdx1-Cre, LSL-KrasG12D/+, 
LSL-Trp53R172H/+) mice, to generate KPC-Rictor!l! mice. We found that deletion 
of Rictor dramatically delayed tumor formation in the KPC model, with median 
survival almost doubled in KPC-Rictor!l! mice (319 days) compared with KPC-
Rictor+/+ mice (182 days) (Figure 2.17A, B). Further, 8 out of 47 KPC-Rictor!l! 
mice were found to be tumor-free at over 200 days old and were sacrificed due to 
other pathologies. Deletion of one copy of Rictor was insufficient to affect tumor 
development, with median survival unchanged between KPC-Rictor+/+ and KPC-
Rictor!l+ mice (Figure 2.17A, B). Interestingly, we did not observe any apparent 
histological or pathological differences in the tumors that eventually developed in 
the KPC-Rictor!l! mice compared with those in KPC-Rictor+/+ mice. /012234562565"7 8"24624 962 1:240#48 "; (.< 1= !"#>Rictor+/+ 6;"36?2 6;8 %(< 1= !"#$ 
Rictor!l! 6;"36?2 65 5@4 5"34 1= 8465@ AB>#6?C4 D .E-.(&FA 8656 ;15 2@19;FE Using 
RNAscope® we confirmed the absence of Rictor RNA demonstrating that the 
tumors were not derived from cells that failed to delete the Rictor locus (Wang, 
Flanagan et al. 2012) (Figure 2.17C). These findings are supported by in vitro 
observations in murine PDAC cell lines in which Rictor knockdown impairs cell 
-.-
proliferation (Figure 2.18A-B, D-E), and reduces anchorage independent growth 
(Figure 2.18C, F). 
 
We next examined the effects of Rictor deletion on mTOR targets by 
immunohistochemistry. Rictor deletion had no effect on phosphorylation of the 
mTORC1 signaling targets, S6 and 4E-BP1, (Figure 2.17D, left panels) but as 
expected, completely abrogated phosphorylation of the mTORC2 downstream 
specific targets pAKTS473 and pNDRG1 (Figure 2.17D, right panels). Thus, we 
conclude that mTORC2 signaling plays a significant role in pancreatic 
tumorigenesis and that targeting mTORC2 could have therapeutic impact in this 
disease.  
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Figure 2.17: Rictor deletion delays tumor formation in a mouse-model of 
pancreatic cancer  
 
(A) Kaplan-Meier survival analysis showing pancreatic tumor-free survival in 
Pdx1-Cre;KrasG12D/+;Trp53R172H/+ (KPC) mice, Pdx1-Cre;KrasG12D/+; Trp53R172H/+; 
Rictor!/+ (KPC-Rictor!/+ mice), and Pdx1-Cre; KrasG12D/+; Trp53R172H/+; Rictor!/! 
mice (KPC-Rictor!/!). Censor ticks indicate mice sacrificed due to extra-
pancreatic pathologies. (B) Table showing number of mice and median survival 
per cohort. P values calculated by Log Rank test. (C) RNAscope® detecting 
Rictor showing absence of Rictor in tumors from KPC-Rictorfl/fl mice (right) 
compared with KPC mice (left). (D) IHC for downstream mTOR signaling 
pathway components in KPC and KPC-Rictor$/$ tumors as indicated. 
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Figure 2.18: Rictor knockdown impairs the transformed phenotype in 
murine PDAC cells 
 
(A, D) Western blot confirming efficient Rictor knockdown in the 9910#1 (A) and 
906 (D) murine PDAC cell lines. Total ERK protein levels are used as a loading 
control. (B, E) Bar graphs showing the impact of Rictor knockdown on PDAC cell 
proliferation. (C, F) Bar graphs showing the impact of Rictor knockdown on 
anchorage independent growth as measured by soft agar colony formation. * 
p<0.05, ** p<0.01, *** p < 0.001 by student’s t- test. 
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Pharmacological inhibition of mTORC1/2 delays tumor formation in KPC 
mice  
To test this hypothesis we used AZD2014, a dual mTORC1/2 inhibitor recently 
investigated in a phase I clinical trial (Basu, Dean et al. 2015, Guichard, Curwen 
et al. 2015). We previously showed that KPC mice were resistant to treatment 
with rapamycin, and therefore not dependent on mTORC1 signaling to S6 kinase 
(Morran, Wu et al. 2014), however, AZD2014 allowed us to evaluate the impact 
of inhibiting both mTOR signaling complexes using a clinically relevant inhibitor.  
We first tested AZD2014 in vitro using KPC tumor cell lines and showed that 
signaling downstream of both mTORC1 and mTORC2, assessed by 
immunoblotting for pAKTS473, pS6 and p4E-BP1, was effectively inhibited (Figure 
19A). We next treated cohorts of KPC mice from 10 weeks of age with 
gemcitabine, AZD2014 or AZD2014 in combination with gemcitabine. This 
timepoint was selected in order to mimic surgically resectable disease, and to 
exclude tumor-promoting effects that may not be evident when mice with late‐
stage disease are treated (Rhim, Oberstein et al. 2014). In line with previous 
studies, gemcitabine treatment offered negligible benefit compared with 
untreated controls (Figure 2.20A, B). In contrast, AZD2014 treatment significantly 
prolonged survival, although not to the same extent as Rictor deletion. 
Combination of AZD2014 and gemcitabine further prolonged survival, and mice 
treated with this combination had a median survival of 280 days compared with 
147 days for those treated with gemcitabine alone (Figure 2.20A, B). These data 
-.(
were supported by our demonstration that AZD2014 and gemcitabine act 
synergistically to induce death of pancreatic tumor cells in vitro (Figure 2.19B). 
When we assessed inhibition of mTOR targets by IHC we found that 
phosphorylation of both mTORC1 and mTORC2 targets was suppressed, 
although mTORC2 signaling was more efficiently inhibited (Figure 2.20C). Taken 
together, our data show that dual mTORC1/2 inhibition can effectively block 
signaling downstream of mTOR, and may hold promise as a novel therapeutic 
strategy in pancreatic cancer. 
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Figure 2.19: AZD2014 treatment blocks signaling downstream of mTORC1 
and mTORC2 
 
(A) Immunoblots showing levels of pAkt, total Akt, pS6, total S6, p4E-BP1, total 
4E-BP1 and %-actin in 3 KPC cell lines, untreated, or treated with either vehicle, 
or 50nM AZD2014. (B) Cytotoxicity assay in K8484 KPC cells (top panel) and 
MIA PaCa-2 human pancreatic cancer cells treated with gemcitabine (x-axis) and 
AZD2014 (y-axis) for 96 hours. Combenefit software was used to analyze the 
experimental data (left, percentage growth inhibition compared with control), 
generate predicted inhibition data (middle), and compare for each combination 
(right). The greater the difference, the more synergistic the combination (shown 
in cyan and blue). 
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Figure 2.20: Pharmacological inhibition of mTORC1/2 delays tumor 
formation in KPC mice  
 
(A) Kaplan-Meier survival analysis showing pancreatic tumor-free survival in 
untreated KPC mice, and KPC mice treated from 10 weeks of age with the dual 
mTORC1/2 inhibitor (AZD2014), Gemcitabine, or AZD2014 in combination with 
Gemcitabine. Censor ticks indicate mice sacrificed due to extra-pancreatic 
pathologies. (B) Table showing number of mice and median survival per cohort. 
P values calculated by Log Rank test. (C) IHC for downstream mTOR signaling 
pathway components in tumors from AZD2014 treated and untreated KPC mice 
as indicated. 
 
 
-.+
Inhibition of mTORC1/2 prolongs survival in late stage tumors 
To determine the efficacy of mTOR inhibition as a therapeutic strategy, we 
tested the effects of AZD2014 treatment in mice with late stage tumors. We 
monitored KPC mice until they exhibited clinical signs of PDAC, including swollen 
abdomen, loss of body conditioning resembling cachexia, hunching, immobility 
and the presence of a palpable tumor. At this stage mice were randomized onto 
treatment with vehicle, gemcitabine, AZD2014, or AZD2014 combined with 
gemcitabine. We found that survival from the commencement of treatment was 
significantly prolonged by AZD2014 treatment in these mice with late-stage 
tumors (Figure 2.21A). Interestingly, combination of AZD2014 with gemcitabine 
did not further extend survival (Figure 2.21A).  When we assessed inhibition of 
mTOR targets by IHC we found that phosphorylation of downstream targets of 
both mTORC1 (S6, 4E-BP1) and mTORC2 (AKT, NDRG1) was suppressed 
(Figure 2.21B), although again, mTORC2 signaling was more efficiently 
suppressed. Although we saw an impact in a very aggressive late stage model, 
mice still rapidly progressed to end stage disease. Consistent with this, in this 
late setting in vivo we did not observe induction of CDK inhibitors that we 
observed earlier, nor did we observe changes in other potential targets of 
RICTOR such as c-MYC (Guo, Zhou et al. 2012, Kuo, Huang et al. 2015), 
showing that as tumors progress in vivo they become less susceptible to 
mTORC2 inhibition as a single agent. 
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Figure 2.21: Pharmacological inhibition of mTORC1/2 prolongs survival in 
mice with late stage tumors  
 
(A) Kaplan-Meier survival analysis showing survival in KPC mice treated from the 
onset of clinical symptoms with vehicle (cyan line, n = 4), AZD2014 (blue line, n = 
8), or AZD2014 in combination with Gemcitabine (pink line, n = 6). (B) IHC for 
downstream mTOR signaling pathway components in treated and untreated KPC 
tumors as indicated. (C) Kaplan-Meier survival analysis showing survival in KPC 
mice treated from the onset of clinical symptoms with vehicle (cyan line, n = 4), 
AZD2014 (blue line, n = 8), PI3K inhibitor (AZD8186, pink line, n = 4), or 
AZD2014 in combination with AZD8186 (purple line, n = 5). P values calculated 
by Log Rank test. 
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Inhibition of PI3K co-operates with mTORC1/2 inhibition to prolong survival 
in late-stage tumor-bearing mice 
Recent studies have suggested that cancer cells can escape the 
requirement for mTOR through uptake of nutrients via other means (Palm, Park 
et al. 2015). In addition, mTORC1 inhibition results in feedback activation of the 
PI3K/AKT axis (O'Reilly, Rojo et al. 2006). Therefore, we tested whether 
inhibiting PI3K signaling could enhance the chemotherapeutic effects of 
AZD2014.  Previous elegant studies have shown deletion of PI3K# alpha blocked 
tumor formation but not established tumor growth (Eser, Reiff et al. 2013), 
consistent with our findings with Rictor gene deletion. Moreover Rac1 deletion 
strongly suppresses pancreatic carcinogenesis and this was suggested to be 
downstream of PI3K (Heid, Lubeseder-Martellato et al. 2011, Wu, Carpenter et 
al. 2014). Given Rac1 can also modify macropinocytosis (West, Prescott et al. 
2000), inhibiting PI3K may also suppress some of the mechanisms of nutrient 
uptake when mTOR is depleted. Since PI3K% is the primary isoform that links 
PI3K signaling to RAC1 (Fritsch, de Krijger et al. 2013, Yuzugullu, Baitsch et al. 
2015), we combined AZD2014 with a PI3K% kinase inhibitor, AZD8186 (Hancox, 
Cosulich et al. 2015). We first investigated whether AZD2014 and AZD8186 
caused an increased loss of cell viability in KPC tumor cells in vitro (Figure 
2.22A). AZD2014 proved potent in reducing cell viability (as observed previously 
with Rictor knockdown) and combined treatment with AZD8186 (which alone had 
little effect on cell viability) further reduced cell viability (Figure 2.22A). 
---
Interestingly, in this scenario we were able to detect diminished Myc expression 
and p27 upregulation by western in the dual treated cell lines (Figure 2.22B). 
 
Therefore, we decided to investigate the effects of inhibiting mTORC1/2 along 
with PI3K in mice with late stage tumors. As previously, we monitored KPC mice 
until they exhibited symptoms of PDAC and a palpable tumor, and then treated 
with AZD2014 and/or AZD8186. We found that survival was extended by 
AZD2014 and AZD8186 co-treatment relative to treatment with either compound 
alone (Figure 2.21C). Taken together, our data show that Rictor-mediated 
signaling plays a crucial role in pancreatic cancer development and progression. 
Moreover, mTORC2 inhibition, particularly as part of a combinatorial approach, 
potentially represents a new therapeutic strategy for this disease. 
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Figure 2.22: AZD2014 and AZD8186 co-treatment blocks downstream 
mTORC2 targets 
 
(A) Bar chart showing the effects of AZD2014 (500nM) and/or AZD8186 (3µM) 
on proliferation of KPC tumor cells. Results are normalized to DMSO treated 
controls (set at 100%). Bars indicate means of 6 wells per treatment and error 
bars indicate standard deviation, * p<0.05 by student’s t-test (compared with 
AZD2014 alone). (B) Immunoblotting for Rictor, Raptor, pAkt, total Akt, pNDRG1, 
pS6, total S6, p4E-BP1, total 4E-BP1, p27, cMyc and GAPDH in KPC tumor 
cells, untreated, or treated with AZD2014, AZD8186 or AZD2014 and AZD8186 
at the concentrations indicated. 
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Discussion 
 
Pancreatic cancer is an almost universally lethal disease, and better 
understanding of the signaling pathways involved in its development and 
progression is required to develop improved therapeutic options for patients. 
Cytotoxic chemotherapy has limited efficacy in this malignancy, therefore the 
development of targeted therapeutic strategies is an attractive approach. 
Mutation of KRAS is almost universally the driving force in pancreatic tumor 
initiation and progression. Indeed, inducible mouse-models have demonstrated 
that pancreatic tumors retain dependence on activated KRAS signaling (Collins, 
Bednar et al. 2012, Ying, Kimmelman et al. 2012). Past attempts to directly inhibit 
KRAS have failed, however inhibition of key signaling pathways downstream of 
KRAS, particularly as part of combination inhibition strategies may hold promise. 
Prior elegant studies have shown PI3K signaling to be a key mediator of 
oncogenic KRAS in the pancreas (Eser, Reiff et al. 2013). mTOR is one of the 
major effectors downstream of PI3K signaling, however the involvement of 
mTOR signaling in pancreatic tumorigenesis was relatively poorly understood 
until now. Clinical trials aimed at inhibiting mTORC1 have failed, and given the 
high cost of trials and the high attrition rate for most novel putative therapeutic 
agents, a far greater understanding of how signaling through the mTOR-
containing signaling complexes mTORC1 and mTORC2 contributes to pancreatic 
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tumor development and progression is required to develop more effective 
therapeutic strategies for targeting mTOR. 
Here we demonstrate that genetic deletion of the required mTORC2 
complex component, Rictor, strongly suppresses tumor development and 
progression in mouse-models of pancreatic cancer. This anti-tumorigenic effect 
of Rictor deletion was associated with increased expression of cyclin dependent 
kinase inhibitors, which may be a result of a G1 arrest, reduced proliferation, and 
features of senescence in cells in vitro. Our findings are in line with recent 
studies, which have demonstrated a requirement for mTORC2 signaling in tumor 
progression in both prostate cancer (Guertin, Stevens et al. 2009) and melanoma 
(Damsky, Micevic et al. 2015). Importantly, while loss of Rictor significantly 
prolonged tumor latency in KPC mice, tumors were ultimately able to progress, 
and the anti-proliferative signals observed in pre-neoplastic lesions were lost in 
late-stage tumors, perhaps due to loss of TRP53. Indeed, the presence of wild-
type TRP53 has previously been shown to augment the anti-proliferative effects 
of mTOR inhibition (Herzog, Bian et al. 2013). Together, these findings 
suggested that mTORC2 signaling plays an important role during pancreatic 
tumorigenesis. However, it remains possible that mTORC2-independent 
functions of Rictor contribute to the observed phenotypes. Additional studies 
utilizing null alleles for other mTORC2 components would address this issue.  
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Given our prior finding that pharmacologic inhibition of mTORC1 with 
rapamycin analogs failed to demonstrate any therapeutic benefit in the ‘gold-
standard’ KPC mouse-model (Morran, Wu et al. 2014), it was important to 
determine whether simultaneous inhibition of both mTOR signaling complexes is 
an effective strategy. Our data using the mTOR kinase inhibitor AZD2014 
demonstrate that blockade of mTOR signaling impairs the progression to end 
stage disease. Moreover, mTOR inhibition enhanced the benefit of gemcitabine 
in mice with established disease. These findings indicate that targeting mTOR 
may represent a potential treatment strategy in PDAC. The mechanism for this 
cooperation is unclear thus far, however, inhibition of mTOR signaling has been 
shown to reduce expression of the low density lipoprotein receptor (LDLR) (John, 
Paraiso et al. 2012), and LDLR depletion in KPC mice can increase the efficacy 
of gemcitabine in vivo (Guillaumond, Bidaut et al. 2015). 
The dual mTORC1/2 inhibitor, AZD2014, has a number of benefits. 
mTORC2 signaling is almost completely abrogated in tumors from treated mice, 
similar to the effects we observed when Rictor was deleted. Further, it was 
recently reported that mTORC1 inhibition alone can actually enhance 
proliferation of activated KRAS-expressing cells in the setting of amino acid 
deprivation, by increasing the efficiency of utilization of extracellular proteins 
(Palm, Park et al. 2015). Considering that PDAC is characterized by a dense 
extracellular matrix that may provide not only physical, but nutritional support for 
pancreatic tumor cells, it is perhaps not surprising that inhibition of both mTORC1 
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and mTORC2 enhances survival whereas inhibiting mTORC1 alone is not 
efficacious. It should also be noted that in all in vitro systems we found that 
AZD2014 or Rictor knockdown had profound effects on soft agar growth and 
tumor cell proliferation suggesting that the tumor microenvironment might also be 
the source of support for the late stage aggressive tumors. 
 Molecularly targeted therapeutics often fail to display expected anti-tumor 
effects due to drug induced stimulation of feedback mechanisms. Indeed, mTOR 
inhibition has been shown to promote feedback activation of PI3K (O'Reilly, Rojo 
et al. 2006). In turn, PI3K activation can specifically activate mTORC2, through 
release of SIN1 mediated suppression of mTOR by PIP3 binding (Liu, Gan et al. 
2015). Therefore, our finding that combined mTOR and PI3K% inhibition 
prolonged survival in mice with end stage disease provides further support for the 
evaluation of mTOR kinase inhibitors in PDAC where the majority of patients 
present with disseminated disease.   
 
The pathways downstream of mTORC2 signaling may also represent potential 
therapeutic targets. For example, in addition to AKT, mTORC2 signaling also 
regulates SGK1 (Garcia-Martinez and Alessi 2008) and PKC# (Sarbassov, Ali et 
al. 2004). SGK is involved primarily in regulating sodium transport, however, 
increased expression has been observed in several cancer types (Tessier and 
Woodgett 2006), while several cancer cell lines bearing PIK3CA mutations have 
been shown to be dependent on SGK (Vasudevan, Barbie et al. 2009). mTORC2 
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can also regulate PKC# and RAC (Jacinto, Loewith et al. 2004, Sarbassov, Ali et 
al. 2004, He, Li et al. 2013), both of which potentially influence tumorigenesis by 
affecting the spatial control of cell growth.  In fact, RAC1 is reported to play an 
important role in KRAS-driven pancreatic tumorigenesis (Heid, Lubeseder-
Martellato et al. 2011, Wu, Carpenter et al. 2014). MYC is also a reported target 
of mTORC2 (Guo, Zhou et al. 2012, Kuo, Huang et al. 2015), and is regulated at 
the level of translation by mTORC1 (Gera, Mellinghoff et al. 2004).  We recently 
demonstrated that pancreatic tumorigenesis is significantly delayed by Myc 
deficiency (Walz, Lorenzin et al. 2014).  Defining the relative contributions of 
these downstream molecules will be required to determine the molecular 
mechanisms underlying the importance of mTORC2 signaling that we have 
described here. In addition, recent work from Yaffee and colleagues 
demonstrated that the temporal sequence of drug delivery can dramatically alter 
cellular response (Lee, Kim et al. 2012). Therefore, it will be vital to determine the 
optimal sequence and timing of delivery of mTOR inhibitors (and other targeted 
drugs) when used in combination with each other or cytotoxic drugs such as 
gemcitabine.  
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Methods 
 
Animal Experiments 
Mice were maintained on a mixed background and given access to standard diet 
and water ad libitum. Ptf1a-cre, Pdx1-Cre, LSL-KrasG12D, Trp53R172H mice and 
Rictorfl/fl mice have been described previously (Kawaguchi, Cooper et al. 2002, 
Hingorani, Wang et al. 2005, Shiota, Woo et al. 2006, Bentzinger, Romanino et 
al. 2008). Rictorfl/+ mice were intercrossed to generate Rictor$/$ and Rictor+/+ 
siblings for comparison in PanIN development and caerulein injection studies. In 
tumor development studies, mice were monitored for symptoms such as 
abdominal distension, cachexia, jaundice, hunching, reduced mobility, staring 
coat and diarrhea. For late stage treatment studies pancreatic malignancy was 
confirmed by abdominal palpation. Mice were euthanized when disease 
progressed and post mortem tissue was harvested for histological analysis. 
Survival between cohorts was compared by Kaplan-Meier and Log Rank 
statistical analysis. Animal experiments were approved by the University of 
Massachusetts Medical School institutional Animal Care and Use Committee or 
performed under Home Office regulations and under license approved by the 
local ethics committee. 
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Caerulein injections 
Caerulein (Sigma C9026, 50µg/kg) was injected intraperitoneally into 5-7-week 
old mice as previously described (Lugea, Nan et al. 2006).  Injection of vehicle 
(0.05M Ammonium hydroxide in PBS) was used as a control.   Mice were 
sacrificed at 2 or 21 days following the final injection series. 
 
In vivo treatment experiments 
For drug treatments, mice were randomly assigned to cohorts. Treatments were 
administered as follows: AZD2014 (AstraZeneca), in 20% w/v Captisol in H2O, at 
15mg/kg daily by oral gavage daily; Gemcitabine (LC labs), in PBS, at 100mg/kg 
by intraperitoneal injection twice weekly; and AZD8186 (AstraZeneca), in 0.5% 
HPMC in H2O, at 50mg/kg by oral gavage twice daily.  
 
Histology 
Following necropsy pancreata were formalin fixed overnight, embedded in 
paraffin, and 4- or 5-micron sections were mounted on positively charged slides.  
H&E staining was done according to field standard.  The quadchrome consists of 
a hybrid protocol derived from Sirius Red staining for collagen and Alcian Blue 
staining for mucin. Briefly, slides were rehydrated through a graded alcohol 
series to distilled water. They were then incubated sequentially in Weigert’s 
Hematoxylin for one hour, Sirius Red for one hour, and Alcian Blue for 30 
minutes, with rapid washes in acidified water (15 dips in 0.5% acetic acid) after 
-%.
each incubation. In this stain, collagen appears bright red, mucin is blue, nuclei 
are black, and cytoplasm is a weak yellow. 
 
A licensed pathologist who was blinded to tissue genotypes performed 
quantification of tissue area. Four images were quantified per section 
representing 1) the area of greatest neoplastic progression, 2) the area of lowest 
neoplastic progression, and 3,4) areas of the pancreas that were consistent with 
the average progression for that tissue section. Acini, ducts, PanINs, ADM 
lesions, and stromal tissue not including blood vessels were manually outlined 
using ImageJ software and are graphed as the percentage area of all areas 
quantified. 
 
Estimation of cell number and cell size in Rictor+/+ and Rictor!/! pancreata. Total 
genomic DNA was isolated using standard phenol-chloroform extraction from a 
tissue fragment resected from the tail of the pancreas. DNA concentration was 
determined by dividing the quantity of DNA retrieved, by the mass of the tissue 
fragment.  The amount of total genomic DNA was extrapolated by multiplying the 
DNA concentration by the mass of the entire pancreas. Calculations assume that 
each cell contains an equivalent amount of genomic DNA.   
 
For estimation of cell size, 5mm thick tissue sections were stained with DAPI and 
the number of DAPI-positive cells in 5-8 fields (100x magnification) counted in 
-%-
ImageJ. Tissue area was calculated in ImageJ.  Cell size was estimated by 
dividing the number of DAPI-positive nuclei in the tissue area.  
 
Immunohistochemistry 
4- or 5-m formalin-fixed paraffin-embedded (FFPE) sections were deparaffinized 
and rehydrated by passage through Xylene and a series of graded alcohols. 
Endogenous peroxidase activity was quenched in 3% hydrogen peroxide, and 
antigen retrieval was performed using citrate buffer, pH6. Sections were blocked 
in 5% serum, and then incubated with primary antibody. Sections were incubated 
in secondary antibody (Vectastain ABC system) and staining visualized using 
3,3.-diaminobenzidine tetrahydrochloride (DAB) or NovaRed. A list of antibodies 
is provided in Table 2.1. 
 
For insulin staining, a FITC-conjugated donkey anti-guinea pig secondary 
antibody (Jackson Immuno 706‐095‐148, 1:500) was used in lieu of a 
biotinylated antibody.  Samples were mounted with DAPI containing hard-set 
(Vector) and observed with a Nikon Eclipse E400 microscope. 
 
RNAscope 
In situ detection of Rictor transcripts in FFPE mouse PDAC samples was 
performed using a Rictor specific RNAscope® assay (Wang, Flanagan et al. 
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2012) (Advanced Cell Diagnostics, USA) according to the manufacturers protocol 
and using the Rictor probe diluted 1:5. 
 
Cell culture experiments 
Primary PanIN lines (AH 2375, RP 2294) were grown on Laminin coated plates 
as previously described (Schreiber, Deramaudt et al. 2004). Cells were infected 
twice at 5 hour intervals with lentiviruses encoding Rictor-targeting shRNAs or 
GFP-targeting shRNAs as a control. shRNA sequences are provided in Table 
2.2.  Cells were plated at a density of 2.7x104 cells/well in 6 well plates. For the 
generation of protein lysates, cells were plated at a density of 1.3x105 cells/10cm 
dish.  
 
Proliferation assay in PanIN cell lines: Viable cells were counted using trypan 
blue exclusion on days 4, 5 and 6 post-infection.  Log2 of cell numbers/well were 
plotted against time and doubling time was derived from the inverse slope. 
Significant differences in doubling time were determined by analysis of 
covariance using Prism Graphpad. 
 
Senescence associated "-galactosidase staining of PanIN cell lines: Senescence 
Associated %-Galactosidase activity was assessed 4 days post lentiviral infection. 
Cells were fixed in PBS containing 2% formaldehyde and 0.2% glutaraldehyde 
for 10 min at RT, stained (40mM Citric acid 0.1M/sodium phosphate 0.2M buffer 
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pH 6.0, 5mM potassium ferrocynide, 5mM potassium ferricynide, 150mM sodium 
chloride, 2mM magnesium chloride and 5-bromo-4-chloro-3-indolyl-%-D-
galactopyranoside 1mg/ml in water) for 16 hours at 37˚C and counterstained with 
nuclear fast red (Sigma). 
 
Proliferation assay in PDAC cell lines: Generation of murine pancreatic cancer 
cell lines from KPC mice has been described previously (Morran, Wu et al. 
2014). Testing was performed by an in-house service to confirm that cells were 
mycoplasma‐free. Cells were maintained at 37ºC and 5% CO2 in Dulbecco’s 
modified eagle medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine 
serum (PAA), 2mM L-Glutamine (Invitrogen), and 1% Penicillin/Streptomycin 
(Invitrogen). Cells were treated with AZD2014 +/- AZD8186. Cell viability was 
measured by absorbance using the Cell Titer Blue assay (Promega). 
Fluorescence was measured using an Envision plate reader (Perkin Elmer). 
 
Synergy assay in PDAC cell lines: Primary KPC tumor cell line K8484 and 
human pancreatic cancer cell line MiaPaca2 were treated with AZD2014 +/- 
Gemcitabine for 96 hours. Cell viability was determined by measuring the total 
protein content using the sulforhodamine B assay. Combenefit software was 
used to analyze the data for potential synergy 
(http://www.cruk.cam.ac.uk/research-groups/jodrell-group/combenefit). 
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Western Blotting 
Cell lysates were prepared and Western blot analysis was performed using 
standard protocols. Antibodies used are listed in Table 2.3. 
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Table 2.1: Antibodies for immunohistochemistry 
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Table 2.2: shRNA sequences 
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Table 2.3: Antibodies for western blotting 
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Chapter III: 
Discussion 
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A Role for mTORC2 in Pancreatic Neoplasia 
 A critical role for mTORC2 signaling has been identified in genetically 
engineered mouse-models of prostate cancer driven by PTEN deficiency 
(Guertin, Stevens et al. 2009), and orthotropic models of glioblastoma driven by 
mutant EGFR (Tanaka, Babic et al. 2011).  My study is the first to identify a 
requirement for mTORC2 in a genetically engineered mouse-model of a KRAS-
driven tumor. Given the prevalence of KRAS mutations in human cancers, and 
the difficulty in treating KRAS-driven tumors (Ostrem, Peters et al. 2013), 
identification of a requirement for mTORC2 in KRAS-driven initiation and 
progression of pancreatic neoplasias expands our understanding the pathways 
by which KRAS induces oncogenic transformation. 
 Pancreatic knockout of Rictor in the context of activated KRAS resulted in 
a dramatic reduction, but not complete prevention, of PanIN lesions (Figure 2.2).  
mTORC2 activity was absent in the PanIN lesions that did form in KC-Rictor!/! 
pancreata (Figures 2.3, A.1); proliferation and progression were reduced in these 
low-grade lesions relative to their KC counterparts (Figures 2.2, 2.4).  These 
PanIN1 lesions also contained a higher percentage of cells positive for nuclear 
CDKIs in the absence of mTORC2, and a lower percentage of cells positive for 
nuclear BMI1 (Figures 2.5, 2.6).  The increased presence of nuclear p16INK4A, 
p21Cip, and p27KIP1, in PanIN lesions lacking mTORC2 signaling suggests that 
KRAS is down regulating these CDKIs in an mTORC2-dependent manner.  The 
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decreased levels of BMI1 in KC-Rictor$/$ lesions supports the possibility that this 
polycomb group protein may be involved in the down regulation of some or all of 
these CDKIs.  While only the inverse correlation between p16INK4A and BMI1 was 
close to significant when calculated in pancreata harvested at 4-months of age 
(Table A.1), by 8-months of age, strong and significant inverse correlations were 
observed between BMI1 and all three CDKIs (p16INK4A, p21CIP, and p27KIP1) 
(Table A.1). In vitro models were unable to recapitulate the in vivo decrease in 
BMI1 and increase in CDKIs observed in the KC-Rictor$/$ PanINs relative to their 
KC counterparts.  However, the proliferative deficit observed in KC-Rictor$/$ 
PanINs was observed upon knockdown of Rictor in PanIN derived cell lines as 
well as in cell lines derived from established KRAS-driven murine PDAC, 
suggesting a robust role for mTORC2 in the maintenance of the KRASG12D 
mediated proliferative phenotype. 
Of all the questions raised by the findings in this work, perhaps the most 
obvious is whether inhibition of mTORC2 in established PDAC provides a 
therapeutic benefit.  Dual inhibition of mTORC1 and mTORC2 in KPC mice 
(Figure 2.13) and knockdown of Rictor in PDAC cell lines (Figures 2.11, A.9), 
suggest that mTORC2 specific inhibition could provide a therapeutic benefit in 
established PDACs.  Although mTORC2 specific inhibitors are not available, the 
genetic tools to ask such a question have already been developed. The use of 
flippase (FLP) based recombination systems, which employ FLP mediated 
recombination of flippase recognition target (FRT) sites in a manner analogous to 
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Cre mediated recombination of flox sites, would allow loss of Rictor and 
activation of KRAS to be accomplished by distinct mechanisms. Similar to the 
LSL-cassettes used in LSL- KRASG12D/+ animals, FRT-Stop-FRT (FSF) cassettes 
prevent read through of the genes they control until the stop cassette is excised 
by FLP.  Combining Pdx1-Flp;FSF-KRASG12D/+ and FSF-Rosa26CAG-CreERT2/+ 
alleles published by the Saur group in Germany (Schonhuber, Seidler et al. 
2014) with the Rictor$/$ model (Shiota, Woo et al. 2006) will produce an animal in 
which flippase expressed under the pancreas specific Pdx1-promoter will excise 
the FSF-cassettes resulting in endogenous levels of activated KRAS beginning at 
embryonic day 8.5. Flippase will also remove the stop-cassette preceding the 
Rosa26CAG-CreERT2/+ allele in pancreatic tissue.  Because delivery of tamoxifen is 
required for CRE expression by this activated allele, Rictor knockout can be 
delayed until animals present with specific stages of PanINs or PDACs. Inhibition 
of mTORC1 can increase AKT signaling by removing feedback inhibition of IRS1 
and mSIN by the mTORC1 target S6K (Harrington, Findlay et al. 2004, Liu, Gan 
et al. 2013), and has been shown to increase proliferation in certain contexts 
(Palm, Park et al. 2015). These animals, and similar models with floxed mTOR or 
Raptor alleles (Risson, Mazelin et al. 2009, Sengupta, Peterson et al. 2010), 
would allow the delayed genetic ablation of mTORC1, mTORC2 or both 
mTORC1 and 2 in the context of established KRAS-driven lesions.  Addition of 
the RosamT/mG allele to this cross would allow confirmation of Rictor deletion via 
GFP and these lesions could be compared to mTOMATO expressing Rictor+/+ 
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lesions; titration of the tamoxifen pulse could allow visualization of both cell types 
within the same pancreas.  These mouse models could provide important in vivo 
insight into potential benefits of an mTORC2 specific inhibitor relative to 
mTORC1, mTORC1/2 or PI3K inhibitors in established PDACs.  One potential 
benefit for mTORC2 specific inhibition, compared to either PI3K or mTOR kinase 
inhibition, is a reduced number of targets.  If mTORC2 specific loss can arrest 
established KRAS driven PDACs, it would suggest that mTORC2 specific 
inhibitors could provide efficacy by impeding a restricted subset of PI3K effectors.  
Although not always the case, reducing the incidental targets of molecular 
therapies should reduce adverse toxicities.   
mTORC2 Signaling in Acinar-To-Ductal Metaplasia 
Activating KRAS mutations in acinar cells have been shown to induce 
acinar-to-ductal metaplasia (ADM) resulting in duct like lesions capable of 
forming PanIN lesions (Habbe, Shi et al. 2008), and it is largely accepted that the 
majority of PanIN lesions observed in the KC model originate from acinar tissue 
that has undergone ADM.  The presence of low numbers of PanIN lesions in the 
KC-Rictor!/! pancreata observed at 4 and 8-months led to my hypothesis that in 
the absence of mTORC2 signaling, these lesions originate from pancreatic ductal 
tissue but not from trans-differentiated acinar tissue.  Recent data demonstrating 
that the P110# subunit of PI3K is required for KRAS-driven ADM in a caerulein 
induced model of pancreatic injury (Baer, Cintas et al. 2014) suggest that 
mTORC2 signaling may also be involved in ADM. Using a model of caerulein 
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induced pancreatic injury known to initiate KRAS-driven ADM (Carriere, Young et 
al. 2009), I found that mTORC2 was not required for ADM (Figures 2.7, 2.8).  
The presence of PanIN1A lesions in both KC and KC-Rictor!/! mice 21 days post 
caerulein injection was equivalent, and a larger percentage of cells were 
identified in the ADM transitional state in KC-Rictor!/! mice than in KC mice 
(Figure 2.8).  One explanation for this finding is that mTORC2 deficiency does 
not prevent ADM but impairs PanIN lesion progression at all stages including 
potentiated acinar cells and cells in an ADM transitional state.  In support of this 
idea, the majority of exocrine cells in KC-Rictor!/! pancreata were observed in an 
acinar, ADM or PanIN1a morphology at 21 days post caerulein insult, while 
exocrine cells in KC pancreata were primarily observed in PanIN1b or PanIN2 
morphologies (Figure 2.8).   
The formation of duct like structures 2 days following pancreatic injury 
(Figures 2.8, A.6) further supports the conclusion that caerulein can induce ADM 
in KRAS potentiated acinar cells even in the absence of mTORC2.  The number 
of duct like structures, and the speed with which they formed, preclude their 
origination exclusively from preexisting ducts, and the most logical conclusion is 
that a significant number of these duct like lesions originate from acinar tissue 
that has undergone ADM.  This assertion is further supported by the 
maintenance of a significant portion of KC-Rictor!/! pancreata in an ADM 
transitional state 21 days following caerulein insult. While mTORC2 does not 
appear to be required for acinar tissue to transition to a ductal phenotype 
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following caerulein insult, the smaller nature and lower concentration of duct like 
structures observed in KC-Rictor!/! pancreata relative to KC pancreata (Figure 
2.8) does support a role for mTORC2 during KRAS-driven progression of acinar 
cells through ADM and into neoplastic ducts.  These experiments show that 
KRAS-driven ADM can, in the context of caerulein injury, proceed to the 
formation of PanIN lesions even in the absence of mTORC2; however, they do 
not necessarily show that this is what occurred in the 4 and 8-month cohorts.  In 
the absence of caerulein injury, the possibility that KC-Rictor!/! PanINs are 
originating from pancreatic ducts remains.  To assess the potential of KRASG12D- 
Rictor!/! acinar tissue to trans-differentiate and form PanIN lesions, a lineage-
tracing approach using inducible-conditional alleles could be employed.  The use 
of Mist1-CreERT2/+ and Ela-CreERT2Tg/+ mouse strains combined with the LSL-
KRASG12D both result in PanIN formation following acinar and acinar/centroacinar 
specific expression of Cre respectively, at 6 weeks of age (Habbe, Shi et al. 
2008).  Adding the Rictor$/$ allele to these mice would allow me to ask if PanINs 
arise from acinar or centroacinar cells in the absence of mTORC2.  The converse 
experiment, to confirm the ability of Rictor-deficient ductal cells to form PanINs, 
could be achieved using a duct specific CK19-CreERT allele (Means, Xu et al. 
2008) combined with LSL-KRASG12D and Rictor$/$.  Although the CK19 driven 
CRE is expressed in multiple epithelial cell types, LSL-KrasG12D activated by this 
allele has been shown to induce PanIN lesions with a pancreatic ductal origin 
(Ray, Bell et al. 2011).  Unless combining Rictor-loss with KRAS-activation in 
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these other cell types results in a lethal or otherwise confounding phenotype, the 
ability of KRAS expressing ductal cells to induce PanINs should be apparent 
within 6 months of induction with tamoxifen. The added utility of tamoxifen 
inducibility in these systems would provide temporal control, allowing initiation of 
KRAS-activation and mTORC2 deletion at a similar developmental age across 
these three models.  Although the PanIN forming potential of the pancreas 
decreases with delayed KRAS-activation, and these models would initiate KRAS-
activation and Rictor deletion later than the Ptf1aCre allele used in my studies, 
KRAS has been shown to induce sufficient PanIN lesions to test this hypothesis 
when initiated at postnatal day 14 (Gidekel Friedlander, Chu et al. 2009).  
Despite the acceptance that PDAC can arise from acinar or ductal tissue in 
pertinent mouse models, conclusive evidence for either of these cellular origins in 
human PDAC is not yet available.  
An alternative interpretation of results obtained from induction of acute 
pancreatitis that cannot be discounted is that caerulein-induced inflammation 
provides a partial in vivo rescue of the KC-Rictor!/! phenotype.  My observation 
of rapid formation of duct like lesions which progress to PanINs in the absence 
mTORC2 signaling, may result from caerulein mediated activation of a 
downstream mTORC2 target essential for KRAS-driven ADM.  Intra-pancreatic 
trypsinogen activation and NF-"B activity act in parallel pathways to induce the 
pancreatic injury and inflammation associated with caerulein induced acute 
pancreatitis (Han, Ji et al. 2001, Dawra, Sah et al. 2011, Sah, Garg et al. 2012).  
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It is possible that mTORC2 is involved in the activation of one or both of these 
pathways during the initiation and progression of KRAS-driven PanIN lesions. 
NF-"B activity has been placed downstream of both mTORC2 and AKT and is a 
likely candidate (Tanaka, Babic et al. 2011, Sah, Garg et al. 2012).  Staining for 
nuclear localization of the REL-A subunit of NF-"B would provide insight into this 
possibility.  If caerulein injection is inducing a partial rescue by activating an NF-
"B mediated inflammatory response, I would predict that nuclear REL-A would be 
decreased in the pancreata of 4 and 8-month KC-Rictor!/! animals relative to 
their KC counterparts, while nuclear REL-A would be observed in the pancreata 
of both KC and KC-Rictor!/! pancreata following caerulein insult.   
It is also possible that active trypsin may act downstream of mTORC2.  
The original identification of PKC enzymes identified them as protease-activated 
protein kinases (Takai, Kishimoto et al. 1977), and proteolytic activation by 
trypsin was shown to result in PKC enzymes whose activity was independent of 
Ca2+ and DAG (Kishimoto, Kajikawa et al. 1983).  Staining for active trypsin as 
well as active PKC isozymes in both caerulein treated and untreated samples 
could provide some insight into the potential roles that trypsin mediated PKC 
activation may play in bypassing mTORC2 signaling in the development of PanIN 
lesions.  
Trypsin can initiate signaling through the PAR-2 receptor (Dery, Corvera 
et al. 1998) which, along with PKC', has been shown to activate ERK in prostate 
stromal cell (Myatt and Hill 2005).  Although my staining for ERK following 
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caerulein injection identifies decreased p-ERK in KC-Rictor$/$ PanIN lesions 21 
days post caerulein injection (Figure 2.8), it is possible that ERK signaling was 
temporarily elevated immediately following insult.  This possibility could be easily 
addressed by staining for p-ERK in the samples harvested 2 days following 
administration of caerulein. The use of an L-arginine driven model of pancreatitis, 
which has been shown to decrease rather than increase pancreatic secretions 
(Lechin and van der Dijs 2008), could be employed to avoid any trypsin mediated 
signaling through PKC or ERK. 
 While PI3K and PDK1 were required for the plasticity of acinar cells, 
preventing the subsequent formation of PanIN and PDAC (Eser, Reiff et al. 2013, 
Baer, Cintas et al. 2014), loss of mTORC2 appears to impair the progression of 
acinar cells through ADM and during their subsequent evolution through the 
PanIN grades.   Although it could be argued that the mTORC2 deficient 
phenotype is a less robust version of that induced by either the PI3K or PDK, the 
cooperation observed when treating established KPC tumors with the dual 
mTORC1/2 inhibitor AZD2014 and the PI3K inhibitor AZD8186 (Figure 2.14), 
suggests that the roles of these pathways are distinct and can be combined for 
clinical benefit.  
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The maintenance of KRAS induced neoplasticity may require mTORC2 
Regression from PanIN lesions back to acinar tissue has been shown in 
caerulein models upon ablation of mutant KRAS expression (Collins, Bednar et 
al. 2012).  Notably, phosphorylation of ERK is dramatically decreased during this 
regression, and treatment of mice expressing pancreatic KRASG12D with a small 
molecule MEK inhibitor is sufficient to induce a PanIN to acinar regression 
(Collins, Yan et al. 2014). My observation of reduced p-ERK staining in KC-
Rictor!/! mice 21 days post caerulein treatment (Figure 2.8) make it worth 
considering the possibility that progression of KC-Rictor!/! PanIN lesions may not 
be linear and that higher grade lesions may regress and even revert back to 
acinar tissue.  Observations of intermediary time points following caerulein insult 
would provide insights regarding this possibility, but to confirm reversion of ductal 
cells into acinar cells, a lineage tracing approach which combines the use of a 
tamoxifen inducible Cre-loxP and flippase-FRT recombination technologies could 
be used. Crossing existing mouse strains to produce CK19CreERT; Rictor!/!; 
Rosa26mT/mG; Pdx1-Flp; FSF-KRASG12D/+ mice (Shiota, Woo et al. 2006, 
Muzumdar, Tasic et al. 2007, Means, Xu et al. 2008, Schonhuber, Seidler et al. 
2014) would afford temporal control of Cre expression under the duct specific 
cytokeratin-19-promoter.  Expression of flippase under the Pdx1-promoter would 
result in KRAS-activation beginning at embryonic day 8.5 (Offield, Jetton et al. 
1996).  Subsequent activation of Cre by intraperitoneal tamoxifen injection could 
be administered after PanIN lesions are known to have developed in the FSF-
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KRAS model both in the context of caerulein induced acute pancreatitis, and in 
its absence.  Cre activation would excise Rictor exon3 and ablate mTORC2-
expression in ducts and PanIN lesions, while also deleting the Tomato marker in 
the lineage tracing Rosa26mT/mG allele and expressing a membrane targeted 
GFP-reporter in its place.  The presence of both positive and negative reporter 
genes is important given that cytokeratin-19 is expressed in multiple epithelial 
cell types.  It is possible that titration of tamoxifen may be able to reduce the 
impact of non-pancreatic Rictor loss.  The development of interfering phenotypes 
would require the design of new mouse lineages, specifically, the development of 
a flp-stop-flp-CK19CreERT, would restrict CRE expression to epithelium derived 
from the pancreas. This model could also be made more equivalent to my current 
model by developing and using a Rictorflp/flp conditional mouse to produce a FSF-
CK19CreERT; Rictorflp/flp; Rosa26mT/mG; Pdx1-Flp; FSF-KRASG12D/+ mouse-model.  
In this model tamoxifen mediated expression of Cre could be restricted to adults 
and coordinated with caerulein insult, and as a result of Rosa26mT/mG, acinar cells 
which had reverted from a ductal state would express GFP.  These mouse-
models could test the hypothesis that the ability of KRASG12D to “lock” pancreatic 
cells in an epithelial state requires Rictor.   
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KRAS Modulation of the Microenvironment Through mTORC2 
The stromal component of PDAC plays a vital role in the development of 
these tumors.  In established PDAC, stromal tissue can represent the majority of 
a tumor mass, and secretions from pancreatic stellate cells have been shown to 
potentiate neoplastic lesions (Hwang, Moore et al. 2008, Feig, Gopinathan et al. 
2012).  In KC-Rictor!/! pancreata observed at 4 or 8-months of age, or 21 days 
post caerulein insult, quadchrome staining showed a dramatic reduction in 
collagen deposition by pancreatic stellate cells relative to KC pancreata (Figures 
2.2, 2.8).  Histopathological analysis confirmed that stromal tissue constituted a 
significantly smaller proportion of KC-Rictor!/! pancreata than their KC 
counterparts.  This supports the possibility that mTORC2 activity contributes to 
KRAS mediated effects on the neoplastic microenvironment.  Although the 
administration of caerulein was not sustained, the fibrotic response in both KC 
and KC-Rictor!/! animals was indicative of chronic pancreatitis.  A cohort of these 
animals was allowed to progress to assess the role that mTORC2 plays on 
KRAS driven PDAC formation in the context of chronic pancreatitis.  Experiments 
to address this question are ongoing but have been confounded by the presence 
of comorbidities such as pancreatic insufficiency.   
Following caerulein insult, KC-Rictor!/! pancreata were not subject to the 
rapid increase in weight and size observed in their KC counterparts (Figure A.5).  
The rapid onset of this phenotype in KC mice precludes a proliferative cause and 
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is consistent with inflammation-associated edema which has been described in 
similar models (Grady, Saluja et al. 1996).  Immunohistochemical staining for 
B220, CD3, and F480 to identify B-cells, T-cells and macrophages respectively, 
within the stromal components of pancreata harvested 2 and 21 days post 
caerulein injection, may provide insight into differential immune responses in KC-
Rictor$/$ and KC pancreata.   
The linear view of PanINs recruiting and activating more stromal tissue as 
they progress has been revised based on work showing that signaling from 
stromal cells promote PanIN progression.  Specifically, IL-6, presumably 
secreted by stromal macrophages, was shown to be involved in this process 
(Lesina, Kurkowski et al. 2011). IL-6 was shown to be a driver of STAT3 activity 
in KRAS-driven PDAC, and while STAT3 activation, achieved by conditional 
knockout of the STAT3 inhibitor Socs3, has not been shown to induce PDAC 
alone, it does cooperate with activated KRAS to dramatically accelerate disease 
in the KC model (Lesina, Kurkowski et al. 2011).  Furthermore, pancreas specific 
deletion of STAT3 in PDAC mouse-models yielded phenotypes similar to the KC-
Rictor!/! model, decreasing, but not eliminating, the formation of PanIN lesions 
(Corcoran, Contino et al. 2011, Lesina, Kurkowski et al. 2011).   
The NF-"B transcription factor has been shown to regulate inflammatory 
cytokines, including IL-6 in multiple cell types (Miyazawa, Mori et al. 1998, Xiao, 
Hodge et al. 2004), and studies showing activation of NF-"B downstream of 
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KRAS and mTORC2 suggest a mechanism by which these proteins may 
influence the inflammatory response which surrounds PanIN lesions and PDACs 
(Tanaka, Babic et al. 2011, Daniluk, Liu et al. 2012).  In vivo analysis of 
inflammatory response in the ischemic hind limb adductor muscle also showed 
that dual mTORC1/2 inhibition, but not low dose rapamycin, reduced IL-6 
expression, further suggesting a connection between mTORC2 and IL-6 
expression (Fan, Cheng et al. 2013).  In MEFs and dendritic cells mTORC2 
repression of FOXO1 has been proposed as a negative regulator of numerous 
cytokines including IL-6 (Brown, Wang et al. 2011).  This suggests that any 
regulation of IL-6 by mTORC2 may be context dependent.  
The robust co-localization of IL-6 with cells expressing the macrophage 
marker CD68 suggests, that in the context of normal acinar tissue, macrophages 
are the major providers of IL-6 (Lesina, Kurkowski et al. 2011).  However, 
activation of KRAS has previously been shown to induce IL-6 secretion from 
multiple cell types, and knockdown of IL-6 in established human PDAC lines 
impaired their growth in an orthotropic mouse-model (Ancrile, Lim et al. 2007).  
Importantly, the SCID/beige mice used for these orthotropic transplants maintain 
normal populations of macrophages despite being deficient in T and B cell 
lineages (Xing, Zganiacz et al. 2001).  Together, these data suggest that 
macrophage derived IL-6 may play a role in the initiation of PanIN lesions, but 
that in established lesions, KRAS may drive secretion of IL-6 from within exocrine 
cells to create an autocrine signaling loop in established lesions.  Combined 
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amplification of the loci expressing the IL-6 receptor (IL6R) and kinase STAT3 in 
over 20% of micro-dissected samples of PDAC support an important role for this 
signaling axis in the development and maintenance of these tumors (Witkiewicz, 
McMillan et al. 2015).  In addition to Immunohistochemical staining for the NF-"B 
subunit REL-A and immune markers for B cells, T cells and macrophages, 
staining for the IL-6 cytokine and its downstream target p-STAT3Y705 will help to 
provide further insight into PanIN formation and progression both in the absence 
of caerulein injury, and in the context of a caerulein induced pancreatitis model.  
If mTORC2 promotes IL-6 and STAT3 signaling, pancreas specific knockout of 
the STAT3 inhibitor SOCS3 should provide, at least in part, a rescue of PanIN 
formation in KC-Rictor!/! pancreata (Lesina, Kurkowski et al. 2011). Should 
SOCS3 rescue mTORC2 deficiency, parsing the autocrine or paracrine nature of 
mTORC2 mediated IL-6 effect by developing a flippase mediated conditional Il-6 
knockout allele and combining it with pancreas specific or macrophage specific 
FLP expression would be an interesting and worthwhile endeavor. 
Given the importance the tumor microenvironment plays in the 
establishment and support of PDAC, understanding the mechanisms employed 
by KRAS to shape the stromal response is an active area of research.  If 
inhibition of mTORC2 proves to be a method by which active KRAS can be 
decoupled from the stromal response, targeting that leg of KRAS signaling may 
provide a significant clinical benefit.  
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 While a decoupling of KRAS activation from the stromal response is 
desirable, in a clinical setting, the inhibition of mTORC2 by small molecule 
inhibitors would not be restricted to pancreatic cells.  As stromal tissue makes up 
a significant portion of pancreatic tumors, mTORC2 inhibition would also affect 
these cells, and understanding the effect that such inhibition would have on the 
stromal element of the tumor is important.  Although our studies don’t allow for 
direct analysis of mTORC2 specific loss in the stroma, the pancreas cell specific 
loss of mTORC2 signaling in KPC-Rictor!/! tumors and the global inhibition of 
mTORC2 with the dual mTORC1/2 inhibitor AZD2014 provide models which 
could provide insight into the effects of mTORC2 inhibition on the stromal tissue.   
To gain the clearest picture possible from these models the differences between 
KPC and KPC-Rictor!/! stroma should be compared to the differences between 
stroma in control treated and AZD2014 treated KPC tumors.  Any distinctions 
identified may be the result of mTORC2 specific inhibition in the stromal tissue, 
but could also be the result of mTORC1 inhibition or combined mTORC1/2 
inhibition.  Furthermore, differences identified could be the result of complete 
mTORC2 loss in the genetic model and less than complete loss in response to 
the drug.  Regardless, information from such an analysis could inform further 
questions and experiments into the role that mTORC2 plays within the stromal 
element of pancreatic tumors. 
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Bypass of KRAS Induced Senescence Involves mTORC2  
My studies show that a greater percentage of PanIN1 cells express 
nuclear CDKIs when mTORC2 signaling is absent.  In pancreata harvested at 4-
months, only p16INK4A was elevated in KC-Rictor!/! relative to KC, but at 8-
months of age the percentage of p21CIP1 and p27KIP1 positive nuclei in KC PanIN1 
lesions decreased, while they remained elevated in KC-Rictor!/! lesions (Figures 
2.5, 2.6).  These findings are supported by Pearson’s coefficients, which showed 
that only the inverse correlation of nuclear p16INK4A with nuclear BMI1 was close 
to being statistically significant at 4-months of age, while at 8-months of age, the 
nuclear frequency of all three CDKIs (p16INK4A, p21CIP1or p27KIP1) showed strong 
and statistically significant inverse correlations with nuclear BMI1 (Figure A.1).  
This combined with the impaired progression of KC-Rictor!/! PanIN lesions 
(Figure 2.2), suggests that mTORC2 is required for the inactivation of CDKIs in 
KRAS mutant PanIN cells.  Previous studies have determined that PDAC 
formation is accelerated when KC mouse-models are combined with conditional 
knockout of Cdkn2a, Cdkn1a or Cdkn1b (Bardeesy, Aguirre et al. 2006, Morton, 
Jamieson et al. 2010, Diersch, Wenzel et al. 2013).  The ubiquitous loss of 
p16INK4A expression in human PDACs suggests that this protein functions as a 
potent suppressor of KRAS-driven oncogenesis (Schutte, Hruban et al. 1997).  
Furthermore, low p21CIP1 levels correlate with poor prognosis following surgical 
resection (Morton, Jamieson et al. 2010), and p27KIP1 loss correlates with more 
advanced tumor grade and clinical stage in human PDAC (Hu, Watanabe et al. 
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2000).  These studies strongly suggest a role for these CDKIs in restricting 
PDAC, and that the function of these cell cycle inhibitors must be eliminated to 
allow KRAS-driven oncogenesis. 
Delayed activation of KRAS has been reported to impair the formation of 
PanIN lesions (Guerra, Schuhmacher et al. 2007, Gidekel Friedlander, Chu et al. 
2009).  The reduced potential for KRAS-driven transformation in adult pancreatic 
murine tissue suggests that actively cycling cells, the numbers of which decrease 
as the pancreas matures (Collado, Gil et al. 2005), are more susceptible to 
KRAS induced transformation.  Deletion of Cdkn2a in a Pdx1-CreERTM;LSL-
KRASG12D model induced at postnatal day 28, accelerated the formation of 
PanINs relative to Pdx1-CreERTM;LSL-KRASG12D mice induced at a similar age 
(Gidekel Friedlander, Chu et al. 2009), suggesting that Cdkn2a expression in 
adult pancreatic tissue may contribute to this resistance.   
Ectopic expression of RAS isoforms can induce expression of CDKIs and 
often results in oncogene-induced senescence (Serrano, Lin et al. 1997).  
However, senescence associated %-galactosidase activity in pancreatic ducts 
occurring in response to caerulein insult was absent in the context of 
endogenous KRASG12D as was p16INK4A expression (Lee and Bar-Sagi 2010).  
Furthermore, when activated KRAS was expressed at endogenous levels in vitro, 
p16INK4A expression was reduced rather than elevated (Lee and Bar-Sagi 2010). 
In vivo, KRAS-driven PanIN lesions identified at 6 weeks of age in KC and KC-
LSL-Trp53R172H animals were positive for senescence associated %-
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galactosidase activity, while PanIN lesions from KC-Cdkn2a-/+ animals were 
negative (Morton, Timpson et al. 2010), suggesting that the proteins encoded by 
Cdkn2a are required for KRAS induced senescence.  Understanding how this 
tumor-suppressor is inactivated by KRAS is important, as a significant number of 
human PDACs maintain intact CDKN2A alleles, but do not express p16INK4A 
(Schutte, Hruban et al. 1997).  
p21CIP1 or p27KIP1 are both reported to be regulated by the mTORC2 target 
AKT.  Direct phosphorylation of these CDKIs by AKT has been shown to localize 
them to the cytoplasm thus preventing their nuclear CDKI functions (Zhou, Liao 
et al. 2001, Sekimoto, Fukumoto et al. 2004).  Additionally, transcriptional 
regulation of Cdkn1a is achieved by AKT mediated down regulation of TRP53 via 
MDM2 activation (Mayo and Donner 2001, Zhou, Liao et al. 2001), and 
transcription of Cdkn1b is repressed by AKT mediated inhibition of FOXO 
transcription factors (Medema, Kops et al. 2000). Given that p-AKT473 was 
absent in KC-Rictor!/! PanINs, while p-AKTT308 remained, it is possible that AKT 
mediated regulation of transcription and post-translational modification of p21CIP1 
and p27KIP1 require a fully activated p-AKT473 protein.  This would be consistent 
with findings in mouse embryonic fibroblasts, which showed that mTORC2 
activity was required for FOXO3a phosphorylation (Guertin, Stevens et al. 2006).   
While my study has identified elevated frequencies of PanIN1 cells with 
nuclear CDKIs in the absence of mTORC2, and has done so in multiple KRAS-
driven PanIN models, these findings are still correlative.  Immunostaining for 
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nuclear TRP53 and FOXO transcription factors in KC-Rictor$/$ PanIN lesions 
could provide some insight into a mechanism for the increased nuclear 
expression of their transcriptional targets; however, these findings would also be 
correlative. Ultimately, combining the KC-Rictor$/$ model with conditional alleles 
for Cdkn2a, Cdkn1a and Cdkn1b would allow an investigation into which, if any, 
of these CDKIs are required for the inhibition of PanIN formation and progression 
seen in the KC-Rictor$/$ animals.   
 
BMI1 is a Potential Mechanism by which mTORC2 Fosters Cell Cycle 
Progression  
Upon identification of CDK inhibitor activity in mTORC2-deficient PanIN 
lesions I became interested in understanding how these inhibitors may be 
regulated.  My inquiry into the status of BMI1 in the absence of mTORC2 
signaling stemmed from its well-established role as an inhibitor of Cdkn2a 
expression (Jacobs, Kieboom et al. 1999). A member of the polycomb repressor 
group, BMI1 is required for the maintenance of hematopoietic and neuronal stem 
cells (Molofsky, Pardal et al. 2003, Park, Qian et al. 2003), as well as 
regeneration of the exocrine pancreas following caerulein insult (Fukuda, Morris 
et al. 2012). A recent study in which BMI1 was knocked out in the KC mouse-
model (KC-BMI1-/-) showed a phenotype similar to knockout of the PI3K pathway; 
PanIN formation was almost entirely prevented upon homozygous deletion of 
BMI1 (Bednar, Schofield et al. 2015). I observed a strong inverse correlation 
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between nuclear BMI1 expression and nuclear p16INK4A expression in vivo 
(Figures 2.5, 2.6,2.8, 2.9 and tables A.1, A.2), and while this finding is correlative, 
it fits with and provides context for the emerging role of BMI1 in KRAS-driven 
PanIN progression.  Although the majority of human PDACs have genetic loss of 
p16INK4A, many retain an intact CDKN2A locus but repress p16INK4A expression.  
The mechanism by which p16INK4A is repressed in KRAS-driven PDACs has not 
been confirmed in vivo, but both BMI1 and TWIST dependent mechanisms have 
been proposed.  While my study did not investigate TWIST, it provides 
correlative in vivo support for a KRAS-driven, mTORC2-dependent, silencing of 
p16INK4A by BMI1 (Figures 2.5, 2.6, 2.8, 2.9). 
It is notable that in KC-BMI1-/- pancreata, PanIN formation was not 
rescued by the additional loss of p16INK4A, suggesting that BMI1 affects additional 
mechanisms involved in PanIN formation (Bednar, Schofield et al. 2015).  A role 
for BMI1 in the regulation of CDKN1A and CDKN1B in cultured NSCLC cells 
suggests that BMI1 may act as a regulator of multiple CDKIs in RAS driven 
tumors (Zheng, Wang et al. 2014).  Significant inverse correlations were 
observed between nuclear frequencies of BMI1 and p27KIP1 at both 8-months of 
age and 21 days post pancreatic injury.  A significant inverse correlation between 
BMI1 and p21CIP1 was only observed in the 8-month cohort (Table A.1).  The lack 
of inverse correlations observed between BMI1 and p21CIP1 or p27KIP1 in 4-month 
cohorts was caused by the maintenance of nuclear CDKIs in KC PanIN1s rather 
than a decrease in the frequency of nuclear CDKI expression in KC-Rictor!/! 
-(-
PanIN1s. It therefore remains possible that mTORC2-dependent activation of 
BMI1 plays a role in KRAS-driven down regulation of multiple CDK inhibitors, but 
that frequencies of nuclear p27KIP1 and p21CIP1 positive PanIN1 cells are 
maintained for a longer period of time than p16INK4A following KRAS-activation.  
My data do not preclude BMI1 independent mechanisms of mTORC2-dependent 
regulation of any of these CDKIs.  
Further studies need to be done to elaborate the connection between 
mTORC2 and BMI1 as well as provide a better understanding of BMI1 regulation 
of CDK inhibitors.   A series of co-immunofluorescence staining experiments in 
the current cohort of KC and KC-Rictor!/! mice could provide insight into how 
individual CDKIs respond to increased BMI1 on a cell by cell basis.  This method 
could also be used to identify expression patterns of BMI1 in relation to CDKIs.  
Mutual exclusion between BMI1 and any of the CDKIs would strongly support 
BMI1 regulation of that CDKI.  
To directly address the role of BMI1 in KRAS-driven PanIN formation and 
its relationship to mTORC2, I propose the integration of a Rosa26-LSL-Bmi1 
allele into the KC-Rictor$/$ model.  The conditional overexpression of BMI1 by a 
CAGs-promoter at the Rosa26 locus would allow overexpression of BMI1 upon 
pancreas specific expression of CRE recombinase (Westerman, Blom et al. 
2012).  If BMI1 is a critical component of KRAS-mTORC2 driven PanIN 
formation, the overexpression of BMI1 in KC-Rictor$/$ pancreata should rescue 
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PanIN formation and decrease CDKI expression in these PanINs.  As BMI1 has 
been shown to cause glioblastoma in the context of RB deficiency (Westerman, 
Blom et al. 2012), it would be important to control for a potential cooperative 
effect of BMI1 over-expression and KRAS-activation by comparing rates of 
PanIN formation in KC and KC-LSL-Bmi1 models to avoid misinterpreting a 
cooperative effect as a rescue. 
 Although, the specific manner in which BMI1 might be regulated by 
mTORC2 or KRAS was not addressed in my studies, previous work in breast 
cancer has shown BMI1 levels to be regulated by the Gli2 transcription factor 
(Liu, Dontu et al. 2006).  In a gene expression array described in Appendix C, 
Gli2 expression levels were found to be elevated in primary ductal epithelial cells 
upon infection with activated KRAS.  The Sonic Hedgehog signaling pathway 
culminates with nuclear translocation of GLI transcription factors (Pasca di 
Magliano and Hebrok 2003) and is known to cooperate with KRAS throughout 
PDAC initiation and development (Morton, Mongeau et al. 2007). Ablation of 
GLI1 and GLI2 activity via expression of a dominant negative Gli3T allele has 
been shown to prevent PanIN formation in the KC model (Rajurkar, De Jesus-
Monge et al. 2012).  To confirm in vivo regulation of BMI1 by Gli2 downstream of 
mTORC2 signaling, the KC-Rictor!/! model could be combined with the 
conditional R26!NGli2/+ knockin allele.  Upon CRE mediated recombination, 
R26$NGli2/+ expresses a constitutively active N-terminally truncated form of GLI2 
(Joeng and Long 2009).  Rescue of a robust PanIN phenotype with increased 
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nuclear BMI1 in KC-Rictor!/!; R26!NGli2/+ pancreata would provide support for 
GLI2 regulation of BMI1 during PanIN progression.  I find this model preferable to 
an alternative conditional model, which expresses active Gli2 constitutively under 
a CAG-promoter and rapidly produced undifferentiated carcinoma of the 
pancreas, likely due to the robust synthetic promoter (Pasca di Magliano, Sekine 
et al. 2006).  The less robust expression in the R26!NGli2/+ model should provide a 
larger window in which to observe rescue of a PanIN phenotype.  Further 
experiments using a conditional BMI1fl/fl animals combined with the 
Ptf1aCre/+;R26$NGli2/+ mice could investigate the in vivo connection of BMI1 
downstream of Gli2 (Bednar, Schofield et al. 2015). 
An additional manner in which BMI1 may be regulated by mTORC2 is 
through post-translational modification.  Post-translational modification of BMI1 
by AKT has been observed in prostate cancer cell lines and in mouse embryonic 
fibroblasts (Liu, Liu et al. 2012, Nacerddine, Beaudry et al. 2012).  These two 
studies reached differing conclusions as to the physiological results of BMI1 
phosphorylation by AKT, with prostate cancers showing increased ubiquitination 
of H2A and MEFs showing decreased ubiquitination in response to BMI1 
phosphorylation.  These contradicting findings may be explained by differences 
in cell types and tumor suppressor backgrounds.  It is also important to recognize 
that in the experiments done in MEFs, Liu et al. utilized BMI1S316A and BMI1S316D 
alleles in which the canonical site of AKT phosphorylation was altered.  In 
Prostate cancer cell lines, Nacerddine et al. identified a more complex pattern of 
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BMI1 regulation in which three serine residues, which lack the canonical AKT 
target motif, appeared to regulate an AKT-dependent pro-tumorigenic role of 
BMI1 (Nacerddine, Beaudry et al. 2012).   
In vivo analysis of PanIN1 lesions showed decreased proliferation, 
decreased nuclear BMI1, and elevated nuclear CDKI, in the absence of 
mTORC2 signaling (Figures 2.3, 2.4, 2.5, 2.6).  While these in vivo findings are 
powerful, they are also correlative.  To establish a direct relationship between 
BMI1, CDKIs and proliferative defects in response to mTORC2 loss, I attempted 
to replicate loss of mTORC2 in PanIN lesions in a tissue culture model. 
Substantial care was taken to select a cell culture system that represented the 
PanIN lesions in which I observed differences in CDKI expression.  With this in 
mind I investigated Rictor knockdown in the context of primary cell lines derived 
from KRAS mutant PanIN lesions provided by Dr. Nabeel Bardeesy.  These cells 
should, in theory, have relatively few mutations and signaling should be similar to 
early PanIN lesions in vivo.  Although Rictor knockdown reproduced the 
decrease in proliferative rate, and increased senescence in these cells, CDKI 
levels and nuclear localization were unchanged, suggesting a fundamental 
difference between mTORC2 signaling in PanIN lesions grown in tissue culture 
verses in vivo.  One possibility explaining the lack of corresponding phenotype is 
that primary PanIN cells grown in culture are under stress from non-physiological 
conditions, and, as a result, baseline levels of CDKI activity are elevated.  
Inhibition of mTORC2 may be unable to further activate CDKIs in these cells, but 
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by impairing proliferative signals from growth factors in the culture media, the 
balance of cell cycle progression verses inhibition is altered and these cells enter 
a senescent state. Alternatively, if the role of mTORC2 in regulating CDKIs were 
primarily directed at their degradation, Rictor knockdown would be unable to 
elevate the levels of CDKIs above the baseline observed in tissue culture.  If 
basal levels of CDKIs in these PanINs are low, providing an additional cellular 
stress, such as serum starvation or cycloheximide, may be required to establish 
a context in which to observe differential CDKI activity.    
The fact that the BMI1 and CDKI signaling observed in multiple in vivo 
settings was unable to be faithfully reproduced in a tissue culture model does not 
negate the findings in mice, but, thus far, it has precluded a robust biochemical 
analysis of how BMI1 and CDKIs are regulated by mTORC2.  Initial observations 
in PDAC cell lines showed no difference in CDKI levels and lead to the selection 
of the PanIN derived cell lines.  While it is possible that epithelial pancreatic 
ductal cells cultured in the continued presence of super-physiological glucose 
and serum levels may be an inappropriate model in which to observe the subtle 
effects of a growth factor mediated signaling pathway involved in metabolism, if a 
KRAS-driven in vitro system, in which mTORC2 loss consistently results in 
decreased BMI1 and increased CDKI nuclear expression, can be developed, 
shRNA mediated knockdown of p16INK4A, p21Cip, and p27 KIP1 should be 
employed to determine if individual or combined loss of CDKIs can rescue the 
proliferative phenotype associated with mTORC2 loss.  Furthermore, ectopic 
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expression of BMI1 following loss of mTORC2 could also be tested in such a 
system. If CDKIs in KRAS mutant cells are down regulated in an mTORC2, 
BMI1-dependent manner, it is possible that targeting this pathway may provide a 
mechanism by which certain CDKIs, silenced but not lost in various subsets of 
human PDACs, could be reactivated to provide clinical benefit.  A more in depth 
understanding of the in vivo effects of mTORC2 signaling in the context of 
KRASG12D mutant PDAC with various tumor suppressor profiles is required to see 
if such an approach is feasible or wise. 
 
Differentiating between PI3K/PDK1 and mTORC2 Signaling  
The data presented in this thesis describe a phenotype in which the 
formation and progression of KRAS-driven PanIN lesions is inhibited by the loss 
of mTORC2.  Perturbation of PI3K signaling through knockout of either PDK1 or 
the PI3K subunit P110# in KC mouse-models of PDAC, resulted in the near 
complete ablation of ADM and PanIN lesions (Eser, Reiff et al. 2013, Baer, 
Cintas et al. 2014).  While the PI3K knockout phenotype was dose dependent 
(Baer, Cintas et al. 2014), mono-allelic loss of Rictor in KC pancreata showed no 
discernable phenotype.  Direct quantifications of PanIN formation in KC-Pdk1fl/+ 
heterozygotes verses KC animals were not reported, however survival of KC-
Pdk1fl/+ animals was not significantly different than KC animals (Eser, Reiff et al. 
2013). Bi-allelic Rictor loss dramatically decreased PanIN lesions and their 
progression, but not to the same extent as PI3K# or PDK1 ablation (Eser, Reiff et 
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al. 2013, Baer, Cintas et al. 2014).  The absolute requirement for the PI3K-PDK1 
pathway in PanIN initiation contrasts with the important, but non-essential, role 
played by mTORC2 signaling.  PDK1 and mTORC2 co-phosphorylate proteins in 
the AKT and SGK families, PDK1 phosphorylates the activation domain, while 
mTORC2 targets the hydrophobic motif.  For SGK family members, 
phosphorylation at the hydrophobic motif primes them for activation by PDK1 and 
is required for their activity.  AKT family members contain PH domains, which 
localize them to the plasma-membrane, allowing partial activation by PDK1, but 
mTORC2 phosphorylation of the hydrophobic motif is required for full AKT 
activity (Guertin, Stevens et al. 2006, Pearce, Komander et al. 2010).  The 
formation of some KRAS-driven PanIN lesions in the absence of mTORC2 
signaling suggested that partial AKT signaling may be sufficient for a subset of 
cells to progress to PanIN lesions.  The presence of these lesions afforded the 
opportunity to characterize these lesions and determine that their proliferative 
potential was reduced in the absence of mTORC2. 
Following the development of focal PDAC, treatment of Pdx1-Cre; LSL-
KrasG12D/+; Trp53fl/+ mice with a PI3K inhibitor failed to significantly improve 
survival relative to mice treated with gemcitabine (Alagesan, Contino et al. 2015). 
In a similar study, Pdx1-Cre; KrasG12D; Cdkn2afl/fl mice treated with a 
combination of PI3K and gemcitabine did not demonstrate a significant increase 
in survival relative to animals treated with gemcitabine mono-therapy (Junttila, 
Devasthali et al. 2015).   
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One of the major downstream consequences of PI3K signaling is the 
activation of mTORC1 signaling (Guertin and Sabatini 2007).  Rapamycin 
provides acute inhibition of mTORC1, although long term exposure has been 
shown to inhibit mTORC2 activity in some cellular contexts (Sarbassov, Ali et al. 
2006).  Rapamycin treatment provided no survival benefit to Pdx1-Cre; LSL-
KrasG12D; LSL-Trp53R172H/+ mice (Morran, Wu et al. 2014), and was shown to 
increase proliferation in the nutrient deprived interiors of tumors derived from this 
model (Palm, Park et al. 2015).  Our findings that the dual mTORC1/2 inhibitor 
AZD2014 improved survival in Pdx1-Cre; LSL-KrasG12D; LSL-Trp53R172H/+ 
animals (Figure 2.13) and that this drug provides a synergistic effect with 
gemcitabine (Figures 2.12, 2.13), while inhibition of mTORC1 provided no benefit 
(Morran, Wu et al. 2014), suggests that mTORC2 inhibition plays an important 
role in this response.  
The failure of mTORC1 specific inhibitors to induce cell death in cancer 
cells is often attributed to the inactivation of negative feedback loops and 
subsequent hyper-activation of AKT; in PDAC cell lines, acute inhibition of 
mTORC1 removed the feedback inhibition of S6K on IRS and mTORC2 (Soares, 
Ni et al. 2013).  Recently, it has also been shown that in nutrient deprived 
settings, inhibition of mTORC1 increases the efficiency of lysosomal degradation 
of extracellular proteins, providing a source of amino acids to these cells (Palm, 
Park et al. 2015).  The use of mTOR kinase active site inhibitors, which inhibit 
both mTORC1 and mTORC2, avoided hyper-activation of AKT in human PDAC 
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cell lines; however, levels of p-ERK increased.  Furthermore, specific inhibition of 
mTORC2 also dramatically increased ERK activity in human PDAC cell lines 
(Soares, Ni et al. 2013, Soares, Ming et al. 2015), a result that contrasts with 
both in vitro and in vivo results from my studies showing no compensatory 
activation of ERK in the absence of Rictor (Figure 2.3, 2.8).  Our data showing a 
cooperative effect of mTORC1/2 and PI3K% inhibition on the treatment of 
established late stage tumors arising in Pdx1-Cre; LSL-KrasG12D; LSL-
Trp53R172H/+ animals (Figure 2.14) and in vitro (Figure 2.15) suggest that 
combining dual mTORC1/2 inhibition with inhibition of appropriate isoforms of 
PI3K may, in some highly relevant contexts, provide therapeutic benefits.   
 
Compensatory ERK Signaling and Its Confounding Role in PDAC 
Treatment  
Both the RAF-MEK-ERK and PI3K-PDK1-AKT-mTORC1 pathways have 
been validated as KRAS effector pathways important for the initiation and 
progression of PDAC (Collisson, Trejo et al. 2012, Eser, Reiff et al. 2013).  AKT 
has been shown to negatively regulate the RAF-MEK-ERK pathway by 
phosphorylating B-RAF at multiple sites within its amino-terminal regulatory 
domain (Zimmermann and Moelling 1999, Guan, Figueroa et al. 2000).  Although 
1 of 2 human PDAC cell lines showed elevated p-ERK levels upon treatment with 
a PI3K inhibitor (Alagesan, Contino et al. 2015), significant increases in p-ERK 
levels were not observed following treatment of advanced PDAC in GEMM 
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models with PI3K inhibitors (Alagesan, Contino et al. 2015, Junttila, Devasthali et 
al. 2015). Upon combined treatment with PI3K and MEK inhibitors, survival of 
Pdx1-Cre;LSL-KrasG12D; Trp53fl/+ and Pdx1-Cre;KrasG12D;Cdkn2afl/fl mice was 
extended relative to vehicle treated mice; however, significant increases in 
survival relative to gemcitabine treated animals were observed only in the Pdx1-
Cre; LSL-KrasG12D; Trp53fl/+ mice (Alagesan, Contino et al. 2015, Junttila, 
Devasthali et al. 2015). This raises an intriguing question as to whether p16INK4A 
may be required for the response to dual PI3K-ERK inhibition.   
In KC-Rictor$/$ PanIN lesions observed at 4 and 8-months of age, ERK 
activity was not changed relative to their KC counterparts (Figures 2.2, A.1), 
suggesting that differential ERK signaling was not involved in the impaired 
progression phenotype.  However, the difference in the average PanIN grades 
between KC and KC-Rictor$/$ mice presents the possibility that the apparent 
equivalence of p-ERK staining resulted from the comparison of RAS driven p-
ERK in late stage lesions of KC mice with compensatory p-ERK seen in lower 
grade PanINs of KC-Rictor$/$ mice.  My observations of low grade PanINs do not 
support this; however, a dual analysis of p-ERK staining intensity and PanIN 
grade, conducted by a certified pathologist, would provide a quantitative analysis 
with a higher resolution of disease state, and might identify differential p-ERK 
levels between PanIN1a, and PanIN1b, or PanIN1b and PanIN2, too subtle to be 
recognized without extensive pathological training.   
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These findings of unchanged p-ERK levels in 4 and 8-month old KC-
Rictor!/! animals are consistent with data from KC mice haploinsufficient for 
P110# as well as KC-Trp53-/- and KC-Cdkn2a-/- mice treated with a small 
molecule inhibitor of PI3K (Baer, Cintas et al. 2014, Alagesan, Contino et al. 
2015, Junttila, Devasthali et al. 2015). These in vivo findings are also supported 
by my own in vitro data, in which any increases in p-ERK levels were minor 
following shRNA mediated Rictor knockdown (Figure A.8).  Results published by 
Soares et al, in which dual mTOR/PI3K inhibition or Rictor knockdown in two 
human PDAC lines resulted in robust elevation of p-ERK levels, differ from my in 
vitro findings (Soares, Ming et al. 2015).  This discrepancy may be explained as 
a difference between mouse and human samples or as an artifact of extended 
time in culture of the human PDAC lines.   Differences in the experimental time 
line might also contribute to these divergent findings.  Cell lysates from siRNA 
mediated knockdown of Rictor in human PDAC cell lines were harvested 48 
hours earlier than from my shRNA mediated knockdown in murine PDAC; the 
robust ERK1/2 phosphorylation induced by dual inhibition of mTOR and PI3K 
was measured 2 hours after treatment (Soares, Ming et al. 2015). While Rictor 
knockdown was maintained in my cells, it is possible that ERK activation in 
response to mTORC2 inhibition is transient, not sustained. 
In the context of caerulein treatment, KC-Rictor$/$ pancreata showed 
decreased levels of p-ERK.  This was an unexpected finding that warrants 
discussion and further investigation.  It is unclear from my data whether or not 
-)%
phosphorylation of ERK in KC-Rictor$/$ pancreata occurs in response to 
caerulein induced acute pancreatitis.  In KC and KC-P110# deficient animals 
ERK phosphorylation was shown to occur rapidly in response to caerulein insult, 
and while p-ERK levels were maintained over time in KC pancreata, they 
decreased in KC-P110#-/+ and KC-P110#-/- pancreata (Baer, Cintas et al. 2014).  
This supports the possibility that ERK may initially be activated in KC-Rictor!/! 
following caerulein insult, but that mTORC2, like PI3K, is required for it’s 
sustained activity.  It is also possible that in the absence of mTORC2, ERK is not 
activated in response to caerulein.    Observation of p-ERK levels in KC-Rictor!/! 
pancreata at 1, 2, and 5 days following caerulein injection should provide insight 
into the role of mTORC2 in the activation and maintenance of ERK signaling in 
response to acute pancreatitis.  If Rictor proves to be required for early activation 
of ERK in response to acute pancreatitis, additional observations of ERK levels in 
KRAS wild-type pancreata, both with and without Rictor, could be used to 
investigate whether mTORC2-dependent ERK activation in response to caerulein 
insult is independent of constitutive KRAS signaling.   Furthermore, the delayed 
progression of caerulein induced KC-Rictor!/! PanINs permits the possibility that 
in the context of pancreatitis, mTORC2 mediated ERK signaling is required for 
the progression of PanINs. 
Given the importance of the RAF-MEK-ERK pathway in the development 
of PDAC (Collisson, Trejo et al. 2012), understanding contexts in which targeted 
inhibition of pathways could enhance signaling through RAF-MEK-ERK is vital.  
-)&
Given the possibility that mTORC2 inhibition may result in elevated signaling 
through this pathway, observing p-ERK levels in the animals treated with 
AZD2014 would provide valuable insight into possible compensatory activation in 
this model.   Identifying common mechanisms of compensation and developing 
therapeutics directed at those pathways has proven effective in the treatment of 
NSLCs refractor to EGFR tyrosine kinase inhibitors (Janne, Yang et al. 2015).  
Predicting and targeting the pathways by which PDAC might evade targeted 
therapies may inform the selection of therapeutics and extend patient survival. 
 
Identifying Phenotypically Relevant Targets of mTORC2  
Both PDK1 and mTORC2 act in concert to phosphorylate targets known to 
play important roles in PDAC signaling. Understanding how these kinases 
function to promote tumorigenesis may provide insights into molecular 
vulnerabilities of this disease.  My data have shown that mTORC2 activity plays a 
role in the formation of PanIN lesions, as well as shaping the microenvironment 
in which these lesions develop into PDAC.  Conditional mouse-models provide 
excellent systems in which to investigate the loss of specific downstream 
components of this signaling complex in the context of a dynamic mammalian 
system.  To further investigate the roles of PDK1 and mTORC2 downstream 
targets, and their contributions to PanIN and PDAC development, the KC mouse-
model could be combined with conditional knockouts of AKT1, AKT2 and SGK1 
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(Bell, Horita et al. 1984, Fejes-Toth, Frindt et al. 2008, Wan, Easton et al. 2012).  
Bridget Shafit-Zagardo at Albert Einstein College of Medicine has proposed a 
conditional allele for AKT3, but such an allele has not yet been published (Shafit-
Zagardo 2014).  No conditional alleles have been published for SGK2 or SGK3.  
Ideally such mice would be developed to enable a full understanding of how the 
members of these two families contribute to PanIN formation and progression. 
Although it is unlikely that pancreatic loss of AKT or SGK isoforms would have 
dramatic developmental phenotypes, given the lack of such phenotypes in the 
absence of mTORC2, PDK1 or PI3Ka (Eser, Reiff et al. 2013, Baer, Cintas et al. 
2014), temporal control afforded by inducible CRE systems would allow both the 
visualization of such phenotypes and the potential to circumvent them.  
Although the development and use of mouse-models to address the 
questions proposed would be ideal, limited time, and money as well as the 
ethical responsibilities that accompany animal research, make the use of cell 
culture models more realistic approach to try and identify relevant targets to be 
further studied in vivo.  I utilized cell lines derived from established PDAC to 
assess the loss mTORC2 signaling in a model of late stage disease.  Increased 
doubling time upon shRNA mediated Rictor knockdown (Figures 2.11, A.9) 
showed that the reduced proliferation observed in early PanIN lesions could also 
be obtained in established PDACs deficient for Trp53 or Cdkn2a by inhibiting 
mTORC2.  Furthermore, the reduction of anchorage independent growth in these 
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cell lines (Figures 2.11, A.9) suggested that RAS driven tumorigenicity, not just 
proliferation, was affected by Rictor knockdown.  
While p-AKT473 and p-NDRG1T346, measures of mTORC2 activity, were 
generally decreased upon Rictor knockdown (Figure A.8), their decrease was 
moderate suggesting that both AKTS473 and SGKS422 may be phosphorylated by 
additional players in the context of mTORC2 knockdown.  These findings 
contrast my in vivo observations, that phosphorylation of AKT473 and NDRG1T346 
were all but eliminated in KC-Rictor$/$ PanIN lesions at 4 and 8-months of age 
(Figures 2.3, A.1).  Furthermore, tumors that arose in KPC mice treated with 
AZD2014 maintained a reduction in mTORC2 signaling (Figure 2.13) suggesting 
that any phosphorylation of AKTS473 and SGKS422 by alternative mechanisms may 
be context specific.  mTORC1 signaling, as assessed by p-S6KT389, was 
moderately elevated following Rictor knockdown and a modest increase (1.0 - 
1.8 fold) in p-ERK was also observed (Figure A.8).  The increase in p-S6K is 
consistent with previously reported data (Soares, Ming et al. 2015), but given the 
quality of these blots, probing with the p-S6K target p-S6 to confirm these 
findings would be prudent.  The mild elevation of p-ERK, which I observed in 
response to Rictor knockdown, is much less robust than observations in human 
PDAC cell lines (Soares, Ming et al. 2015).   
Although PDK1 and mTORC2 share many targets, they target different 
sites and have varying effects on the activity of such targets.  Understanding the 
signaling changes effected by mTORC2 inhibition and how they differ from those 
-))
resulting from PDK1 inhibition may provide valuable insight into efforts to inhibit 
this pathway.  Rather than probing for all known proteins effected by mTORC2 
and PI3K, a more global in vitro screening approach, such as a dot blot or 
reverse phase protein array, in which the signaling responses of KRAS-driven 
PDAC lines to mTORC2 or PDK1 loss are compared, should provide valuable 
insight into the differences between these two collaborators. 
In attempting to determine which downstream mTORC2 pathway is 
required for the anchorage independence phenotype observed upon Rictor 
knockdown, I utilized constitutively active SGK1 and myristoylated-AKT1.  
Elevated SGK1 in Breast cancer has been shown to increase resistance to AKT 
inhibitors (Sommer, Dry et al. 2013), while myristoylated-AKT1 is strongly 
activated and has been shown to gain some functions of the AKT2 isoform 
(Kohn, Summers et al. 1996). The activated SGK1S422D mutant increased the 
phosphorylation of its target NDRG1; however, it did not rescue the Rictor 
knockdown phenotype and mTORC2 retained its influence on SGK1 activity 
Figure A.10).  Of note, multiple NDRG1 bands recognized by both the p-NDRG1 
and total NDRG1 antibodies are the result of a recently identified proteolytic 
cleavage event and not phosphorylation or glycosylation (Ghalayini, Dong et al. 
2013).   
The ectopic expression of myristoylated-AKT1 provided a robust 
expression of phosphorylated AKTS473, which was insensitive to mTORC2 
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inhibition.  While mTORC2 is the primary mechanism by which AKTS473 is 
phosphorylated (Guertin, Stevens et al. 2006), other kinases, including IKBKE, 
can phosphorylate this site in the absence of mTORC2 activity (Rajurkar et. al. 
2016 under review).  Localization of myristoylated-AKT1 to the membrane 
appears to increase phosphorylation of AKTS473 through mTORC2 independent 
mechanisms, as expression of myristoylated-AKT1 rendered the endogenous 
AKTS473 insensitive to mTORC2 inhibition (Figure A.10).  
In addition to the anticipated increase of AKTS473 levels, myristoylated-
AKT1 increased NDRG1 phosphorylation in an mTORC2 independent fashion 
(Figure A.10).  AKT and SGK recognize nearly identical consensus sequences 
as targets for phosphorylation (Alessi, Caudwell et al. 1996, Kobayashi, Deak et 
al. 1999), and subtle differences in binding site preference, as well as localization 
of kinase-targets, play roles in the specificity of SGK and AKT isoforms (Tran, 
Brunet et al. 2003).  It is therefore reasonable to conjecture that expression of 
myristoylated-AKT1 may target proteins and phosphorylation sites that fall 
outside its normal regulatory sphere.  A similar expansion of AKT1 targets was 
demonstrated by the ability of membrane bound AKT1 to localize Glut4 to the 
membrane, a function normally specific to AKT2 (Kohn, Summers et al. 1996, 
Calera, Martinez et al. 1998).  This is likely the cause of the increased mTORC2 
insensitive NDRG1 phosphorylation seen in response to myristoylated-AKT1 
expression (Figure A.10).  It is possible that increased AKT activity in PanIN 
lesions and PDAC might also result in phosphorylation of a broadened spectrum 
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of targets.  The inability of myristoylated-AKT1 to rescue anchorage 
independence suggests that AKT alone is not responsible for this phenotype.   
PDAC cells lines infected with SGK1S422D demonstrated elevated SGK1 
activity as measured by p-NDRG1T346, and while these p-NDRG1 levels were 
decreased upon Rictor knockdown, they decreased only to the levels of the 
empty vector controls, suggesting that the SGK1 activity was roughly equivalent 
to the unperturbed empty vector control (Figure A.10).  Thus, constitutive 
activation of SGK1 does not, by itself, rescue Rictor knockdown, and SGK1 alone 
is not responsible for the anchorage independent growth phenotype. 
The phosphorylation of NDRG1 in response to expression of 
myristoylated-AKT1 suggests that this protein activated at least some of the 
downstream targets of SGK1.  This further supports a failure of SGK1 to rescue 
the Rictor knockdown phenotype, and suggests that combining constitutively 
active SGK1 and AKT1 would not rescue the anchorage independent growth 
phenotype perpetuated by Rictor knockdown.   
While rescue experiments conducted with additional isoforms of AKT and 
SGK might result in the identification of a critical downstream target, identification 
of additional targets through an unbiased approach may provide clearer direction 
to future investigations.  A temporal analysis of signaling following Rictor 
knockdown would provide a useful understanding of the compensatory signaling 
responses in PDAC, and help to explain how these cells arrive at a new, less 
tumorigenic homeostasis.  It would be wise to consider broadening such an 
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analysis beyond well described mTORC2 targets and feedback loops, employing 
approaches such as multiplexed reverse phase protein arrays, to identify novel 
targets and pathways in which they are altered.   
 
A Role for mTORC2 in Pancreas Size 
Given the importance of AKT signaling on proliferation (Testa and Tsichlis 
2005), and regulation of cell size (Fingar, Salama et al. 2002), it was not 
surprising to find that both the number and size of cells was reduced in Rictor!/! 
pancreata (Figure2.1).  While a portion of the decreased organ mass was a result 
of smaller cells, I found a reduction in overall cell number to be primarily 
responsible for this phenotype.  This contrasts findings in whole body 
hypomorphic PDK1 mice, in which the sizes of the kidney, pancreas, spleen and 
adrenal gland were reduced. The decrease in the size of the adrenal gland was 
determined to be the result of decreased cell size; however, the pancreata were 
not analyzed regarding cell size and number (Lawlor, Mora et al. 2002). My 
findings suggest that mTORC2 signaling may regulate cellular proliferation during 
pancreatic development.  Published data showing that beta-cell specific knockout 
of Rictor decreases their proliferation also supports my findings (Gu, Lindner et 
al. 2011).  Although opposing studies observing conditional knockout of PDK1 in 
pancreatic development have not been published, they could help to identify 
disparities between PDK1 and mTORC2 signaling and may identify in vivo 
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differences between mTORC2 and PI3K-PDK1 signaling during pancreatic 
development. 
PTF1a-CRE is expressed at some point during the development of all 
acinar and most ductal cells as well as 95% of %-cells and 75% of #-cells.  Given 
the importance of exocrine and endocrine function in digestion and glucose 
homeostasis respectively, disruption of either of these pancreatic roles could 
produce phenotypes including development of diabetes or decreased mouse 
weight. %-cell specific knockout of Rictor did not alter the size of these cells or the 
weight of mice; however, a decrease in %-cell mass and subsequent decrease in 
pancreatic insulin content were observed (Gu, Lindner et al. 2011).  The finding 
that %-cell content was decreased while %-cell size was maintained (Gu, Lindner 
et al. 2011) supports my conclusion that the differences in pancreas size in Rictor 
knockout pancreata are primarily driven by decreased cell numbers.  
Furthermore, this study supports my finding that Rictor-deficient pancreata did 
not affect the overall fitness of the mice and adds credence to my assertion that 
pancreatic function was normal, or at least sufficient for the needs of mouse 
development despite the loss of Rictor during organogenesis (Figure 2.1).   
With regards to pancreas specific Rictor deletion, the intent of my analysis 
was to identify systemic defects that might preclude subsequent development of 
this model to observe the role of mTORC2 in PDAC.  My data provided a 
snapshot of pancreatic composition roughly 2.5 months following Rictor loss at 
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embryonic day 9.5, and, while sufficient to answer my question, it was not a 
comprehensive analysis of pancreatic development and function, and would be 
insufficient to identify subtle changes in total islet numbers or sizes. Additionally, 
my findings were obtained at 2-months of age and do not preclude the possibility 
that pre-natal or juvenile Rictor$/$ mice may have pancreatic deficiencies that 
resolve by this point.  These data do, however, show the viability and generally 
equivalent fitness of Rictor$/$ mice.  The development of a functional, albeit 
smaller, pancreas suggests that the phenotypes observed in the context of 
activating KRAS mutations were not a result of a developmental defect. 
 
The Role of mTORC2 Signaling in Metastasis Remains Unclear 
 Patients diagnosed with PDAC usually succumb to metastatic disease 
rather than the primary tumor; however, due to their aggressive nature, the 
primary tumors in KPC mice are usually responsible for the demise of the 
animals.  The KPC animals used in our study contained a gain of function 
p53R172H allele and, consistent with previous studies, gross metastatic lesions 
were observed in roughly 50% of these animals.  In KPC-Rictor!/! animals, gross 
metastatic disease was observed in roughly 25% of these animals at the time of 
death, although this difference was not statistically significant.  Histological 
analysis of these samples for micro-metastatic lesions has not yet been 
conducted.  The increased lifespan of the KPC-Rictor!/! animals relative to the 
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KPC animals presents increased time for the development of metastatic disease 
and the presence of metastatic lesions in the long-lived KPC-Rictor!/! animals 
may suggest that mTORC2 deficient metastatic lesions have reduced 
proliferative capacity.  An analysis of micro-metastatic frequency would be 
required to determine if fewer lesions occur or if these lesions are simply growing 
more slowly in the absence of Rictor. 
 A role for mTORC2 has been implicated in metastatic disease in both 
bladder cancer and colorectal cancer.  Phosphorylation of the mTORC2 target 
AKTS473 was observed in invasive bladder carcinoma cell lines and the migratory 
ability of these cells, as measured by wound healing assay, was impaired by 
Rictor knockdown (Gupta, Hau et al. 2013).   Both mTOR and RICTOR were 
found to be elevated in late stage colorectal cancers and metastatic lesions 
relative to normal colon epithelium.  Furthermore, trans-well migration was 
impaired by siRNA mediated knockdown of RICTOR, and intravenous injection of 
RICTOR deficient colorectal cancer cell lines into athymic nude mice prevented 
these cells from establishing lesions in the lungs, bones, and lymph nodes of 
these mice (Gulhati, Bowen et al. 2011).  Notably, the role for mTORC2 in 
metastatic bladder and colorectal cancers has been linked to RAC1, and while 
RAC1 has been shown to regulate the localization of both mTORC1 and 2 (Saci, 
Cantley et al. 2011), it has not been shown to be a target of either mTOR 
complex. RICTOR has, however, been shown to regulate RAC1 in an mTORC2 
independent manner. 
-*&
 
mTORC2 Independent Roles of RICTOR 
Throughout this thesis I have equated the expression of Rictor with 
mTORC2 activity, and while it is true that RICTOR is required for the formation of 
mTORC2, other mTORC2 independent functions of RICTOR also exist.  
Specifically, RICTOR, but not the mTORC2 specific cofactor mSIN1, has been 
identified as a regulator of cell migration.  Knockout of RICTOR in MEFs reduced  
cell migration as well as GTP bound levels of the Rho family members CDC42 
and RAC1(Agarwal, Chen et al. 2013).  CDC42 and RAC1 are known to be 
involved in the dynamic assembly of actin filaments, an important function during 
cell migration.  RICTOR inhibits Rho-GDP dissociation inhibitor 2 (RHOGDI2), 
which interacts with RAC1 and CDC42 to prevent GTP binding in these proteins. 
In the absence of Rictor, knockdown of RHOGDI2 rescued the migratory ability of 
MEFs (Agarwal, Chen et al. 2013) confirming this relationship.  RICTOR has also 
been identified in a complex with the actin-based molecular motor myosin 1c 
(MYO1C).  This complex is reported to regulate the actin filament regulatory 
protein paxillin by phosphorylation at tyrosine 118.  Knockdown of either Rictor or 
Myo1c impaired this phosphorylation and the formation of membrane ruffles, 
implying a role for the RICTOR-MYO1C complex in cortical actin remodeling 
(Hagan, Lin et al. 2008).   
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Confirmation that the phenotypes observed in my research are specific to 
mTORC2 and not an mTOR independent function of RICTOR would be achieved 
by conducting parallel experiments with a conditional mSIN1 knockout allele in 
vivo or mSIN1 knockdown in vitro.  A rescue of the Rictor knockdown phenotype 
with subsequent knockdown of RHOGDI2 would also support an mTORC2 
independent role for RICTOR.  It is notable, however, that the mTORC2 
independent functions of RICTOR have centered around cell migration, while 
neither my in vitro or in vivo data recognized a migratory phenotype.  
Furthermore, the increased survival in KPC mice treated with mTORC1/2 
inhibitors support an mTORC2-dependent rather than independent role for 
RICTOR in the support of KRAS-driven PDAC. 
 
Translational Implications for Understanding mTORC2 Signaling in PDAC 
 For decades the treatment of pancreatic cancer remained stagnant.  While 
the sequencing of the human genome and the advent of targeted therapies held 
great promise for the introduction of personalized therapies, the cures that were 
envisioned have been slow to materialize for pancreatic cancer.  In recent years 
pancreatic cancer oncology has seen some movement; the addition of 
nanoparticle bound albumin–paclitaxel to gemcitabine, and the introduction of the 
more effective, albeit more toxic, FOLFIRINOX regiment, have greatly improved 
the treatment options for this disease.  Although these drugs are cytotoxic at their 
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core and are not molecularly targeted therapeutics in the classical sense, the use 
of albumin bound–paclitaxel, which is likely sequestered by SPARC in pancreatic 
fibroblasts and successfully diminishes pancreatic stromal content, signals a 
movement towards smarter drug development (Al-Batran, Geissler et al. 2014).  
Furthermore, erlotinib, which targets the EGF-receptor, combined with 
gemcitabine, provides a robust clinical benefit (10.5 months) in a subset of 
patients, who present with a rash upon treatment (Moore, Goldstein et al. 2007).   
These therapies prove that smarter drug design and molecularly targeted 
therapeutics have the potential to dramatically improve outcomes for individuals 
diagnosed with PDAC.  With significant efforts to target members of the 
PI3K/PDK1 pathway ongoing, an understanding of how mTORC2 regulates its 
downstream targets may provide great insight into the design of future 
therapeutics targeting these pathways.  While the preventative in vivo effects of 
Rictor ablation are less robust than PI3K/PDK1 knockout, it is possible that this 
difference may allow for differential regulation of oncogenic signals, preventing 
the loss of anti-proliferative negative feedback signals.  Furthermore, an 
understanding of the role played by CDKIs in the response to mTORC2 and PI3K 
inhibition will be critical to predicting patient response to such targeted therapies. 
My data suggest that specific targeting of mTORC2 may constitute a 
rational drug target that, in combination with other targeted therapies, including 
but not limited to mTORC1 and PI3K% inhibitors, would provide increased 
therapeutic options to PDAC patients. Further understanding of the mechanism 
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by which mTORC2 signaling enables KRAS-driven PanIN formation and tumor 
maintenance, combined with proper genetic screening of tumors, will enable 
treatment design that is specific to an individual’s disease, and allow more 
accurate predictions of drug response. 
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Appendix A: 
 
Additional Data Regarding the Impact of mTORC2 Signaling on the 
Initiation and Progression of KRAS-Driven Pancreatic Neoplasias  
-*+
 
 
Preface 
 
 This appendix contains data that are relevant to a more complete 
understanding of the role of mTORC2 and its signaling in the context of KRAS-
driven PDAC.  These data are meant to complement and provide further insight 
into the findings presented in Chapter II, and have been discussed in Chapter III. 
 
 All data in this appendix were produced and analyzed by David Driscoll. 
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Results 
Rictor-null PanIN Lesions Display Impaired mTORC2 Activity 
Although the inhibition of PanIN formation in KC-Rictor$/$ mice was 
dramatic, it was incomplete. I therefore hypothesized that PanIN lesions in these 
mice arose from cells in which KRAS was activated, but at least 1 Rictor allele 
escaped recombination.  To determine the status of mTORC2 signaling in these 
lesions, pancreata from 4 and 8-month old mice (Figures 2.3 and A.1) were 
stained for targets of mTORC2 activity.  Relative to their KC counterparts, KC-
Rictor!/! PanINs had significantly reduced mTORC2 signaling, as measured by 
p-AKTS473 and SGK1 activity measured by p-NDRG1T346 (Figures 2.3 and A.1).  
Reduced mTORC2 signaling is consistent in KC-Rictor!/! PanINs observed at 4 
and 8-month of age, thereby disproving my hypothesis and showing that early 
PanIN lesions were indeed formed and maintained in the absence of mTORC2 
signaling.   
Pharmacological attempts to inhibit mTOR activity have identified 
inhibitory feedback mechanisms which, when impaired, can negate the 
therapeutic benefit of mTOR inhibition.  In PDAC cell lines, inhibition of mTORC1 
via rapamycin, or inhibition of both mTORC1 and mTORC2 via mTOR active site 
inhibitors, resulted in increased AKT or ERK phosphorylation respectively 
(Soares, Ni et al. 2013).  To better understand the effects of mTORC2 specific 
loss on oncogenic signaling in PanINs, these lesions were further characterized 
for PDK1 activity as measured by p-AKTT308 , and RAF/MEK/ERK activity as 
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measured by p-ERK1/2T202/T204.   No difference was observed in the levels of p-
AKTT308 or p-ERK1/2T202/T204 in PanINs from 4 or 8-month old mice (Figures 2.3 
and A.1).  These data suggested that the effects of mTORC2 loss did not alter 
signaling of the MEK pathway or mTORC2 independent signaling of PDK1.  
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Figure A.1:  PanIN lesions form in the absence of mTORC2 signaling.  
 
IHC staining for the mTORC2 target p-AKTS473, the SGK1 target p-
NDRG1T346, the PDK1 target p-AKTT308, and the MEK target p-ERK1/2T202/Y204 
at 4-months of age. 200X magnificaiton. 
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mTORC2 does not regulate CDKI nuclear localization through TGF-! 
signaling 
To determine the mechanism by which mTORC2 may regulate CDKI 
activity, I looked for alterations in pathways known to regulate multiple CDKI 
proteins.  Signaling through the TGF-% pathway has been shown to increase 
expression of the p16INK4A, p21CIP1 and p27KIP1 CDKIs (Reynisdottir, Polyak et al. 
1995).  Given the differences in stromal reaction between KC and KC-Rictor!/! 
pancreata, as well as the importance of TGF-% signaling in the tumor 
microenvironment and PDAC progression, I hypothesized that differential TGF-% 
signaling may be present between KC and KC-Rictor!/! PanIN lesions.  However, 
immunostaining of p-Smad3 showed no difference in levels of canonical TGF-% 
pathway activity at 4 or 8-months of age (Figure A.2). 
A second protein with the potential to coordinately regulate these CDKIs 
was the proto-oncogene B lymphoma Mo-MLV insertion region 1 homolog 
(BMI1).  The inverse correlations between BMI1 and the CDKIs reported in 
Chapter II (Figures 2.5 and 2.6) were quantified using Pearson’s product-moment 
coefficients (Pearson r).  A Pearson r was calculated between BMI1 and each of 
the CDKIs for both 4 and 8-month sample sets.  At 4-months of age, the inverse 
correlation between BMI1 and p16INK4A was moderately strong with a P value of 
0.0576, while the correlations between BMI1 and p21CIP1 and p27KIP1 were weak 
and not significant (Table A.1).  At 8-months of age strong inverse correlations 
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were observed between BMI1 and p16INK4A, p21CIP, and p27KIP1; these 
correlations were highly significant with P values of 0.0032, 0.0099 and0.0068 
respectively (Table A.1). 
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Figure A.2: TGF-! signaling, as measured by nuclear p-Smad3, was 
unaffected by Rictor loss in PanIN1 lesions. 
 
IHC staining for p-Smad3 in KC and KC-Rictor!/! PanIN lesions from 4 (A) and 8-
month(B) old mice.  (C)Quantification of nuclear p-Smad3 staining in PanIN1 
lesions of 4-month old mice (n=4).  (D) Quantification of nuclear staining in 
PanIN1 lesions of 8-month old mice (n=3-4). P value: No significant differences 
observed. Arrows and arrowheads indicate representative positive and negative 
nuclei respectively. 
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Table A.1  Quantification of Inverse correlation between BMI1 and CDKIs 
 
Pearson’s product moment coefficients were calculated between BMI1 and each 
individual CDKI (p16INK4A, p21CIP, and p27KIP1) by comparing the percentages of 
positive nuclei within PanIN1 lesions for each sample harvested at either 4 or 8-
months of age.  Negative Pearson r values represent an inverse correlation and 
the correlation strengthens as the absolute value of r approaches 1. 
 
"#$%&'( % " )$*+#
"#$%&'( ,-./0123 )&4 56/- -0.6913252 0.05755543 
,7-8/"- )&4 56/- -0.3072842 0.4590833 
,791/"- )&4 56/- -0.2802371 0.501417 
)#$%&'( ,-./0123 )&4 56/- -0.9211026 0.003217379 
,7-8/"- )&4 56/- -0.8751158 0.009886242 
,791/"- )&4 56/- -0.8928242 0.006812295 
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Impaired Proliferation and Induction of Senescence Following Rictor 
Knockdown in PanIN Derived Cell Lines 
While staining of paraffin embedded tissues provides valuable insights 
regarding the in vivo consequences of Rictor knockout in the context of KRAS, 
they are observations of a static point in time.  Cell lines provide an in vitro 
system, which, while artificial, can be manipulated and subjected to biochemical 
analysis.  To assess mTORC2 signaling in a comparable in vitro model, I 
employed an shRNA mediated knockdown of Rictor in primary cell lines derived 
from KRAS-driven murine PanIN lesions.  Efficient knockdown of Rictor in two 
such cell lines, RP 2294 and AH 2375, was confirmed by western blot in two cell 
lines generously provided by Dr. Nabeel Bardeesy (Corcoran, Contino et al. 
2011) (Figure A.3 A,B) Given the proliferative phenotype and induction of CDKIs 
observed in vivo, I hypothesized that Rictor knockdown would impair proliferation 
and induce senescence in vitro.  Consistent with this hypothesis, Rictor 
knockdown decreased proliferation, as measured by increased doubling time 
(Figures 2.5E and A.3C) and increased expression of senescence associated 
beta-galactosidase (Figures 2.5F, 2.6E and A.3D).  Consistent with the lack of 
CDKI or BMI1 protein level changes observed following Rictor knockdown in 
AH2375 cells (Figure 2.6F,G), quantification of nuclear p21CIP1and p27KIP1 by 
immunostaining showed no difference in the frequency of nuclear localization of 
these proteins in either the AH 2375 or RP 2294 PanIN cell lines following Rictor 
knockdown (Figure A.4).  Notably p16INK4A protein was not detected in the RP 
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2294 cell line, precluding its necessity for the senescence phenotype.  While 
senescence was induced upon mTORC2 depletion, the absence of differential 
CDKI or BMI1 levels highlights a disparity between tissue culture and in vivo 
PanIN models. Therefore, reduction of RICTOR in vitro decreased proliferation 
and increased senescence in PanIN derived cell lines, but these in vitro 
phenotypes appear to be independent of nuclear expression of BMI1 or the 
observed CDKIs.  
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Figure A.3:  Rictor knockdown impairs proliferation and induces 
senescence in PanIN derived cell lines. 
 
(A,B) Western blots for RICTOR in of RP 2294 and AH 2375 cells 6 days post 
shRNA mediated knockdown of Rictor or a GFP control.  #-tubulin was used as a 
loading control. (C) Doubling time of RP 2294 cells between 5 and 7 days post 
Rictor knockdown.  (D) Quantification of beta-galactosidase positive RP 2294 
cells.  P value: *<0.05, **<0.01, ***<0.001. 
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Figure A.4:  Nuclear localization of CDKIs is unaffected by Rictor 
knockdown in cultured PanIN cells. 
 
Immunocytochemical staining for p21CIP(A) and p27KIP1 (B) in cultured PanIN 
cells from Pdx1-Cre;LSL-KRASG12D pancreata following shRNA mediated 
knockdown of Rictor.  Quantification of nuclear p21CIPand p27KIP1 in the indicated 
cell lines (C).  No significant differences were observed. 
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mTORC2 Loss Impairs KRAS Mediated Responses to Pancreas Injury 
 Pancreatitis is a major risk factor for the development of PDAC and can be 
modeled in mice using caerulein induced pancreatic injury (Niederau, Ferrell et 
al. 1985, Malka, Hammel et al. 2002).   Upon caerulein injury, acinar cells 
dedifferentiate, and, in the context of mutant KRAS these cells undergo acinar-to 
ductal-metaplasia (ADM) culminating in the formation of neoplastic ducts 
(Carriere, Young et al. 2009).  ADM is a well-observed phenomenon in the KC 
model and, in some adult onset models of activated KRAS, ADM, driven by an 
inflammatory response, is required for initiation of PDAC (Guerra, Schuhmacher 
et al. 2007).  Given the limited number of PanIN lesions in KC-Rictor$/$ 
pancreata, I hypothesized that mTORC2 signaling may be required for ADM, 
thus restricting the cells of origin for PanINs formed in KC-Rictor$/$ pancreata to 
ductal cells, and preventing their formation from acinar cells.  The pancreatic-
caerulein response was used to assess the requirement for mTORC2 in acinar 
cell trans-differentiation within the contexts of both wild-type and activated KRAS.  
To induce acute pancreatitis, mice were subjected to 2 sets of 7 hourly caerulein 
injections separated by a days rest. 
Gross observation of KC pancreata 2 days post caerulein injection 
revealed enlarged organs with dissociated acinar clusters.  On average, the ratio 
of pancreas weight to mouse weight in caerulein treated KC mice was elevated 
relative to PBS injected control mice when measured 2 days post injections (P 
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value = 0.0688) (Figure 2.6).  Only 1 in 4 KC-Rictor!/! pancreata showed a 
similar increase when observed 2 days post injections (Figure A.5).  By 21 days, 
the average pancreas to body mass ratio for both KC and KC-Rictor!/! caerulein 
injected cohorts were comparable to their respective controls measured 2 days 
post PBS injection (Figure A.5).  At 21 days post injection, the caerulein treated 
pancreata of both phenotypes were fibrotic, as observed by necropsy. 
Histopathological analysis and quadchrome staining of the pancreata 21 days 
post caerulein insult confirmed that the stromal composition was reduced in the 
KC-Rictor!/! pancreata (Figure2.8 A,B).  In both genotypes, the deposition of 
collagen by pancreatic stellate cells, as measured by quadchrome staining 2 
days post caerulein insult, was minimal (Figure A.6) and did not correlate with the 
rapid increase of pancreatic weight observed in KC pancreata 2 days post 
caerulein insult (Figure A.5).  Interstitial pancreatic edema is a well-established 
response to caerulein injury (Grady, Saluja et al. 1996), and the rapid increase in 
organ mass over a short period of time and its subsequent resolution, suggests 
that this phenotype is the result of pancreatic edema.  These data suggest that 
mTORC2 plays a role in regulating the response of KRAS mutant pancreata to 
injury. 
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Figure A.5:  The rapid initial increase in KC pancreas mass following 
caerulein injection requires Rictor.  
 
Following intraperitoneal injection of caerulein (50 µg/kg) or sterile phosphate 
buffered saline, administered in 2 sets of 7 hourly injections spaced 48 hours 
apart, the ratio of pancreas mass to mouse mass was determined at the time of 
harvest.     
 
 
 
 
  
-,&
Figure A.6  Collagen deposition is unaffected by Rictor status directly 
following caerulein insult.  
 
KC and  KC-Rictor$/$ mice were subjected to intraperitoneal injection of caerulein 
(50 µg/kg) or sterile phosphate buffered saline, administered in 2 sets of 7 hourly 
injections spaced 48 hours apart.  Quadchrome stains of pancreata from mice 
sacrificed 2 days after the second set PBS injections (top row), or 2 days after 
the second set of caerulein injections (bottom row).  Red is collagen, blue is 
mucin, yellow is cytoplasm and grey is nuclear staining.  All images taken at 50x 
magnification. 
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mTORC2 Loss Reduces SGK Signaling Following Pancreatic Injury 
 Signaling through the SGK pathway, as measured by immunostaining for 
p-NDRG1T346, was reduced in KC-Rictor!/! PanINs relative to their KC 
counterparts in pancreata harvested 21 days post caerulein injection (Figure 
A.7).  These data complement findings presented in Figure 2.8C showing 
reduced p-AKTS473 levels in KC-Rictor!/! following pancreatic insult.  Together 
these data provide evidence that both these downstream readouts of mTORC2 
activity are decreased in the absence of Rictor following pancreatic insult by 
caerulein, and are consistent with observations in uninjured 4 and 8-month old 
pancreata. 
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Figure A.7:  mTORC2 signaling through SGK1 is impaired in KC-Rictor!/! 
PanIN lesions 21 days post caerulein insult.   
 
Pancreata harvested from KC and KC-Rictor!/! mice 21 days post caerulein 
injection were stained by IHC for p-NDRG1T346.  Images taken at 200x 
magnification. 
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Nuclear BMI1 Ratios Inversely Correlated With Nuclear CDKIs in Caerulein 
Provoked KC and KC-Rictor!/! PanIN1s  
 Given the accelerated context of PanIN development in my caerulein 
injected model, I sought to determine the role of mTORC2 loss on cell cycle 
progression in KRAS-driven PanINs following caerulein insult.  Characterization 
of CDKI activity in these lesions was accomplished by immunohistochemical 
staining and quantification of positive nuclei within PanIN1 lesions and was 
described in Chapter II (Figures 2.8 and 2.9).  The inverse correlations observed 
between BMI1 and the CDKIs were quantified by deriving Pearson’s product-
moment coefficients for nuclear BMI1 relative to each CDKI (p16INK4A, p21CIP1 
and p27KIP1) in PanIN1 lesions from samples harvested 21 days following the 
second caerulein injection set (Table A.2).  Both p16INK4A and p27KIP1 showed 
strong, statistically significant, inverse correlations with BMI1, while the inverse 
relationship between nuclear p21CIP1 and BMI1 was weaker and not significant.  
These data provide correlative evidence suggesting that BMI1 is a potential 
mechanism by which KRAS may regulate these CDKIs in PanIN lesions.    
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Table A.2  Quantification of inverse correlation between BMI1 and CDKIs 
following caerulein insult. 
 
Pearson’s product moment coefficients were calculated between BMI1 and each 
individual CDKI (p16INK4A, p21CIP, and p27KIP1) by comparing the percentages of 
positive nuclei within PanIN1 lesions for each sample harvested 21 days 
following the second set of caerulein injections.  Negative Pearson r values 
represent an inverse correlation and the correlation strengthens as the absolute 
value of r approaches 1. 
 
 
 
 
  
Pearson r P value 
21 Days Post 
Caerulein 
Injection 
p16INK4A vs. BMI1 -0.8288 0.011 
p21CIP1 vs. BMI1 -0.4259 0.2927 
p27KIP1 vs. BMI1 -0.8444 0.0083 
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KRAS-driven PDAC Cell Lines Require mTORC2 for Maintenance of 
Tumorigenic Properties 
Having established a role for mTORC2 in the development and 
progression of PanIN lesions, I sought to provide insight into the worth of 
mTORC2 specific inhibition as a therapeutic intervention in established PDAC by 
assessing its role in tumor maintenance. I hypothesized that disruption of 
mTORC2 activity would impair the proliferative rates and anchorage independent 
growth abilities of PDAC cell lines.  To determine the necessity for mTORC2 
signaling in established PDAC, cell lines derived from LSL-KRAS driven tumors, 
designed to be deficient in Trp53, were infected with 2 independent shRNAs 
targeting the essential Rictor component of mTORC2.  Puromycin selection 
began 30 hours post infection and cells remained in selection for the duration of 
these assays.  Whole cell lysates were harvested, following 24 hour serum 
starvation and 15 minute re-stimulation, and showed robust knockdown of 
RICTOR. Reductions of the mTORC2 target p-AKTS473, and SGK signaling 
through p-NDRG1T346 were consistent between both shRNAs in the Cdkn2a; 
Smad4-deficient 906 cell line (Figure A.8).  Decreased p-AKTS473 was observed 
following knockdown of Rictor with either shRNAs in the Trp53-deficient 9910#1 
cell line, however only one of the two Rictor targeting shRNAs reduced levels of 
p-NDRG1T346 (Figure A.8).  The mTORC1 target p-S6K showed a 1.3 to 4.5 fold 
increase, with shRic 2 providing a greater increase in phosphorylation of S6K 
(Figure A.8).  The MEK1/2 target p-ERK showed little change in the 9910 cells 
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and a moderate increase in the 906 cells following RICTOR knockdown (Figure 
A.8).     
Anchorage independent growth, as measured by the formation of colonies 
in soft agar, and proliferation rate, inversely measured by doubling time, were 
was significantly reduced upon Rictor knockdown in the KRAS-driven, Trp53-
deficient, 6823#3 and 9415#1 (Figure A.9), consistent with the findings for 906 
and 9910#1 cells presented in Figure 2.11.    
  
%..
Figure A.8:  Knockdown of Rictor in PDAC cell lines reduced 
phosphorylation of mTORC2 targets but not mTORC1 or MEK targets. 
 
Cell lines derived from KRAS-driven mouse PDAC were infected with lentiviral 
shRNAs targeting Rictor.  At 4 days post infection cells were serum starved for 
24 hours.  Following starvation, cells were fed with 10% serum for 15 minutes 
and harvested for whole cell lysates.  In addition to activated KRAS, 9910#1 cells 
are Trp53-deficient, and 906 cells lack Smad4 and Cdkn2a. Numbers below the 
phosphorylated protein bands represent the quantification of band intensities for 
phosphorylated proteins normalized first to the corresponding total protein level 
and then to the normalized value for the shGFP control.  
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Figure A.9 Anchorage independent growth and proliferation of KRAS-
driven PDAC cell lines is impaired by Rictor knockdown. 
 
Following shRNA mediated Rictor knockdown and puromycin selection in 
6823#3, and 9415#1 mouse PDAC cell lines, (A,B) colony formation in soft agar 
was measured by seeding 1x105  cells in 0.4% agar and allowed to grow for 2-3 
weeks.  Assays were plated in triplicate and 12 fields of view were counted for 
each plate. P values were derived via Student’s T-test.  (C,D)  To measure 
proliferative rates cells were seeded at 1x104 cells/well.  Counts were taken at 24 
hour intervals for 72 hours. Proliferative rate was plotted on a log2 scale and 
doubling time was determined as the inverse slope of this line. P values were 
derived from the inverse slopes of doubling times using analysis of counter 
variance.  Error bars represent 95% confidence intervals. 
 P values: *<0.05, **<0.01, ***<0.001. 
 
 
 
%.%
 
 
I hypothesized that constitutive activation of either AKT or SGK signaling 
would replace the oncogenic activity lost by mTORC2 ablation and rescue the 
anchorage independent growth deficit induced by Rictor knockdown.  To assess 
the roles of these downstream mTORC2 targets, constitutively active SGK1S422D 
and myristoylated AKT1 were ectopically expressed using a pBABE-neomycin 
retroviral system.   Cells were maintained in selection for 4 days prior to lentiviral 
knockdown of Rictor after which cells were maintained in dual puromycin and 
neomycin selection for the remainder of these assays.  Consistent with our 
previous findings, knockdown of Rictor decreased soft agar colony formation in 
pBABE-neomycin infected cell lines.  Decreased anchorage independent growth 
mediated by Rictor knockdown was unaffected by ectopic expression of either 
SGK1 or AKT in either Trp53 (9910#1) or Cdkn2a/Smad4 (906) deficient cell 
lines (Figure A.10A).   
Whole cell lysates harvested 5 days post infection, following 24 hours of 
serum starvation and 15 minute re-stimulation, were probed for levels of 
phosphorylated p-NDRG1T346 and p-AKT473  via western blot as measures of 
mTORC2 pathway activity.  Knockdown of Rictor decreased p-NDRG1T346 and p-
AKTS473 levels in cells lacking ectopic expression of SGK1 or AKT1 (Figure 
A.10B).  Phosphorylation of NDRG1T346 was increased by ectopic expression of 
SGK1S422D,  and this activity was reduced upon mTORC2 depletion.  
Surprisingly, myristoylated AKT1 also increased NDRG1 activity in an mTORC2 
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independent manner.  Phosphorylated AKT473 levels were not altered by ectopic 
expression of  SGK1S422D and remained sensitive to Rictor knockdown (Figure 
A.10B).  Expression of myristoylated AKT1 at levels similar to endogenous AKT 
resulted in an mTORC2 insensitive elevation of p-AKT473 levels.  Moreover, in the 
context of myristoylated AKT, the faster migrating endogenous AKT473 was also 
insensitive to Rictor knockdown (Figure A.10B).    Taken together these data 
suggest that the anchorage independent growth phenotype seen in PDAC cells is 
independent of AKT1.  However, given that the constitutively active SGK1S442 
was still susceptible to mTORC2 depletion, SGK1 mediated regulation of this 
phenotype cannot be completely ruled out. 
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Figure A.10:  Following Rictor knockdown, neither AKT1 nor SGK1 rescued 
transformative ability of KPC cells.   
 
KRASG12D driven mouse PDAC cell lines, 9910#1, and 906 were infected with 
either myristoylated-AKT1 or constitutively active SGK1S422A.  Cells were then 
selected with neomycin and infected with lentiviral shRNAs targeting Rictor.  (A) 
Following puromycin selection 1x105 cells/plate were seeded in 0.4% agar. 
Colonies were maintained in the presence of puromycin but not neomycin, and 
were counted between 2 and 3 weeks. (B) Protein levels of phosphorylated and 
total AKT and NDRG1 were probed by western blot. 
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Expanded Materials and Methods 
 
Mouse strains  
All procedures and care were provided under protocols approved by the 
University of Massachusetts Institutional Animal Care and Use Committee.  The 
Ptf1aCre allele was developed and previously described by Kawaguchi et al. 
(Kawaguchi, Cooper et al. 2002); these mice were a gift from Chris Wright.   The 
LSL-KRASG12D allele was developed and previously described by Jackson et al. 
(Jackson, Willis et al. 2001) and was obtained from Jackson laboratories.  The 
conditional Rictor allele has also been previously described (Shiota, Woo et al. 
2006), and was a gift from David Guertin.  Ptf1aCre/+;LSL-KRASG12D/+;Rictor+/+ 
(KC) and Ptf1aCre/+;LSL-KRASG12D/+;RictorEx3cond/Ex3cond (KC-Rictor!/!) siblings 
were euthanized for analysis at 4 or 8-months of age. F2 of the Rictor 
heterozygous crosses provided Ptf1aCre/+ (Rictor+/+) and 
Ptf1aCre/+;RictorEx3cond/Ex3cond (Rictor!/!) animals for the characterization of 
pancreatic Rictor knockout and caerulein injections, as well as KC and KC-
Rictor!/! animals for caerulein injections.  Rictor+/+ and Rictor!/! animals were 
euthanized at 2-months of age to assess the role of Rictor in pancreatic 
development.   
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Caerulein injections 
Caerulein (Sigma C9026, 50 µg/kg) was delivered intraperitoneally into 5 - 
7 week old mice in a series of two sets of 7 hourly injections separated by 42 
hours.  Injection of vehicle (0.05M Ammonium hydroxide in PBS) was used as a 
control.   Mice were sacrificed at 2 or 21 days following the final injection series. 
 
Histology 
Following necropsy, pancreata were formalin fixed overnight, embedded in 
paraffin (FFPE), and 5-micron sections were mounted on positively charged 
slides.  H&E staining was done according to field standard. For quadchrome 
staining, previously described staining methods for picro-sirius red staining for 
collagen (Junqueira, Bignolas et al. 1979, Whittaker, Kloner et al. 1994), and 
alcian blue staining for mucin (Steedman 1950) were adapted to allow co-
staining of these components.  Rehydrated slides were stained with fresh 
Wigerts’ hematoxylin (Sigma HT-1079) for 1 hour, alcian blue (2.5g alcian blue 
8GX in 250ml 3% glacial acetic acid, pH 2.5) for 30 minutes, and sirius red 
staining (0.5g of Sirius Red (Sigma 365548) in 500ml of saturated picric acid 
(Sigma P6744)) for 1 hour.  Each stain was followed by a brief wash in acid water 
(3% glacial acetic acid). Samples were rapidly dehydrated in ethanol and Xylene 
prior to mounting with PermountTM mounting media.  In this stain, collagen 
appears bright red, mucin is a bright blue, nuclei are grey to black, and cytoplasm 
is a weak yellow. 
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 A blinded histopathological analysis was conducted on H&E stained slides 
by Dr. Makoto Sano, a licensed pathologist.  Tissue type composition was 
determined for 4 fields of view per sample; fields with the greatest and least 
neoplastic progression as well as two fields that were consistent with the average 
progression seen on that tissue section were quantified.   
 
Immunohistochemistry 
Five-micron sections from FFPE samples were deparaffinized and 
rehydrated  by passage through Clear-Rite 3TM(Thermo Scientific, 6901) and a 
graded series of ethanols, 100% to 20%.  Antigen exposure was accomplished 
using Antigen Unmasking Solution (Vector H-3300) and heating the samples to a 
gentle boil via microwave.  This was followed by inactivation of endogenous 
peroxidases with 3% hydrogen peroxide, and overnight blocking with 3% normal 
goat serum or Mouse on Mouse blocking reagent (Vector labs M.O.M kit BMK-
2202).  Samples were incubated with primary antibody diluted into blocking 
solution as listed in Table 2.2 for 1 hour at room temperature.  Subsequent 
incubation with biotinylated secondary antibodies for 1 hour at room temperature 
was followed by Avidin/biotinylated enzyme complex (Elite ABC, Vector labs PK-
6101) incubation for 30min at room temperature and development using Nova-
Red (Vector Labs SK4800).   Specimens were observed using a Leica DM LB2 
microscope. 
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For insulin staining, a FITC-conjugated donkey anti-guinea secondary 
(Jackson  Immuno 706‐095‐148, 1:500) was used in lieu of a biotinilated 
antibody.  Samples were mounted with dapi containing hard-set (Vector H-1500) 
and observed with a Nikon Eclipse E400 microscope.   
 
Estimation of relative cell number and size  
Total gDNA was isolated from a tissue fragment resected from the tail of 
the pancreas by standard phenol-chloroform extraction.  The gDNA 
concentration of the tissue was determined by dividing the mass of the gDNA 
isolated by the weight of the fragment.  The amount of total genomic DNA was 
extrapolated by multiplying the gDNA tissue concentration by the mass of the 
pancreas.  These calculations assume equivalent amounts of gDNA in all cells. 
To estimate cell size, 5µm thick sections from formalin fixed, paraffin 
embedded tissues were deparaffinized and stained with dapi (1:2000 in PBS) for 
5 minutes. Followed by 2 washes in PBS.   The number of dapi positive nuclei in 
5-8 fields of view per sample was counted using ImageJ.  The area of pancreatic 
tissue, measured in pixels, was determined via ImageJ, and an image of a 
hemocytometer was used to determine that 400µm2 is equal to 450pixels and 
derive a conversion factor of 0.8888889 µm2/pixel.  The average number of 
pixels/cell was calculated and multiplied by this conversion factor to convert to 
µm2/cell. 
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PanIN Cell culture experiments 
Cell lines 
Primary PanIN lines (AH 2375, RP 2294), a gift from Dr. Nabeel Bardeesly 
(Corcoran, Contino et al. 2011), were grown on laminin coated plates in media 
described by Schreiber et al in 2004 (Schreiber, Deramaudt et al. 2004) for 
culture of pancreatic ductal cells.  Lentivirus was produced by transfection of 
HEK 293T cells (5x105 cells in a 9.5cm2 area) with pCMV delta 8.9 packaging 
plasmid (0.3µg), pMDG envelope plasmids (0.2µg) and a pLKO plasmid (0.5µg) 
targeting either Rictor or GFP (Table 2.2).  PanIN cell were subject to 2 lentiviral 
infections at 5-hour intervals.  Cells were plated at concentrations of 2.7x104 
cells/well in 6 well plates for proliferation assays, and %-galactosidase assays, 
and 1.3x105 cells/10cm dish for cell lysates.  All cells were maintained in 3µg/ml 
puromycin selection beginning 30 hours after the initial infection.  
 
Proliferation assays 
Viable cells were counted using trypan blue exclusion on days 4, 5 and 6 
post-infection.  Log2 of cell/well numbers were plotted against time and doubling 
time was derived from the inverse slope.  Significant differences in slopes, and 
thus doubling time, were determined by analysis of covariance using Prism 
Graphpad. 
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Senescence associated !-galactosidase staining  
Senescence Associated %-Galactosidase activity was assessed 4 days 
post lentiviral infection. Cells were gently fixed, stained (40 mM Citric acid 
0.1M/sodium phosphate 0.2M buffer pH 6.0, 5mM potassium ferrocynide, 5 mM 
potassium ferricynide, 150mM sodium chloride, 2mM magnesium chloride and 5-
bromo-4-chloro-3-indolyl-%-D-galactopyranoside 1mg/ml in water) for 16 hours at 
37˚C and counterstained with nuclear fast red (sigma N3020). 
 
Western blots 
Cell pellets for whole cell lysates were obtained from sub-confluent plates 
6 days post infection.  Cell pellets were lysed in fresh phospho-lysis buffer 
(10mM EDTA, 5mM EGTA, 10mM MgCl2, %-glycerophosphate 50mM, nonidet P-
40 0.5%, brij-35 0.1%, dithiothreitol 1mM, sodium orthovanadate 1mM, 
phenylmethanesulfonyl fluoride 1mM, CompleteTM Protease inhibitor cocktail 1 
tablet/20ml recipe from Kelliher lab).   
Protein lysates (15ug) were subject to SDS-Page in acrylamide gels and 
transferred onto polyvinylidene difluoride transfer membranes (Amersham 
Hybond, pore size 0.45 -m, 45004110).  Membranes were blocked in 5% milk in 
TBS+ 0.1% Tween 20 (TBST) for 1.5 hours at room temperature followed by 
overnight 4˚C incubation in primary antibodies as listed (Table 2.1).  Blots 
washed in TBST were incubated for 1 hour with peroxidase conjugated 
%--
secondary antibody, diluted 1:5000 and developed using Westernbright 
(Advansta, K-12045). 
 
PDAC cell culture experiments 
Cell lines  
906, 9910#1, 9415#1, 6823#3 were cultured in Dulbecco’s Modified Eagle 
Medium, 4.5 g/L D-Glucose, + L-Glutamine (Gibco 11965-092), with 10% Fetal 
Bovine Serum (FBS) and 1% penicillin streptomycin (Gibco 15140-122).  PDAC 
cell lines were infected with a single round of lentivirus as described for PanIN 
cell lines.  Cells were split and placed in selection (3ug/ul puromycin) 30 hours 
post infection and remained in selection for the duration of the experiments.  All 
assays were plated 4 days post-infection. 
Infection with retrovirus for constitutively active SGK1 or myristoylated 
AKT1 were preformed as described for PanIN cell lines, 6 days prior to lentiviral 
knockdown.  Retroviruses were produced using the Effectene transfection 
reagent kit with 0.5 µg of SGK1S422D-pBABE-neo, myristoylated AKT1-pBABE-
neo, or empty vector pBABE-neo and 0.5 µg of /-eco, in 5x10^5 phoenix cells 
plated on 6 well plates.  48 hours post transfection, viral supernatant (2 ml from 
each well) was filtered through a 0.45 micron syringe filter and 1.5 ml of filtered 
viral supernatant was combined with 15 µg of polybrene, added to the cells, and 
spun at 1800 RPM at room temperature for 45 minutes.  The cells were then 
incubated for 4.25 hours at 37˚C after which fresh DMEM with 10% FCS and 1% 
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antibiotics was added.  Cells were subjected to 4 days of neomycin selection 
(1mg/ml G418 reagent) and then subjected to lentiviral knockdown as described 
above. 
 
Anchorage independent growth assays 
Soft agar assays were seeded at 1x105 cells/10cm dish in 3 ml of media 
with 0.4% agarose and 3ug/ml puromycin poured over solidified media with 0.7% 
agarose.  Once solidified the cell suspension was covered with 7ml of complete 
media with 3ug/ml puromycin. Colonies were counted 2-3 weeks post plating 
using size exclusion criteria. 
 
Proliferation assays 
Proliferation assays were seeded in quadruplet at 1x104 cells/well in 24 
well plates. Using trypan blue exclusion viable cells were counted at 24, 48 and 
72 hours via hemocytometer.  Doubling time and significance were determined 
as described above. 
 
Western blots 
Cell pellets for whole cell lysates were obtained from sub-confluent plates 
5 days post infection following 24 hours of serum starvation and a 15 minute 
retreatment with media containing 10% FBS.  Cell pellets were lysed in fresh 
phospho-lysis buffer (10mM EDTA, 5mM EGTA, 10mM MgCl2, %-
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glycerophosphate 50mM, nonidet P-40 0.5%, brij-35 0.1%, dithiothreitol 1mM, 
sodium orthovanadate 1mM, phenylmethanesulfonyl fluoride 1mM, CompleteTM 
Protease inhibitor cocktail 1 tablet/20ml recipe from Kelliher lab).   
Protein lysates (15ug) were subject to SDS-Page in acrylamide gels and 
transferred onto polyvinylidene difluoride transfer membranes (Amersham 
Hybond, pore size 0.45 -m, 45004110).  Membranes were blocked in 5% milk or 
bovine serum albumin (BSA) in TBS+ 0.1% Tween 20 (TBST) for 1.5 hours at 
room temperature followed by overnight 4˚C incubation in primary antibodies as 
listed (Table 2.1).  Blots washed in TBST were incubated for 1 hour with 
peroxidase conjugated secondary antibody diluted 1:5000 and developed using 
Westernbright (Advansta, K-12045). 
 
Generation of Plasmids 
pBABE-neo was a gift from Hartmut Land & Jay Morgenstern & Bob 
Weinberg (Addgene plasmid # 1767) (Morgenstern and Land 1990).  pBabe-
Neo-Myr-Flag-AKT1 was a gift from William Hahn (Addgene plasmid # 15266) 
(Boehm, Zhao et al. 2007).  pBABE-Puro-SGK1S422D$60N was a gift from David 
Guertin and the SGK1S422D$60N insert was cloned into the pBABE-neo 
backbone using the BamHI-HF and SalI-HF restriction enzymes from New 
England Biolabs.   
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Location of Reagents 
Plasmids are located in the west – 20˚C freezer located in 570P1 as are the all 
CST antibodies.  All other antibodies are located in the 4˚C glass front 
refrigerator located in 570P1.  shRic1 was a gift from David Guertin.  Ric2 was a 
gift from David Sabatini (Addgene plasmid # 21341)(Thoreen, Kang et al. 2009). 
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Table A3:  Antibodies, dilutions and blocking medium used in IHC, IF and 
western blots 
 
Target Host Company IHC dilution WB dilution WB 
blocking 
Amylase rabbit Abcam 
21156 
1:500   
Glucagon rabbit Dako 
A0565 
1:50   
Insulin guinea pig Dako 
A0564 
1:150   
pAKTS473   rabbit CST 4060 1:400 1:2000 5% BSA 
pAKTT308 rabbit CST 4056 1:200    
Total AKT rabbit CST 9272  1:1000 5% BSA 
pNDRG1T436 rabbit CST 5482 1:500 1:1000 5% BSA 
Total 
NDRG1 
rabbit CST 9408  1:1000 5% BSA 
pERK1/2 
T202/Y204 
rabbit CST 9101 1:400 1:2000 5% BSA 
KI67 rabbit Abcam 
66155 
1:500   
Cleaved 
Caspase3 
Rabbit CST 9664 1:800   
p16INK4A mouse  Santa Cruz 
1661 
1:250   
p16INK4A rabbit SC 1207  1:1000 5% milk 
p21CIP1 mouse Santa Cruz 
6246 
1:250 1:1000 5% milk 
p27KIP1 mouse Santa Cruz 
1641 
1:250 1:1000 5% milk 
BMI1 rabbit CST 5856 1:300   
BMI1 rabbit Abcam 
3829 
 1:2000 5% milk 
RICTOR rabbit CST 1224  1:1000 5% milk 
Alpha 
tubulin 
mouse DSHB 
12G10 
 1:1000 5% milk 
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Table A.4  shRNA sequences targeting Rictor delivered in pLKO lentiviral 
constructs 
 
 
Name Target  Vector Stem Sequence 
 
shRIC1 Rictor pLKO.1 5’-GCGGTTCATACAAGAGTTATT-3’ 
 
shRIC2 Rictor pLKO.1 5’-GCCAGTAAGATGGGAATCATT-3’ 
 
shGFP GFP pLKO.1 5’-TACAACAGCCACAACGTCTAT-3’ 
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Appendix B: 
Pancreas Specific Loss of mTORC1 Impairs Pancreas Development 
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Introduction 
mTOR kinase was originally discovered as the target of the drug 
rapamycin, a natural product isolated from Streptomyces hygroscopicusa 
collected in soil samples from Easter Island(Vezina, Kudelski et al. 1975).  
Rapamycin works by simultaneously binding hydrophobic pockets in the mTOR 
protein and the FK506-binding protein (FKBP12) (Choi, Chen et al. 1996), thus 
creating a protein dimer whereby FKBP12 is inappropriately bound to the FRB 
domain of mTOR by rapamycin.  mTOR kinase is known to be present in two 
functionally distinct complexes, mTORC1 and mTORC2.  Rapamycin has been 
shown to be a specific inhibitor of mTORC1 (Thoreen, Kang et al. 2009, Kang, 
Pacold et al. 2013).  While mTORC2 was originally believed to be insensitive to 
rapamycin, chronic treatment with rapamycin has been shown to inhibit mTORC2 
activity levels in some cell types (Zeng, Sarbassov dos et al. 2007).  
mTORC1 is a master regulator of cellular metabolic processes and is 
responsible for regulation of protein biosynthesis, ribosome biogenesis and 
autophagy in response to nutrient levels in the cell (Gibbons, Abraham et al. 
2009).  Interestingly, while mTORC1-dependent phosphorylation of S6K requires 
the FRB domain and is sensitive to rapamycin, phosphorylation of 4E-BP1 and 
ULK1 by mTORC1 are insensitive to rapamycin (Thoreen, Kang et al. 2009, 
Kang, Pacold et al. 2013).  While the precise mechanism by which rapamycin 
provides its inhibition is still being worked out, it appears that the mTOR - 
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FKBP12 - rapamycin complex prevents the recruitment and positioning of some 
but not all substrates resulting in a selective inhibition for some mTORC1 targets 
(Shimobayashi and Hall 2014). 
 Although originally used as an anti-fungal and immune suppressant, 
rapamycin has since been investigated for its potential uses as an anti cancer 
therapy (Zaytseva, Valentino et al. 2012).  The ability of rapamycin to decrease 
proliferation as well as its ability to specifically target one of the major 
downstream effectors of the PI3K-AKT signaling pathway made rapamycin a 
promising cancer therapeutic (Chiang and Abraham 2007).   Encouraging results 
were observed in phase II trials with the rapalog everolimus with objective 
response rates of 47%, 30% and 12%, in Hodgkin lymphoma, non-Hodgkin’s 
lymphoma and breast cancer respectively and phase II/III trials with the rapalog 
temsirolimus produced objective responses in 4 to 14% and 22% of endometrial 
cancers and mantle-cell lymphomas, respectively (Populo, Lopes et al. 2012). 
Temsirolimus is a more soluble analog of rapamycin that is processed into the 
natural form of the drug, and it has proven to be efficacious in treating renal cell 
carcinomas, a malignancy which is notoriously resistant to therapies and has 
been approved for treatment of this disease (Hudes, Berkenblit et al. 2009) 
It has been proposed that tumors derived from cell types in which 
rapamycin also inhibits mTORC2 functions may be more sensitive to rapalogs, 
while in cell types with rapamycin insensitive mTORC2, release of negative 
feedback loops may enhance AKT signaling (Soares, Ni et al. 2013). It has also 
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been suggested that tumors with activated PI3K signaling may be “addicted” to 
mTORC1 activity and be sensitive to rapamycin and its analogs (Meric-
Bernstam, Akcakanat et al. 2012).  The PI3K-AKT signaling cascade is known to 
be involved in numerous human malignancies and correlates with reduced 
survival in multiple tumor types (Castellano and Downward 2011). Although 31% 
of renal cell carcinomas have decreased PTEN expression (Shin Lee, Seok Kim 
et al. 2003), the baseline levels of PTEN in renal cell carcinomas did not 
correlate with efficacy of Temsirolimus (Figlin, de Souza et al. 2009).  
 Human pancreatic tumors with low levels of the PI3K inhibitor PTEN have 
a poorer prognosis than those with high PTEN (Morran, Wu et al. 2014).  Mouse-
models show that KC driven PDACs deficient for PTEN are more sensitive to 
rapamycin treatment.  Pdx1-Cre; KrasG12D/+; Ptenflox/+ animals responded better 
to rapamycin than the standard of care gemcitabine; however, tumors in Pdx1-
Cre; KrasG12D/+; LSL-Trp53R172H animals were insensitive to rapamycin (Morran, 
Wu et al. 2014).   
The tumor suppressor LKB1 is mutated in Peutz-Jeghers syndrome, which 
carries an increased risk of developing PDAC (Hezel and Bardeesy 2008, 
Wolfgang, Herman et al. 2013).  In the context of low ATP levels, LKB1 has been 
shown to regulate mTOR1 activity in an AMPK, TSC1/2 dependent manner 
(Shaw, Bardeesy et al. 2004).   Pancreas specific homozygous deletion of Lkb1 
was shown to be sufficient for the development of pancreatic cancer, and 
%%-
haploinsuficency in Lkb1 cooperated with KRASG12D to accelerate PDAC 
formation (Morton, Jamieson et al. 2010). 
Loss of mTOR kinase function due to ablation in the germ line results in 
embryonic lethality between day 5.5 and 6.5 (Gangloff, Mueller et al. 2004, 
Murakami, Ichisaka et al. 2004).  mTOR-deficient embryos implanted but, being 
unable to proliferate or differentiate, they subsequently died (Gangloff, Mueller et 
al. 2004, Guertin, Stevens et al. 2006).  Germ line loss of mTORC1 by ablation of 
the obligate subunit RAPTOR resulted in a similar phenotype (Guertin, Stevens 
et al. 2006); while animals with germ line loss of the mTORC2 obligate subunit 
RICTOR die around embryonic day 10.5 (Guertin, Stevens et al. 2006, Shiota, 
Woo et al. 2006). 
 Given the connection between efficacy of rapamycin on a subset of PDAC 
tumors as well as the cell type specific effect of rapamycin on mTORC2 activity, I 
became interested in the specific roles of mTORC1 and mTORC2 in the 
development of PDAC. Due to the lethality of germ line loss of mTORC1 and 
mTORC2, conditional knockout alleles for Raptor and Rictor were developed to 
aid in the observation of the role these compounds play in specific tissues 
(Shiota, Woo et al. 2006, Sengupta, Peterson et al. 2010).  To address the 
differential role of these mTOR complexes during the development of PDAC, I 
combined these conditional models with the Ptf1aCre/+;LSL-KRASG12D/+ mouse-
model (Hingorani, Petricoin Iii et al. 2003).  While the role of mTORC2 in KRAS-
driven PDAC is the central theme of this dissertation, the role of mTORC1 was 
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also of particular interest due to the cooperative effect of reduced LKB1 activity 
on KRAS-driven PDAC, and the effectiveness of rapamycin on KRAS-driven 
mouse-models deficient for PTEN.  The incomplete inhibition of mTORC1 activity 
by rapamycin leaves the possibility that fully inhibiting mTORC1 activity might still 
be effective in treating PDAC.  My ability to investigate the role of mTORC1 in the 
context of KRAS-driven PDAC was hampered by impaired pancreatic 
development and incomplete Raptor loss.  The phenotype described in this 
appendix suggests that mTORC1 is required during the development of the 
pancreas. 
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Results 
Pancreata in Raptor Conditional Knockout Mice Retain RAPTOR  
  mTORC1 plays a central role in regulating protein and ribosomal 
biogenesis in response to cellular levels of nutrients, oxygen, and amino acids.  
Given the importance of mTORC1 in regulating both cell growth and autophagy, I 
hypothesized that mTORC1 may be required for pancreatic development.  To 
address the specific requirement of mTORC1 in the development of the 
pancreas, I utilized a conditional knockout of the Raptor gene, which is an 
essential component of mTORC1.  Pancreas specific knockout of the Raptor 
gene was achieved by crossing mice with LoxP sites flanking exon 6 of Raptor 
(Sengupta, Peterson et al. 2010), with the pancreas specific Ptf1aCre allele 
(Kawaguchi, Cooper et al. 2002).  Upon expression of CRE at embryonic day 
9.5, Exon 6 is excised resulting in a frame-shift and subsequent early termination 
in exon 8 (Figure B.1 A).  To confirm pancreatic knockout of the Raptor allele, 
whole tissue lysate was prepared from Ptf1aCre/+;Raptor+/+ (Raptor+/+) and 
Ptf1aCre/+;Raptorflox/flox (Raptor$/$) pancreata.  Levels of RAPTOR protein were 
unchanged in these organs (Figure B.1B).  Although the histology of the 
pancreatic tissue in Raptor$/$ mice was similar to Raptor+/+ pancreata, containing 
both endocrine and exocrine components (Figure B.1 C), Raptor$/$ pancreata 
were significantly smaller than their Raptor+/+ counterparts.   
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Figure B.1 Raptor!/" mice form pancreata that retain RAPTOR expression. 
 
A. Schematic describing the conditional Raptor knockout allele and the 
frameshift and truncation resulting from exon6 excision by Ptf1a driven 
CRE recombinase. 
B. Western blots with pancreatic tissue lysates probed for RAPTOR or #-
TUBULIN as a loading control. 
C. H&E staining of formalin fixed and paraffin embedded pancreatic tissue 
from 2-month old mice. 
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Raptor"/" animals and their pancreata were smaller than Raptor+/+ animals 
Raptor$/$ pups were frequently runty and were noticeably smaller when 
weaned at 21 days of age.  The body weight of males sacrificed at 2, 4, and 8-
months of age was significantly lower in Raptor$/$ mice at all time points (Figure 
B.2 A).  The smaller mouse size correlated with lower pancreatic weight in 
Raptor$/$ mice relative to Raptor+/+ mice of the same age (Figure B.2B).  To 
determine if the decreased pancreas mass was simply a function of smaller mice, 
the mass of the pancreas relative to body mass was calculated for each mouse.  
This showed that Raptor$/$ pancreata were indeed smaller than Raptor+/+ even 
when corrected for differences in body size (Figure B.2C).  The pancreas to body 
mass ratio did not change significantly as mice aged (Figure B.2C). 
 
Raptor-deficient pancreata are smaller in both sexes due to reduced cell 
numbers 
At 2-months of age the average body mass of female Raptor$/$ mice was 
lower than Raptor+/+ mice, however, unlike males, this difference was not 
significant (Figure B.3A).  Enrolling more female mice into this study may provide 
significance.   Both the pancreatic weight and mass of the pancreas relative to 
body mass were significantly lower in Raptor$/$ females at 2-months of age.  
While the weights of the female pancreata were generally lower than their male 
counterparts, the pancreas to body mass ratios were similar between the sexes 
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(Figure B.3 B-C).  The decreased pancreatic proportions suggest that the 
decreased pancreas size was not simply a function of smaller animal size.  Given 
the expression of Raptor in the residual pancreas and the similar histological 
appearance of the acinar tissue, I hypothesized that the difference in size was a 
result of decreased cell number in the pancreas.  To test this, genomic DNA from 
a pancreatic fragment of known mass was isolated and quantified.  The total 
amount of genomic DNA was extrapolated using the total mass of the pancreas.  
These results supported my hypothesis, showing that the total amount of genetic 
material in Raptor$/$ pancreata of both males and females was significantly less 
than in their Raptor+/+ counterparts (Figure B.3). 
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Figure B.2:  Decreased animal weight and pancreatic mass in Raptor"/" 
animals. 
 
A. Whole body weight of males sacrificed at 2, 4 and 8-months of age.  
B. Weight of pancreata from males sacrificed at 2, 4, and 8-months of age. 
C. Percentage of mouse weight comprised of pancreas mass in males 
sacrificed at 2, 4, and 8-months of age. 
P. values : **<0.01, ***<0.001. (n=4-10) 
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Figure B.3: Smaller pancreata in Raptor!/! animals have fewer cells. 
 
A. Whole body weight of males and females sacrificed at 2-months of age. 
B. Weight of pancreata from males and females sacrificed at 2-months of 
age. 
C. Percentage of mouse weight comprised of pancreas mass in males and 
females sacrificed at 2-months of age. 
P values : ***<0.001. (n=4-6) 
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Size, proliferation, and apoptosis were similar in acinar cells of Raptor"/" 
animals  
To characterize the pancreas Raptor$/$ mice, I looked specifically at acinar 
cells as they comprised the majority of the pancreatic tissue and as such would 
play the greatest role in organ size.  Furthermore, Ptf1a driven CRE expression 
should be maintained in acinar tissue and I hypothesized that delayed activation 
in a subset of these cells might reduce cell size or induce apoptosis.  The relative 
size of acinar cells was similar between the genotypes in 2-month old animals, 
and no significant difference was seen in proliferation rates, as measured by 
KI67 staining, or apoptotic rates, as measured by cleaved-Caspase 3 staining 
(Figure B.4).  These findings suggest that the acinar cells comprising the 
pancreata of Raptor$/$ mice are of normal size and that the decreased organ 
mass is due to reduced cell numbers.  The statistical power of these findings is 
low, as only 2 animals per cohort were analyzed. 
 
Raptor knockdown impairs proliferation and anchorage independent 
growth in a PDAC cell line 
Although the maintenance of RAPTOR in the residual pancreas of 
Raptor$/$ mice precludes the use of this model for observations of mTORC1 in 
the traditional KC mouse-model, shRNA mediated knockdown of Raptor in 
KRAS-driven tumor cell lines decreased protein levels of RAPTOR (Figure B.5 A) 
allowing for the observation of mTORC1 inhibition in vitro.   Anchorage 
%&.
independent growth in this KRAS-driven, Trp53-deficient cell line was 
significantly decreased by two independent shRNAs (Figure B.5 B).  Proliferation 
rate was approximated by measuring the formazan produced by viable cells upon 
reduction of MTS tetrazolium.  The doubling time, derived from the inverse slope 
of the natural log of the absorbance readings, trended towards significance, with 
one shRNA providing a significant increase in doubling time and the other near 
significance (Figure B.5 C).   
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Figure B.4  Cell size, proliferation, and apoptosis rates of acinar cells are 
unchanged in pancreata of Raptor"/" mice. 
 
A. Relative area of acinar cells from 2-month old mice. (n=2) 
B. Percentage of KI67 positive acinar nuclei in 2-month old mice, stained by 
IHC. (n=2) 
C. Percentage of cleaved-Caspase 3 positive acinar nuclei in 2-month old 
mice, stained by IHC. (n=2) 
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Figure B.5  Anchorage independent growth and proliferation are impaired 
by Raptor loss in vitro. 
 
A. Western blot with whole cell lysates of 6823#3 cells harvested 5 days post 
Raptor knockdown.  Membranes were probed for RAPTOR or #-TUBULIN 
as a loading control.  The vertical line indicates the movement of the GFP 
lanes from the same blot image to provide presentation consistency. 
B. Anchorage independent growth of 6823#3 cells following Raptor 
knockdown was measured by colony formation in 0.4% agar over 2 
weeks.  Assay was plated in triplicate and 12 fields of view per plate were 
counted.   P.Values **<0.01 
C. Doubling time of cells as determined by metabolism of MTS tetrazolium to 
formazan by viable cells.  Formazan levels were assessed by absorbance 
at 490nm 24, 48, 72, and 96 hours after seeding of 1x103 cells/well.  
Doubling time was determined as the inverse slope of the log2 of the 
absorbance values.  P.Values were derived from the inverse slopes of 
doubling times using analysis of covariance of a line.  Error bars represent 
95% confidence intervals. 
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Discussion 
 
Reduced pancreatic function in Raptor"/" animals 
The pancreata obtained from two month old Raptor$/$ animals retained 
expression of RAPTOR protein.  This suggests that a subset of tissue has 
avoided CRE expression or CRE mediated excision of Raptor exon 6 at one or 
both alleles and that this subset has expanded to constitute a pancreas 
functional enough for these mice to survive.   The decreased pancreas to body-
mass ratio in these animals suggests that they are smaller due to the reduced 
pancreatic function and that reduced pancreas size is not a consequence of 
reduced animal size.  Interestingly, pancreas size did not increase substantially 
relative to body mass as mice aged from 2 to 4 to 8-months, suggesting that the 
reduced pancreas size measured at 2-months of age meets the basic needs of 
the adult mouse; these pancreata either lack the capacity or the physiological 
impulse to regenerate a full sized pancreas.  Measurements of relative 
proliferative and apoptotic rates in acinar tissue of 2-month old Raptor$/$ males 
showed possible increases in both relative to their wild-type counterparts; 
however, due to the low number of samples tested these findings have little 
statistical value.  If increases in proliferation and apoptosis in this tissue are 
substantiated it might suggests a cycle in which acinar tissues lacking CRE 
expression proliferate to maintain the pancreas while activation of CRE and 
subsequent loss of Raptor occurring in the adult acinar tissue results in 
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apoptosis.  This cycle could prevent the expansion of the pancreas beyond the 
observed size. 
 
Origins of the RAPTOR positive acinar tissue in Raptor"/" pancreata 
The reduced size of Raptor$/$ pancreata and the expression of RAPTOR 
therein suggested that mTORC1 was required for pancreatic development.  The 
question posed by the expression of Raptor in the Raptor$/$ pancreata is how it 
has avoided recombination.  Possible mechanisms for the maintenance of Raptor 
include, silencing of the CRE expressing Ptf1a allele either through loss of Ptf1a 
expression or by failure to produce CRE recombinase following its transcription 
under the Ptf1a-promoter.  Alternatively, changes to one of the floxed Raptor 
alleles might prevent CRE mediated recombination of exon 6.  Mice lacking 
PTF1A expression failed to form pancreatic exocrine tissue and died within 2 
days of birth (Krapp, Knofler et al. 1998). The possibility that acinar tissue is 
being reconstituted from a lineage that has not expressed PTF1A is unlikely as 
continued expression of this protein is required for the maintenance of acinar 
tissue and loss of PTF1A promoted ADM (Krah, De La et al. 2015).  To address 
the question as to how these cells have avoided CRE recombination, these 
tissues could be stained for PTF1A expression, which should be present in 
acinar tissue, CRE expression, which, under the control of the Ptf1a-promoter, 
should also be expressed in the acinar tissue, and p-S6, to confirm the lack of 
functional mTORC1 in acinar tissues.  From the results of this staining I could 
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ascertain if Ptf1a gene expression is silenced in these cells, if CRE expression is 
somehow impaired, or if recombination of Raptor is somehow blocked.    
It is possible that mTORC1-deficient pancreata develop some level of 
exocrine tissue, which is sufficient to allow survival of these animals, and that in 
the absence of mTORC1 this exocrine tissue eventually dies or fails to 
proliferate.  The pancreas is subsequently populated by trans-differentiation of 
cells, a small number of endocrine cells develop in the absence of PTF1A 
(Krapp, Knofler et al. 1998), which have retained Raptor.  This possibility does 
not explain how acinar tissue is avoiding expression of Ptf1a driven CRE. 
Ptf1a-null embryos lack pancreatic exocrine structures at embryonic day 
18 (Krapp, Knofler et al. 1998).  Morphological observations of Raptor$/$  
pancreata at embryonic day18 and in newborns would help to answer whether or 
not the pancreas is forming in the absence of mTORC1. If exocrine tissue in 
these embryos and newborns exists, staining for markers of mTORC1 activity, 
apoptosis, proliferation and autophagy should provide some insight into how 
these cells are responding to mTORC1 deficiency. 
 
mTORC1 loss in the context of KRASG12D 
 The data presented suggest that loss of mTORC1 in KRAS-driven PDAC 
may have an effect on proliferation and tumorigenicity, however my ability to test 
this in vivo was obscured by a developmental phenotype.  Mouse crosses which 
resulted in KC-Raptor$/$ animals were conducted and the pancreata of their 
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progeny displayed lesions consistent with KC pancreata.  While the weight of 
these KC-Raptor$/$ pancreata was lower than their KC counterparts (data not 
shown), consistent with these pancreata originating from smaller organs, the 
possibility that mTORC1 deficiency is tolerated in the context of activated KRAS 
during pancreatic development has not been fully excluded.  Due to the presence 
of extensive stromal infiltration, these tissues were not probed for RAPTOR via 
western blot, but immunostaining for p-S6 and p-4EBP1 could confirm the 
presence of RAPTOR in these pancreata.  
 
Delaying mTORC1 loss until adulthood 
 While the data presented suggest that mTORC1 is required during 
pancreatic development, a more pertinent question with regard to pancreatic 
cancer is how the adult pancreas responds to loss of mTORC1 and how the adult 
pancreas responds to such a loss in the context of activated KRAS.  To address 
this question a pancreas specific inducible Cre allele is being utilized, 
Ptf1aCreERTM/+;Raptorflox/flox animals (Sengupta, Peterson et al. 2010, Kopinke, 
Brailsford et al. 2012) are being produced. By adding tamoxifen at 6 weeks of 
age, the requirement of mTORC1 for the maintenance of exocrine tissue in the 
adult pancreas can be observed.  Furthermore, I will be able to assess the 
requirement of mTORC1 in KRAS-driven PanIN formation.  Combining Flippase 
and Cre recombinase systems by generating Pdx1-Flp;FSF-KrasG12D/+; FSF-
Rosa26CreERTM/+;Raptorflox/flox animals (Sengupta, Peterson et al. 2010, 
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Schonhuber, Seidler et al. 2014) would cause pancreas specific activation of 
KRASG12D while allowing pancreas specific tamoxifen inducible loss of Raptor 
which could be delayed to observe the effects of mTORC1 loss during various 
stages of PanIN and PDAC. This would provide insight into the effectiveness of 
mTOR inhibitors and, combined with data from the similar mTORC2 model, may 
suggest benefits to targeting mTOR complexes independently as opposed to the 
combined or semi-combined inhibition observed in rapalogues and mTOR active 
site inhibitors.   
  
Development of neurological phenotypes 
One empirical observation in Raptor$/$ animals was an increased rate of 
hydrocephaly.  Although determination of the pancreatic lineage is the first and 
best known function of PTF1A, this protein is also expressed in a neuroepithelial 
region of the embryonic hindbrain tail (Yamada, Terao et al. 2007), and during 
the development of GABAergic neurons in both the cerebellum and dorsal spinal 
cord (Glasgow, Henke et al. 2005).  This phenotype was not investigated further, 
however it is plausible that hydrocephaly resulted from defects in the hindbrain or 
cerebellum due to the loss of Raptor and thus mTORC1 during their 
development.   
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Materials and Methods 
Mouse Strains  
All procedures and care were provided under protocols approved by the 
University of Massachusetts Institutional Animal Care and Use Committee.  
Ptf1aCre/+ animals have been previously described and were obtained from Chris 
Wright (Kawaguchi, Cooper et al. 2002). Conditional Raptorfl/fl alleles have also 
been previously described (Sengupta, Peterson et al. 2010), and were a gift from 
David Guertin.  Ptf1a+/+ -;Raptorfl/fl (Raptor+/+) and Ptf1aCre/+; Raptorfl/fl (KC-
Raptor!/!) siblings were euthanized for analysis at 2-months of age.   
 
Characterization of mouse and pancreas mass 
The weight of each animal was measured immediately following sacrifice, 
after which the animals were perfused with 15-20 ml of phosphate buffered 
saline.  The pancreas was harvested and weighed and the pancreatic 
percentage of body mass was calculated as the ((pancreas weight / mouse 
weight) x 100). 
 
Estimation of relative cell number by DNA content 
Total gDNA was isolated from a tissue fragment resected from the tail of 
the pancreas by standard phenol-chloroform extraction.  The gDNA 
concentration of the tissue was determined by dividing the mass of the gDNA 
isolated by the weight of the fragment.  The amount of total genomic DNA was 
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extrapolated by multiplying the gDNA tissue concentration by the mass of the 
pancreas.  These calculations assume equivalent amounts of gDNA in all cells. 
 
Histology 
  Formalin fixed, paraffin embedded pancreata from Raptor+/+ and Raptor$/$ 
animals were sectioned at 5 microns and mounted on positively charged slides.  
These sections were deparaffinized and rehydrated  by passage through Clear-
Rite 3TM(Thermo Scientific, 6901) and a graded series of ethanols, 100% to 20% 
followed by water.  Samples were then stained for H&E according to the field 
standard.   
 Two samples each of Raptor+/+ and Raptor$/$ were immunostained 
for KI67 and cleaved caspase 3.  Antigen exposure was accomplished using 
Antigen Unmasking Solution (Vector H-3300) and heating the samples to a 
gentle boil via microwave.  This was followed by inactivation of endogenous 
peroxidases with 3% hydrogen peroxide, and overnight blocking with 3% normal 
goat serum or Mouse on Mouse blocking reagent (Vector labs M.O.M kit BMK-
2202).  Samples were incubated with primary antibody against KI67 (Abcam 
66155) diluted 1:500 or CC3 (CST 9664) diluted 1:800 in blocking solution for 1 
hour at room temperature.  Subsequent incubation with biotinylated rabbit 
secondary antibodies (1:300) for 1 hour at room temperature was followed by 
Avidin/biotinylated enzyme complex (Elite ABC, Vector labs PK-6101) incubation 
for 30min at room temperature and development using Nova-Red (Vector Labs 
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SK4800).   Specimines were counterstained in hematoxylin, dehydrated through 
graded ethanol to xylenes, fixed with Permount, and observed using a Leica DM 
LB2 microscope.  Positive KI63 and CC3 cells were quantified in five 100x fields 
of view per sample with the exception of one Raptor$/$ sample for which only 2 
fields of view were countable.  The number of positive cells was compared to the 
total number of nuclei stained by hematoxylin. 
 
Estimation of cell size 
The average area of an acinar cell was calculated using the total number 
of cells counted in the KI67 quantifications, calculating the total area of acinar 
tissue in these images, measured in pixels using ImageJ, dividing the number of 
cells by the tissue area, and normalizing this ratio to the average cells/pixel in 
Raptor+/+ tissue. 
 
Western blots 
Whole tissue lysates were prepared from flash frozen tissue from the body 
of the pancreas, pulverized by mortar and pestle on dry ice.  Cell pellets for 
whole cell lysates were obtained from 6823#3 cells 5 days post Raptor 
knockdown.  Both powdered whole tissue and cell pellets were lysed in fresh 
phospho-lysis buffer (10mM EDTA, 5mM EGTA, 10mM MgCl2, %-
glycerophosphate 50mM, nonidet P-40 0.5%, brij-35 0.1%, dithiothreitol 1mM, 
sodium orthovanadate 1mM, phenylmethanesulfonyl fluoride 1mM, CompleteTM 
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Protease inhibitor cocktail 1 tablet/20ml recipe from Kelliher lab) for 2 hours at 
4˚C.  Cell debris was cleared by centrifugation and the protein lysates were 
stored at -20˚C.   
Protein lysates (15µg) were subject to SDS-Page in acrylamide gels and 
transferred onto polyvinylidene difluoride transfer membranes (Amersham 
Hybond, pore size 0.45 -m, 45004110).  Membranes were blocked in 5% milk in 
TBS+ 0.1% Tween 20 (TBST) for 1.5 hours at room temperature followed by 
overnight 4˚C incubation with RAPTOR (Abcam ab40768) #-TUBULIN (DSHB 
12G10) primary antibodies diluted 1:1000.  Blots were triple washed in TBST, 
incubated for 1 hour with peroxidase conjugated rabbit or mouse secondary 
antibody respectively; both were diluted 1:5000.  Membranes were then triple 
washed again and developed using Westernbright (Advansta, K-12045). 
 
Lentiviral production and infection 
 Lentivirus was produced by transfection of HEK 293T cells (5x105 cells in 
a 9.5cm2 area) with pCMV delta 8.9 packaging plasmid (0.3µg), pMDG envelope 
plasmids (0.2µg) and a pLKO plasmid (0.5µg) targeting Raptor or GFP (Table 
A.1).  6823#3 cells were subject to a single round of lentiviral infection which 
included a 45 minute room temperature spin at 1800 RPM followed by a 4 hour 
and 15 minute incubation at 37˚C.  Cells were placed in 3µg/ml puromycin 
selection 48 hours after the infection. Assays were set up and cell lysates were 
obtained 5 days post infection. 
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Anchorage independent growth assay 
6823#3 cells were seeded at 1x105 cells/10cm dish in 3 ml of media with 
0.4% agarose and 3µg/ml puromycin poured over solidified media with 0.7% 
agarose.  Once solidified the cell suspension was covered with 7ml of complete 
media with 3µg/ml puromycin. Colonies were counted 2-3 weeks post plating 
using size exclusion criteria. 
 
Proliferation as measured by MTS assay 
In 6823#3#3 cells with Raptor knockdown, the ability of cells to metabolize 
MTS tetrazolium was used as to estimate the relative number of viable cells.  
Cells maintained in 3µg/ml puromycin selection were seeded in triplicate at 1x103 
on a 96 well plate.  At 24, 48, 72, and 96 hours media was replaced with 
complete media containing 16.7% MTS reagent (Abcam ab197010).  The cells 
were incubated at 37˚C for 30 minutes after which formazan produced by 
reduction of MTS tetrazolium was measured by absorbance at 490 nm.  
Absorbance of the MTS-media in the absence of cells was subtracted from the 
readings and the average OD 490 was plotted for Raptor knockdown verses GFP 
knockdown in 6823#3 cells. 
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Table B.1  shRNA sequences targeting Raptor delivered in pLKO lentiviral 
constructs 
 
 
Name Target  Vector Stem Sequence 
shRaptor1 Raptor pLKO.1 5’-CCTCATCGTCAAGTCCTTCAAC-3’ 
shRaptor2 Raptor pLKO.1 5’-GCCCGAGTCTGTGAATGTAATC-3’ 
shGFP GFP pLKO.1 5’-TACAACAGCCACAACGTCTAT-3’ 
 
Raptor targeting shRNAs were a gift from David Guertin. 
These plasmids are stored in the western -20 freezer in 570-P. 
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Appendix C: 
 
KRASG12D Specific Gene Expression Changes in Primary Pancreatic Ductal 
Epithelial Cells 
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Introduction: 
 
 SHH is a ligand in the hedgehog family, which binds to the patched 1 
(PTCH1) receptor, removing PTCH1 inhibition of the smothened (SMO) 
transmembrane protein and subsequently activating GLI signaling (Hooper and 
Scott 2005).  Although SHH is absent in the developing and mature pancreas 
(Kim and Hebrok 2001), its presence is observed in PanIN lesions and its 
expression increases as these lesions progress to PDAC (Berman, Karhadkar et 
al. 2003, Thayer, di Magliano et al. 2003). Previous work in our lab showed that 
when primary ductal epithelial cells (PDECs) lacking Cdkn2a, Trp53, or both 
were infected with KRASG12D, or SHH, the KRASG12D infected PDEC cells were 
capable of producing pancreatic tumors upon orthotropic injection into the 
pancreata of nude mice, while PDEC cells infected with SHH did not form tumors 
(Morton, Mongeau et al. 2007).  Although infection with either SHH or KRASG12D 
increased the p-ERK and p-AKT levels in PDECs, the PDECs expressing SHH 
produced nothing more than microscopic lesions over a 4-month period (Morton, 
Mongeau et al. 2007). 
Increased outputs of the ERK and AKT signaling pathways are hallmarks 
of KRAS-driven tumorigenesis, yet activation of these pathways was not 
sufficient for SHH infected PDEC to form tumors, even in the context of tumor 
suppressor deficiency (Morton, Mongeau et al. 2007).  This provided an 
opportunity to identify the differences between the changes effected by activated 
KRAS and SHH.  I hypothesized that differences in the gene expression profiles 
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of PDECs stimulated by KRAS and SHH would include genes required for KRAS-
driven tumorigenesis.  Identification of genes and pathways required for the 
transformative ability of RAS might provide novel sets of targets for therapeutic 
intervention. 
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Results 
Identification of genes differentially regulated by KRASG12D and SHH 
Both KRASG12D and SHH increased p-AKT and p-ERK levels in PDEC, yet 
only KRASG12D was capable of imparting tumor forming potential to PDECs 
(Figure C.1A).  To identify differential expression of genes resulting from 
KRASG12D and SHH expression in PDECs, I obtained gene expression profiles 
using an affymetrix microarray.  PDEC cells expressing the avian retroviral 
receptor TVA under the cytokeratin-19-promoter, and lacking both Cdkn2a and 
Trp53 as a result of Ptf1a-driven CRE expression during pancreatic 
development, were infected with retroviral RCAS viruses encoding KRASG12D, 
SHH, or GFP  (Figure C.1).  Three independent infections were conducted at 
passage 5, passage 8, and passage 9.   Following each infection mRNA was 
isolated and stored at -80˚C.  Infections and RNA isolations were done by 
Victoria Appleman.  The mRNA was processed by the Genomics Core Lab at 
Memorial Sloan Kettering Cancer Center and run on an MOE430 2.0 Affymetrix 
Expression Array to probe for mRNA levels of known and estimated genes 
(Figure C.1B).  This Array contained 45000 probe sets for 39000 transcripts of 
34000 genes.  The density of the array was 1.3 probes per gene. 
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The changes in gene expression of KRASG12D relative to GFP infected 
PDECs were compared to changes in gene expression of SHH relative to GFP 
infected PDECs.  The bioinformatics analysis was conducted by Julie Zhu and 
Jianhong Ou.  Triplicate samples were compared as blocks and a threshold of 
log2(1.5) fold change with an unadjusted P. value of 0.01 was used to identify 
genes for which the changes induced by KRASG12D relative to GFP infection were 
significantly different than the changes induced by SHH relative to GFP infection.   
By these criteria, expression of 693 genes were increased by KRAS and 
expression of 788 genes were decreased; these genes included both validated 
and predicted genes. Multiple probes were present for many of these genes, but 
only sterile alpha motif and leucine zipper containing kinase AZK (ZAK) had 
probes identified in both data sets. 
To select targets for validation, these data sets were curated using a 
combination of gene ontology, and a review of published literature.  Gene 
ontology analysis was conducted using the functional annotation clustering tool in 
the DAVID bioinformatics resource (Figure C.2) (Huang da, Sherman et al. 2009, 
Huang da, Sherman et al. 2009).  Using the pathways flagged by the gene 
ontology analysis as a guide, a review of published literature was used to select 
29 gene targets known to be involved in or related to pathways involved in 
cancer, that were up regulated in KRAS infected cells relative to their SHH 
infected counterparts.  These genes were validated by qPCR (Figure C.3) and 
included secreted factors, genes involved in epithelial to mesenchymal transition, 
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growth factor receptors, Wnt family ligands, and Fmo gene family responsible for 
metabolism of xenobiotics (Lawton, Cashman et al. 1994).  With the exception of 
Mmp20, elevated expression of mRNA was confirmed for all genes of interest in 
passage 5 (data not shown) and passage 8 KRAS infected cells (Figure C.3).   
To further investigate the roles these proteins were playing in KRAS-
driven PDAC, shRNA mediated knockdown of selected targets was conducted in 
cell lines derived from KRAS-driven murine pancreatic tumors.  Based on the 
notion that genes involved in transcriptional regulation may be drivers of the 
observed differential gene expression, Gli2, Id3, Tbx3, and Yap1 were selected 
for knockdown.  Gli2 and Yap1 are transcription factors while ID3 and TBX3 are 
transcriptional repressors.  All four of these genes have been implicated in 
cancer development and metastasis, and had multiple shRNAs available from 
the UMass shRNA core (Narita, So et al. 2008, Yarosh, Barrientos et al. 2008, 
Hall, Wang et al. 2010, Liu, Xu et al. 2010, Shuno, Tsuno et al. 2010, Javelaud, 
Alexaki et al. 2011, Mowla, Pinnock et al. 2011).  Following infection of 170#3 
cells, derived from a tumor resulting from orthotropic transplant of KRAS infected 
Trp53-/-, Cdkn2a-/- PDECs into the pancreas of athymic nude mice, with lentiviral 
constructs targeting these four genes, consistent knockdown of Yap1 was 
achieved with multiple independent shRNAs (Figure C.4-A).  The shYapB and 
shYapE constructs were the most effective and were used for phenotypic assays.  
Knockdowns of Gli2, Id3, and Tbx3 were unsuccessful despite testing with all 
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available shRNAS designed to target these genes in the UMass shRNA library 
(data not shown). 
 Knockdown of YAP in the 170#3 cell line was confirmed by western blot  
(Figure C.4-A).  To characterize relevant phenotypic changes following loss of 
YAP, proliferation, migration, and soft agar colony formation were measured.  
YAP knockdown significantly decreased anchorage independent growth as 
measured by soft agar colony formation (Figure C.4-B).  However, Yap 
knockdown did not provide consistent changes to migration or proliferation rates 
as measured by trans-well migration towards a chemo attractant and MTS assay 
respectively (Figure C.4-C-D). 
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Figure C.2 Gene ontology analysis of microarray data sets 
 
A. Functional annotation clustering of transcripts significantly increased in 
KRAS infected PDECs relative to SHH infected PDECS.   
B. Functional annotation clustering of transcripts significantly decreased in 
KRAS infected PDECs relative to SHH infected PDECS.   
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Figure C.4  Knockdown of Yap in an orthotropic transplant tumor cell line. 
  
A. Protein levels of YAP and B-ACTIN following shRNA mediated knockdown 
of YAP with 6 independent shRNA constructs 
B. Anchorage independent growth as measured colony formation in soft 
agar. Cells were plated at 1x105 cells/ dish 14 days prior to counting 
colonies using size exclusion criteria. 
C. Migration potential following Yap knockdown was measured as successful 
migration towards a serum gradient through 8micron pores. 
D. The ability of cells to metabolize MTS was assessed by formazan 
production, measured by absorbance at 490 nm.  Metabolic rates were 
used to compare the relative numbers of cells with active metabolism over 
a 4-day period. 
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Knockdown of Yap in KRASG12D; Trp53-/-; Cdkn2a-/- PDECs  
To assess the contributions of increased Yap expression to the 
tumorigenic role played by KRAS, I sought to determine if YAP knockdown could 
impair KRAS-driven phenotypes in PDECs.  Following retroviral infection with 
RCAS-KRASG12D, qPCR confirmed an increase in YAP mRNA levels, but the 
magnitude of this change was less than seen in the microarray (Figure C.5-A).  
These KRAS expressing PDECS were then subject to shRNA mediated 
knockdown of Yap via lentiviral infection.  Knockdown was confirmed at the 
protein level by western blot (Figure C.5-B), and the mRNA level by qPCR 
(Figure C.5-C).  Knockdown of Yap in KRAS infected PDECs did not have a 
significant impact on proliferation of these cells (Figure C.5-D).  
To more closely model the system from which the rational for the gene 
expression profiling was conceived, I wanted to test if YAP-deficient KRASG12D 
PDECs were capable of tumor formation in vivo.  I injected KRASG12D expressing 
Cdkn2a-/-,  Trp53-/- PDECs cells, expressing shRNAs targeting YAP or GFP, 
subcutaneously into athymic nude mice.  These mice were sacrificed 32 days 
following injection and the tumors were excised (Figure C.6A).  Tumors derived 
from PDECs with either Yap targeting shRNA did not have significantly reduced 
tumor volumes relative to tumors formed with PDECS expressing shRNAs 
targeting GFP (Figure C.6B).   Tumor cell lines were successfully grown from 10 
of the subcutaneous tumors. mRNA and protein lysates were derived from these 
cell lines and YAP mRNA and protein levels were measured by qPCR and 
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western blot respectively (Figure C.6C-D).  Yap knockdown was not maintained 
in these cell lines, and neither mRNA nor protein levels of YAP correlated with 
tumor size (Figure C.6).  
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Figure C.5  Knockdown of Yap in PDEC did not significantly decrease 
proliferation. 
 
A. Relative quantification of Yap mRNA as measured by qPCR following 
independent infections of Trp53-/-, Cdkn2a-/- PDECs with RCAS-GFP or 
RCAS-KRASG12D. 
B. Western blot for Yap1 and %-Actin protein levels following shRNA 
mediated knockdown of Yap with 2 independent hairpin sequences. 
C. Relative quantification of Yap1 mRNA in KRASG12D infected PDECs 
following shRNA mediated knockdown. 
D. Doubling time of KRASG12D infected PDECs was not significantly altered 
following Knockdown of Yap.  Analysis of covariance of a line determined 
that the slopes derived from 4 independent cell counts at days 5, 10 and 
15, plotted on a log2 scale were not significantly different. 
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Figure C.6  Subcutaneous  injection of KRAS infected YAP-deficient PDEC. 
 
A. Injection of 1x106 RCAS-KRASG12D infected PDEC with lentiviral 
knockdown of GFP or Yap.  Mice were sacrificed at 32 days.  
B. Average volume of subcutaneous tumors 32 days post injection.  
(Volume=1/2 (height x width x length).  No significant difference by T.Test 
was observed in mice injected PDECs containing shRNAs targeting YAP.   
C. Yap levels measured by mRNA in select tumors isolated from 
subcutaneous tumors. 
D. YAP protein levels in select subcutaneous tumors measured by Western 
blot. 
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Possible coordinate regulation of Chromosome 11q22 
The locus that encodes the YAP protein is located on chromosome 11 in 
the q22 region.   The results of my microarray found that 7 genes in a 1Mb region 
of this chromosome were upregulated in KRASG12D verses SHH infected PDECs 
(Figure C.7 A).   Because YAP is a transcription factor, I hypothesized that 
increased YAP in response to KRASG12D may be responsible for the upregulation 
of these additional proteins.  To begin to assess this possibility, I observed 
mRNA levels of Birc2, Mmp8 and Mmp10 following knockdown of Yap in PDEC 
cells.  While Birc2 levels were not significantly altered, both Mmp10 and Mmp8 
were decreased following knockdown of Yap (Figure C.7 B-D), supporting the 
possibility that the YAP transcription factor may be regulating expression of 
multiple genes in this region.  
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Figure C.7  Close proximity of KRAS up-regulated genes to Yap on 
chromosome 11q22 (Ch 9a1 in mus musculus). 
 
A. A screenshot from NCBI map viewer tool showing a 1 mb region in which 
7 genes were identified  by microarray as upregulated in KRAS vs SHH 
infected PDECs.  Genes present in microarray are boxed. 
B. Q-PCR measuring Birc2 levels following shRNA knockdown in KRASG12D 
Infected Trp53-/-, Cdkn2a-/- PDECs. 
C. Q-PCR measuring Mmp8 levels following shRNA knockdown in KRASG12D 
Infected Trp53-/-, Cdkn2a-/- PDECs. 
D. Q-PCR measuring Mmp10 levels following shRNA knockdown in 
KRASG12D Infected Trp53-/-, Cdkn2a-/-  PDECs. 
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Discussion 
Identification of functional groups upregulated by KRAS 
 The question as to which downstream effectors of activated KRAS are 
required for its tumorigenic potential remains an active area of research, and the 
answers to this question will provide valuable information in the fight against 
KRAS-driven tumors.  By using ectopic expression of SHH in the pancreas as a 
gate to screen out changes specific to the ERK and AKT pathways, which have 
been shown to play major roles in PDAC initiation and progression, but were not 
sufficient to drive PDAC in our pancreatic orthotropic transplant mouse-model, I 
acquired a novel data set which I believe has identified important downstream 
pathways enhanced by activated KRAS in PDECs.   
Independent studies have identified pathways flagged by this microarray 
as vital to PDAC. The formation of PDACs has been shown to increased anabolic 
metabolism, and loss of KRAS resulted in decreased expression of the Glut1 
glucose transporter(Ying, Kimmelman et al. 2012).   My array identified 
upregulation of the neuronal glucose transporter GLUT3 in PDECs expressing 
activated KRAS, suggesting that upregulation of additional glucose transporters 
may result for KRAS-activation.  The identification of Pdgfra, Pdgfrb Pdgfrl, Fgfr1 
suggest that KRASG12D increases transcription of numerous growth factor 
receptors resulting in increased sensitivity of PDAC cells to extracellular signals.  
My array also identified multiple genes involved in epithelial the mesenchymal 
transition (EMT).  The identification of Snai1, Snail2, Twist1, Twist2, Zeb1 and 
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Zeb2 strongly suggests a role for KRAS in the activation of an EMT 
transcriptional program.  Genetic loss of YAP in the pancreas has since been 
shown to prevent KRAS-driven tumor initiation (Zhang, Nandakumar et al. 2014, 
Yang, Zhang et al. 2015) and YAP has been shown to regulate EMT in PDAC 
(Shao, Xue et al. 2014). Furthermore, upon withdrawal of activated KRAS PDAC 
tumors regress, but YAP activity can drive recurrent tumors (Kapoor, Yao et al. 
2014).  Taken together, these studies providing a positive validation for this data 
set. 
While KRAS is not a transcription factor, it is known to activate 
transcription factors through multiple downstream effectors including ERK and 
AKT.  The prevalence of transcription factors upregulated in my data sets 
suggest that KRAS activates a transcriptional cascade whereby KRAS mediated 
regulation of specific proteins results in enhanced transcription of a transcription 
factor which in turn, upregulates other transcription factors. This possibility is 
supported by previous findings that Twist1 expression is increased upon KRAS-
activation in PDEC (Lee and Bar-Sagi 2010), however the manner by which 
KRAS-activation increases Twist1 expression has not been identified and it may 
be secondary or tertiary to KRAS-activation.  I did investigate the levels of the 
Twist, Snail, and Zeb genes in response to YAP knockdown to inquire if YAP 
may be regulating some or all of these EMT regulating transcription factors, but I 
found the levels of these genes to be unchanged (data not shown). Interestingly, 
regulation of Glut3 by Zeb2 has been shown in in non-small cell lung cancers 
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(Masin, Vazquez et al. 2014) suggesting that transcription factors in my screen 
may be directly responsible for the regulation of other transcripts identified in the 
screen.  The concept of transcription factors regulating a series of targets, some 
of which may be other transcription factors, is not novel.  In the context of my 
microarray results, however, it is important to identify which transcription factors 
are the primary players resulting from KRAS-activation and which are secondary 
or tertiary players regulated by the primary transcript factors.  Additional 
bioinformatics analysis of my data sets, such as mapping transcription factors to 
their known targets, may provide a more substantial understanding of the gene 
regulation which results from activation of KRAS and should allow for the 
changes in signaling to be mapped back to a few transcription factors.  As 
secondary and tertiary transcription factors may be altered more robustly than 
the primary transcription factors, it is possible that increases in some primary 
transcription factors may fall below the current threshold and would need to be 
confirmed in the original microarray data set.  Understanding how the identified 
transcription factors are regulated by KRAS will provide insight into pathways 
required for KRAS mediated transformation of pancreatic ductal cells, and could 
direct future therapeutic efforts. 
 
Coordinate regulation possible 
 The identification of 7 genes in a 1 Mb region that are up regulated 
in response to activated KRAS but not SHH raises the possibility of coordinate 
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regulation.  An analysis of 145 human PDACs from The Cancer Genome Atlas 
(@55BWXX76;740H4;134E;"@EH1#XF did not identify any amplifications of this 
chromosomal region in human disease, suggesting that increased expression is 
occurring as a result of transcription rather than amplification. There are multiple 
possibilities that could lead to coordinate regulation of gene expression including 
binding of strong promoting factors in this region, and alterations to the tertiary 
structure of the DNA that facilitates transcription.  Analysis of histone densities 
throughout this region and looking for repetitive sequences to which promoters 
are known to bind, may provide some insight into coordinate regulation of this 
region.  A more thorough analysis could be achieved using a 5C analysis to map 
the cis- and trans- interactions and identify changes in the higher order 
chromosome structure associated with this region. The use of primary ductal 
epithelial cells may provide an ideal system in which to investigate KRASG12D 
mediated changes in chromosome structure of untransformed pancreatic ductal 
cells.   
 The multiple gene targets upregulated on chromosome 11q22 were 
identified in the normal course of investigating the attributes of YAP.  It is 
possible that other regions of the genome also contain clusters of genes 
regulated by KRAS-activation.  The gene expression profiles obtained in this 
study provide a ready source to further investigate this possibility by simply 
mapping these genes on their chromosomes.  
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Materials and Methods 
Microarray and Q-PCR validation. 
 RNA was isolated from Keratin-19-tv-a; Ptf1aCre/+; Trp53fl/fl;Cdkn2afl/fl  
PDECs infected with RCAS-KRAS, RCAS-SHH or RCAS-GFP at passage 5, 
passage 8 or passage 9.  These PDEC isolations, RCAS infections and RNA 
isolations were conducted by Victoria Appleman.  RNA was stored at -80˚C.  
RNA aliquots with concentrations ranging from 0.08µg/ul to 2.07 µg/µl (median of 
0.42 µg/µl) were sent to the Memorial Sloan Kettering Cancer Center Genomics 
Core Laboratory where the samples were labeled and hybridized to a MOE430 
2.0 Affymetrix microarray.  Julie Zhu and Jianhong Ou analyzed data from these 
microarrays.  The three independent infections with each RCAS virus were 
compared as blocks and a threshold of log2(1.5) fold change with an unadjusted 
P. value of 0.01 was used to identify targets up and down-regulated in KRAS 
infected PDEC verses SHH infected PDEC. 
 Twenty-nine targets from the upregulated in KRAS verses SHH gene set 
were selected and q-PCR primers were designed using the promega primer 
design tool Plexor  (http://www.promega.com).  These primer sets were 
functionally validated for q-PCR by confirming the generation of a linear standard 
curve for each set.  Primer sets are listed in Table B.1.  Validations of selected 
targets were done using mRNA from the passage 5 and passage 8 infection sets.  
Superscript III First Strand Synthesis System for RT-PCR (ThermoFisher 
Scientific 18080-51) was used to produce cDNA from the RNA templates with 
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OligoDTs as the primers.  200ng of cDNA was combined with sybr green 
(Quanta Biosciences) and appropriate primer pairs at a final concentration of 
0.5µM.  Simultaneous PCR amplification and signal detection was accomplished 
on an ABI 7300 Real Time PCR system.  Amplification of "-Actin was used as an 
endogenous control. 
 
Mouse-models and animal care 
The keratin-19-tv-a; Ptf1aCre/+; Trp53fl/fl;Cdkn2afl/fl have been described previously 
(Morton, Mongeau et al. 2007).  Athymic nude mice used for subcutaneous 
orthotropic transplants were purchased from Charles River Laboratories.   All 
animals were housed in pathogen free environments and food and water were 
provided ad libitum.  Care and euthanasia of these animals was conducted under 
the guidelines approved by the University of Massachusetts Medical School 
Institutional Animal Care and Use Committee. 
 
Culture and Infection of Pancreatic Ductal Epithelial Cells (PDECs) 
 Isolation and culture of PDEC were accomplished as previously described 
(Schreiber, Deramaudt et al. 2004).  Of note, the PDECs for these experiments 
were cultured on a layer of type-I collagen and not laminin, which has 
subsequently been used in the lab. 
 RCAS-Kras, RCAS-Shh, and RCAS-GFP vectors have been previously 
described (Morton, Mongeau et al. 2007).   Virus was produced by transfecting 5 
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µg of RCAS plasmid into DF1 chicken fibroblasts using Superfect Transfection 
reagent (Quiagen  301305).  DF1 cells were cultured in Dulbecco’s Modified 
Eagle Medium, 4.5 g/L D-Glucose, + L-Glutamine (Gibco 11965-092), with 10% 
Fetal Bovine Serum (FBS) and 1% penicillin streptomycin (Gibco 15140-122).  
The virus produced is replication competent in avian cells and transfected DF1 
cells were maintained for at least 1 week prior to viral harvest to allow the viral 
titer to reach its maximum sustainable levels.  These virus producing DF1 cells 
were never cultured for more than 4 weeks in an attempt to prevent propagation 
of advantageous replicative errors in the RCAS virus or the gene it is designed to 
express.   
 Following expansion of transfected virus producing DF1 cells into three 
10cm dishes, 30 ml of viral supernatant was collected from these confluent plates 
(10ml each), filtered through 0.45 micron syringe filters, concentrated by 
centrifugation at 27,000 RPMs for 90 minutes at 4˚C, resuspended in 100µl of  
DMEM media, and added to a single 10 cm diameter dish of  K19-tv-a; Ptf1aCre/+; 
Trp53fl/fl;Cdkn2afl/fl PDECs.  Fresh DMEM was added to the virus producing DF1 
cells and subsequent infections were conducted for a total of 4 infections in a 48 
hour window.  DF1 cells were incubated at 39˚C while PDEC were incubated at 
37˚C.  Both cell lines were maintained at 5% CO2 in humidified incubators. 
 Lentivirus was produced by transfection of HEK 293T cells (5x105 cells in 
a 9.5cm2 area) with pCMV delta 8.9 packaging plasmid (0.3µg), pMDG envelope 
plasmids (0.2µg) and a pLKO plasmid (0.5µg) targeting Yap or GFP (Table B.2).  
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PDEC cells previously infected with RCAS-KRAS or RCAS-GFP were subject to 
a single round of lentiviral infection, which included a 45 minute spin at 1800 
RPM and a 4 hour and 15 minute incubation at 37˚C.  These cells were placed 
into 3µg/ml puromycin selection 48 hours following lentiviral infection. 
 
Proliferation in PDEC cells 
Ten days following lentiviral infection, and 8 days following selection, 
1x105 cells/well were plated on 6-well plates.  Cells were plated in duplicate on 
three 6-well plates. Viable cells were counted using trypan blue exclusion on 
days 5, 10 and 15 post-infection.  Log2 of cell/well numbers were plotted against 
time and doubling time was derived from the inverse slope.  The significance of 
the difference in these slopes, and thus doubling time, were determined by 
analysis of covariance using Prism Graphpad. 
 
Processing of PDECs for orthotropic injection 
 To remove the collagen layer on which PDECs were grown, 1mg/ml 
collagenase V (Sigma C9263) was used to dissolve it.  Cells were then treated 
with 0.25% trypsin-EDTA (TCF-Invitrogen 25200056) for 10 minutes at room 
temperature and washed three times in DMEM.  Cells were pelleted by 
centrifugation at 1000RPM for 5 min at 4˚C between each step.    
PDEC cells with Yap knockdown used for subcutaneous orthotropic 
transplant were resuspended in 10 ml of DMEM following the third wash.  Cells 
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were counted in duplicate with a hemocytometer to ensure accuracy, and 8x106 
cells were pelleted and resuspended in 800µl of sterile PBS at 4˚C.   Athymic 
nude mice were injected subcutaneously with 100µl of PBS containing 1x106 
cells their left and right flanks.  A total of six injections in three mice were 
completed for each PDEC variant.  Tumors harvested 32 days after 
subcutaneous injections were measured and the volumes of these tumors were 
calculated as 1/2 the (height x width x length).   
 
Culture of cell lines from subcutaneous orthotropic transplants 
  Tumors harvested following subcutaneous injections of KRASG12D PDEC 
cells were cultured in Dulbecco’s Modified Eagle Medium, 4.5 g/L D-Glucose, + 
L-Glutamine (Gibco 11965-092), with 10% Fetal Bovine Serum (FBS) and 1% 
penicillin streptomycin (Gibco 15140-122).  Ten of the 16 cell lines grew out and 
these cells were scraped into PBS, pelleted and used to isolate mRNA or make 
whole cell lysates.  RNA isolation and whole cell lysate preparation is described 
below. 
 
Confirmation of target gene knockdown  
 The ability of shRNAs to knockdown their target genes was assessed in a 
cell line derived from orthotropic pancreatic transplant of KRASG12D infected 
PDECs (170#3).  Production of lentivirus was produced by transfection of HEK 
293T cells (5x105 cells in a 9.5cm2 area) with pCMV delta 8.9 packaging plasmid 
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(0.3µg), pMDG envelope plasmids (0.2µg) and a pLKO or pGIPZ plasmid (0.5µg) 
targeting Yap, Gli2, TBX3, ID3 or GFP (Table B.1).  170#3 cells were subject to a 
single round of lentiviral infection, which consisted of a 45 minute at 1800 RPM 
and a 4 hour and 15 minute incubation at 37˚C.  Infection was confirmed by 
maintaining cells in 3ug/ml puromycin selection beginning 48 hours following 
lentiviral infection.  Cells were used to set up phenotypic assays and harvested 
for protein lysates 10 days following infection. 
 
RNA Isolation 
RNA was extracted from PDECs using TRIzol reagent (Thermo Fisher 
Scientific 15596026).  TRIzol (1ml) was added to the washed cell pellets and 
incubated at room temperature for 5 minutes.  Chloroform (0.2ml) was added, 
tubes were vortexed, incubated for 3’ at room temperature and centrifuged for 10 
minutes at 13000 RPM.    The aqueous phase was transferred, RNA was 
precipitated with 0.5ml of isopropanol and resuspended in DEPC treated water.  
Production of cDNA and subsequent qPCRs are described above. 
 
Western blots 
Cell pellets for whole cell lysates were obtained from 170#3 cells 10 days 
post Yap knockdown and from subcutaneous tumor cell lines 18 days they were 
isolated in culture.  Cell pellets were lysed in fresh phospho-lysis buffer (10mM 
EDTA, 5mM EGTA, 10mM MgCl2, %-glycerophosphate 50mM, nonidet P-40 
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0.5%, brij-35 0.1%, dithiothreitol 1mM, sodium orthovanadate 1mM, 
phenylmethanesulfonyl fluoride 1mM, CompleteTM Protease inhibitor cocktail 1 
tablet/20ml recipe from Kelliher lab).   
Protein lysates (15ug) were subject to SDS-Page in acrylamide gels and 
transferred onto polyvinylidene difluoride transfer membranes (Amersham 
Hybond, pore size 0.45 -m, 45004110).  Membranes were blocked in 5% milk in 
TBS+ 0.1% Tween 20 (TBST) for 1.5 hours at room temperature followed by 
overnight 4˚C incubation in YAP1 (Cell signaling technology 4912), %-ACTIN 
(Santa Cruz 1615R) or GAPDH (Cell signaling technology 2118) primary 
antibodies diluted 1:1000.  Blots washed in TBST were incubated for 1 hour with 
peroxidase conjugated rabbit secondary antibody diluted 1:5000 and developed 
using ECL (Fisher 45-000-885). 
 
MTS assay 
In 170#3 cells with Yap knockdown, the ability of cells to metabolize MTS 
tetrazolium was used as to estimate the relative number of viable cells.  Cells 
maintained in 3ug/ml puromycin selection were seeded in triplicate at 1x103 on a 
96 well plate.  At 24, 48, 72, and 96 hours media was replaced with complete 
media containing 16.7% MTS reagent (Abcam ab197010).  The cells were 
incubated at 37˚C for 30 minutes after which formazan produced by reduction of 
MTS tetrazolium was measured by absorbance at 490 nm.  Absorbance of the 
MTS-media in the absence of cells was subtracted from the readings and the 
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average OD 490 was plotted for Yap knockdown and GFP knockdown in 170#3 
cells verses time. 
 
Anchorage independent growth assays 
Soft agar assays were seeded at 1x105 cells/10cm dish in 3 ml of media 
with 0.4% agarose and 3ug/ml puromycin poured over solidified media with 0.7% 
agarose.  Once solidified the cell suspension was covered with 7ml of complete 
media with 3ug/ml puromycin. Colonies were counted 2-3 weeks post plating 
using size exclusion criteria. 
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Table C.1  Validated qPCR primers for murine target genes 
  Primer F   Primer R 
PdgfrbF1 
GCCATGGTCGTTCA
CACTCAC PdgfrbR1 
CTCCATCCTGCATATC
CCCAC 
PdgfrbF3 
ATGATCTCATAGATC
TCGTCGGAGG PdgfrbR3 
TTACCCAGAG
CTGCCCATGA
AC 
        
PdgfraF1 
AGTGTCATTATTACA
TTTCTTAATATGCTT
GCAGA PdgfraR1 
ACCCTAGTTCCTGCAT
CCATTTT 
PdgfraF2 
CGGTGGACACAATTT
TTCGAAGC PdgfraR2 
GGGTCTGACTTTGCTG
GATCTATTG 
        
PdgfrlF1 
TTGAGTCAGTGGAGT
CCCTGT PdgfrlR1 
GGAGCAGGGAGAAAA
CAGGATCAA 
PdgfrlF3 
CGGAGATTCTGAGC
TGTGCATA PdgfrlR3 
TGGGACACACCACAAG
AATCTCC 
        
Fmo1F2 
GGACCTGAACAACC
CATCGAG Fmo1R2 
CGCATCTGCCAAAACC
AACTC 
 
Fmo1F4 
 
 
 
TGGATGTTTATACTG
TCGGCTGTGG 
Fmo1R4 
 
TAACTAACCCACATCT
GCCCCTG 
 
        
Fmo3F1 
CCTTGGCAAATGAAG
TGATGTATTCT Fmo3R1 
CCAAAGAGATGATGTG
TTTTCCAGAC 
Fmo3F3 
AACTCCTTTACATTA
GGCTTGATGGT Fmo3R3 
TGCCTTTAAACAGAAC
ACTCAGGAAAG 
        
Fmo4F2 
GGGGTAATCTTCTCG
GAATGGGAA Fmo4R2 
GTTTGCTGACACTTCC
GAGGAT 
Fmo4F4 
CGTGAAGGCAGAAC
TCGTACAAG 
Fmo4R4 
 
TCAGCACTAGAACTGG
CACCTG 
 
        
SparcF1 
TGTTGTCATTGCTGC
ATACCTTCTC SparcR1 
TGTGAGCTGGACGAGA
GCAACA 
SparcF3 
ATACCTTCTCAAACT
CGCCAATGG SparcR3 
TTGCAAACATGGCAAG
GTGTGTGA 
        
Glut3 CTTCTAACCGCTCTT Glut3 ACGATCGGCTCTTTCC
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CCAAAGTG AGTTTG 
Glut3 
CAGGTCCAATCTCAA
AGAAGGCTAC Glut3 
CATGACGATTTCGCTG
TTACTAAAGG 
        
Ces1F1 
ATTAGGGTTCCCATT
CCGAGCAAA Ces1R1 
CCGTTTTTAAAAGAGG
GTGCTTCAGA 
  
Ces1F4 
GTAGGGGACAGTGT
TGAAACTCTT Ces1R4 
GAGAGCTATCCCTTCC
TCCCTAC 
        
Mmp10F1 
GGAACTTCTGCATTT
CTTGAATTTTTTTGA
CA 
Mmp10R
1 
GCTCAGCAATACCTAG
AAAAATACTACAACT 
Mmp10F2 
GGTACTGAAGCCAC
CAACATCAG 
Mmp10R
2 
GTTGTCAAAAAAATTCA
AGAAATGCAGAAGT 
        
Mmp19F3 
TTTGGCATGGGACC
AGGTTTT 
Mmp19R
3 
CCAGAGACAAGAGATG
AGGAGGAAGA 
 
Mmp19F4 
AAACAGGAACACCTT
TTGATTAACAGG 
Mmp19R
4 
ATGTGGATTTCAAGAT
GTCTCCTGG 
        
Mmp2F2 
TGGTCAGTGGCTTG
GGGTATC Mmp2R2 
AGAAAAGATTGACGCT
GTGTATGAGG 
        
Mmp8F3 
CCCTGTAAGCATAGT
TTGGGTACA Mmp8R3 
TCTTTGGGACTCTCTC
ACTCCAC 
        
Mmp20F1 
GGGTTCTGGTACTTA
TAAGTTGGGTACA 
Mmp20R
1 
GACTATGGGAACGAAT
GGGTTCAAT 
Mmp20F3 
GTTCAGAGGGACAG
CTGTACTCCA 
Mmp20R
3 
ACAGAATCTCTAAGTA
CACACCCTCC 
        
Zeb1F1 
GGGACTACATTTACA
ACTGGTTCTGAG Zeb1R1 
CCCTTGAACTTGTCTT
GTGCAAAAAAG 
        
Zeb2F2 
CCAACTTGTTCCTTA
ACTGAGTAATGG Zeb2R2 
AATGGCCGAATGAGAA
ACAATATCAAG 
        
Snail1F3 
CTGCTGGAAGGTGA
ACTCCAC Snail1R3 
TGCCGCGCTCCTTCCT
GGTCA 
 
Snail1F4 
 
TGGTCGTAGGGCTG
CTGGAA 
 
Snail1R4 
 
CGGAAGCCCAACTATA
GCGAG 
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Snail2F3 
GCCCAGAGAACGTA
GAATAGGTCTT Snail2R3 
GTTCAGAAAGTCCCAT
TAGTGACGAAG 
Snail2F4 
GAGAAGGTTTTGGA
GCAGTTTTTGC Snail2R4 
 CAGATCAAACCTGAG
GGCACATC 
        
Twist1F3 
CCATCTTGGAGTCCA
GCTCG Twist1R3 
GCTGAGCAAGATTCAG
ACCCTC 
 
Twist1F4 
 
 
TGCAGCTCCTCGTAC
GACTG 
 
 
Twist1R4 
 
 
CAAGAAATCTGCGGGC
GGAG 
 
        
Twist2F1 
GCTGGTCATCTTATT
GTCCATCTCG Twist2R1 
AGCAAGATCCAGACGC
TCAAG 
Twist2F2 
CTTCGCTCGATTTCT
TGCTGTAG Twist2R2 
CCAGTGAGGAAGAGCT
GGAGAG 
        
Fgfr1F2 
CTTGAAAAGTTCCTC
CACAGGCACA Fgfr1R2 
TGTGTGGTCTTTTGGA
GTGCTCT 
        
Tbx3F1 
GCCTCTCCTCAAACA
CTCTCATG Tbx3R1 
GGGTTTTCGAGACACT
GGCAA 
Tbx3F2 
TCGCCTTCCTGACTT
CGTGATGA Tbx3R2 
GGAACCCGAAGAAGA
CGTAGAAG 
        
Yap1F1 
CATGTTGTTGTCTGA
TCGTTGTGATT Yap1R1 
TTGAGATCCCTGATGA
TGTACCACT 
Yap1F3 
CCATTTCATCCACAC
TGTTGAGG Yap1R3 
GTGGCACCTATCACTC
TCGAGA 
        
Birc2F1 
GGGATCCATCCTTGA
TGAGAAGTCT Birc2R1 
AGATTTGCACATTCGT
CACCTCT 
Birc2F4 
CAAGAACTCACACCT
TGGAAACC Birc2R4 
 GTCAAGTGCTTTTGTT
GTGATGGT 
        
Akt3F2 
AGGCTTAAAAGGAG
GTACAAGCTT Akt3R2 
GGCCAGATGATGCAAA
AGAAATCATG 
Akt3F3 
GCTTAAAAGGAGGTA
CAAGCTTTTTGTC Akt3R3 
TGGAGGGCCAGATGAT
GCAAAA 
        
Id3F1 
CTATGACACGCTGCA
GGATTTC Id3R1 
CTCTTGGACGACATGA
ACCACTG 
Id3F2 CCACCTGAAGGTCG Id3R2 GGGAACTGGTGCCGG
%*+
AGGATGT GAGTC 
        
Gli2F2 
TCTTCACATGCTTGC
GGAGTG Gli2R2 
ACTCACTCCAATGAGA
AACCCTACA 
Gli2F3 
GCTGGCTTCTGTTG
GACCACA Gli2R3 
GCAGTGGAATGAGGT
GAGTTCT 
        
Wnt5aF1 
GCGCTCTCATAGGA
ACCCTTAG Wnt5aR1 
CTGCGGAGACAACATC
GACTATG 
Wnt5aF2 
ATTTGCACACGAACT
GATCCACA Wnt5aR2 
GACCAGTTTAAGACAG
TGCAGACC 
        
Wnt6F1 
GAAAGCTGTCTCTCG
GATGTCCTG Wnt6R1 
GGGGTTCGAGAATGTC
AGTTCCA 
Wnt6F2 
GTCTTGACTTCTCAT
CCCCGAAG Wnt6R2 
TTCTGGGCACTCCTGG
ACCTC 
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Table C.2  shRNA clones used for knockdown of target genes. 
shRNA clones used to attempt knockdown in murine cell lines.  Only 
constructs targeting Yap were effective and the clones used in phenotypic 
assays and orthotropic transplant are labeled shYAP-B and shYAP-E. 
 
Gene Vector Clone ID 
TBX3 pLKO.1 
TRCN00000
05079 
TBX3 pLKO.1 
TRCN00000
95873 
TBX3 pLKO.1 
TRCN00000
95869 
TBX3 pLKO.1 
TRCN00000
95870 
TBX3 pLKO.1 
TRCN00000
95871 
TBX3 pLKO.1 
TRCN00000
95872 
YAP1 pLKO.1 
TRCN00000
95864 
YAP1 
(shYAP-B) pLKO.1 
TRCN00000
95864 
YAP1 pLKO.1 
TRCN00000
95865 
YAP1 pLKO.1 
 TRCN0000
095866 
YAP1 
(shYAP-E) pLKO.1 
 TRCN0000
095867 
YAP1 pLKO.1 
TRCN00000
95868 
Id3 pLKO.1 
TRCN00000
71438 
Id3 pLKO.1 
TRCN00000
71439 
Id3 pLKO.1 
TRCN00000
71440 
Id3 pLKO.1 
TRCN00000
71441 
%+.
Gli2 pGIPZ V2LMM_111857 
Gli2 pGIPZ V3LMM_441632 
Gli2 pGIPZ V3LMM_441635 
Gli2 pGIPZ V3LMM_441631 
TBX3 pGIPZ V3LMM_494986 
TBX3 pGIPZ V3LMM_520617 
TBX3 pGIPZ V2LMM_83163 
TBX3 pGIPZ V2LMM_190516 
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